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Thesis Abstract 
The health benefits of fish oil supplementations have been proven to be effective by 
several studies which are discussed in this thesis. It was found that these compounds had 
potent anti-inflammatory properties and since then has prompted much research into the 
use of these compounds as potential treatments for chronic inflammation based diseases, 
where the overuse of current anti-inflammatory drugs cause many problems with 
undesired side-effects. The aim of this research is to study the bioactivity of resolvin E1 
and various analogues, and to determine a novel route towards resolvin E1 natural 
product so that bioactivity tests may be conducted in comparison of synthetically 
produced resolvin E1 and naturally extracted resolvin E1.  
The initial aim of this research was to develop a range of analogues of a fragment of 
Resolvin E1. This was so that a series of compounds could be produced with various R 
groups to identify any structure-activity relationships for this part of the natural product. 
There is one stereocentre in this fragment of resolvin E1 and it was decided that a racemic 
version of these compounds would be tested for bioactivity, and if any of the compounds 
had significant anti-inflammatory properties then the R and S versions could be separated, 
allowing for the testing of both enantiomers to determine which gave the most potent 
anti-inflammatory response. This led to the creation of several novel fragments and their 
biological testing. 
The secondary aim of the project was to complete the total synthesis of the resolvin E1 
natural product. We devised a novel route towards resolvin E1 which used MIDA 
boronate protecting group to introduce a fixed trans double bond which was useful in a 
compound with multiple alkene systems. Resolvin E1 also contains three stereocentres, 
the synthesis from the fragment work was recycled to begin the synthesis, and made use 
of 1,2:5,6-di-O-isopropylidene-D-mannitol and Noyori’s catalyst to setup the 
stereocentres. The use of new MIDA-boronate moieties were also explored in order to 
develop a new, efficient synthesis toward resolvin E1.  
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1. Introduction  
Inflammation is an essential response in the body to infection or injury, and whilst it 
provides protection from these anomalies, it can also have deleterious consequences on 
the host. In the inflammatory response, pro-inflammatory mediators are released which 
initiate and augment the acute phase of the response.1 In this stage of the response, there 
is an accumulation of neutrophils (white blood cells) and edema formation, this is 
normally counterbalanced by endogenous anti-inflammatory signals which limit the 
severity and duration of this early onset phase to prevent damage by further leukocyte 
passage into tissue. These stopping signals include lipoxins, resolvins and D-series 
prostaglandins. It has been found that the internal biochemical pathways activated during 
defence mechanisms can counter-regulate inflammation and promote resolution which is 
the stage of the response where monocyte migration occurs and their differentiation to 
phagocytosing macrophages, which causes the removal of dead cells and the exit of the 
site of inflammation.2 
 
Figure 1. Inflammation response showing consequences of failed resolution phase.3 
As can be seen in fig. 1, the first box shows the natural progression of cellular 
components in the acute inflammation response, showing the intensities of pro-
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inflammatory mediators in the infected tissue. The second box shows the events which 
occur in chronic inflammation where there is a failure of removal of pro-inflammatory 
mediators due to constant harmful stimuli. This failure of the resolution phase of 
inflammation can cause untold harm to an already inflamed site, leading to damaged 
tissue and eventual loss of function. This highlights how essential the resolution phase 
is to the inflammation process, without this stage, fibroblast activity continues forming 
granuloma, substances which are large masses of weak scar tissue, and this causes 
retardation of muscle fibre and eventual loss of function. Resolvins are known to 
promote the resolution phase of inflammation which has led to great interest in creating 
these substances as potential therapeutic treatments for chronic inflammation based 
diseases. 
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1.1 Inflammation 
To effectively deduce how resolvins are helpful in the inflammation response it is 
important to understand what happens during inflammation. During the initial phase of 
inflammation polymorphonuclear leukocytes are recruited to the inflamed site and release 
pro-inflammatory mediators to eradicate or neutralize the harmful stimuli. As the 
inflammatory response progresses, a switch is activated which starts the release of anti-
inflammatory and pro-resolving lipid mediators to the site to initiate the termination of 
inflammation, this is the transition from initiation of inflammatory response to the 
beginning of the resolution response. Resolution is achieved through several 
mechanisms, some of which are; the triggering of apoptosis of polymorphonuclear 
leukocytes; inhibiting further infiltration of the polymorphonuclear leukocytes; the 
attraction of more monocytes which differentiate into macrophages; and the stimulation 
of efferocytosis, tissue repair, egression of macrophages to lymphatics etc. 
 
Figure 2. Time lapse image to show the progression of acute inflammation. 4 
Prolonged inflammation will cause damage to the host due to polymorphonuclear 
leukocytes (PMNs). Polymorphonuclear leukocytes release toxic contents of their 
granules, including, reactive oxygen and nitrogen species, proteinase, and elastase to 
eliminate or neutralize harmful entities. However, they do not just harm the invading 
microbes but can also damage the host’s tissues if they are persistently released. 5  
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Resolution of inflammation is the ideal outcome of the inflammatory response; it reduces 
the chance of excessive tissue injury and prevents the development of chronic and 
immune related inflammation. The first stage of resolution is the down regulation of pro-
inflammatory signalling, then the apoptosis of polymorphonuclear leukocytes (called 
efferocytosis) and finally it ends with migration to the draining lymph node. The initial 
phase involves the suppression of pro-inflammatory signalling and the release of 
endogenous anti-inflammatory mediators including interleukin (IL)-10, transforming 
growth factor-β (TGβ), proteolytic enzymes and lipid mediators. The change to an anti-
inflammatory environment means that the apoptosis of inflammatory polymorphonuclear 
leukocytes and removal by macrophages is better facilitated. After phagocytosis, 
macrophages are stimulated to produce high levels of anti-inflammatory and pro-
resolving mediators (ie, resolvins) and leave the inflamed site via the nearest lymph 
node.4 
 
Figure 3. Arachidonic acid and eicosapentaenoic acid cascade.6 
Figure 3 briefly outlines the metabolic processes of arachidonic acid (pro-inflammatory 
precursor) and eicosapentaenoic acid (pro-resolving and anti-inflammatory precursor) to 
producing their lipid metabolites which both have importance in the inflammatory 
response. Pro-inflammatory mediators such as, lipoxins and leukotrienes, are involved 
with actively stimulating the inflammatory response whereas eicosapentaenoic acid is 
metabolised to form the E-series of resolvins which have been shown to be pro-resolving 
and anti-inflammatory in nature. 7 
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1.2 Resolvins 
Resolvins are a series of compounds which can be metabolized from omega-3 fish oil 
fatty acids and they have been found to have significant anti-inflammatory and pro-
resolving properties. Making them a very interesting set of compounds to study as 
possible new analgesics for chronic inflammatory diseases. The E-series of resolvins 
were found to be of special importance due their particularly potent anti-inflammatory 
effects, however, the extraction process of resolvin E1 from omega-3 fish oils is very 
lengthy and inefficient, creating a need for a simple and reproducible synthetic route to 
the natural product to enable further testing. 
 
Figure 4. Resolvin E1 chemical structure. 
Lipoxins and aspirin triggered lipoxins are lipid mediators which are generated from 
arachidonic acid. Through investigations studying these mechanisms of actions of these 
substances, two new families of lipid mediators were discovered, these were resolvins 
and protectins, both of whom are derived from omega-3 polyunsaturated acids.  
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Scheme 1. Biosynthesis of Resolvin E1.8 
Scheme 1 outlines the biosynthesis of resolvin E1, which is always an important piece of 
information to know when embarking upon natural product synthesis. Interestingly, it 
was found that aspirin can have a key role in the biosynthesis by acetylating COX-2 in 
vascular endothelial cells which can stereoselectively form 18R-hydroperoxy-EPE (blue 
route). Resolvin E1 is then formed in a lipoxygenase type mechanism through the 
biosynthesis of 18R-hydroperoxy-EPE by leukocytes. An alternative biosynthesis to this 
uses cytochrome P450 and microbial enzymes to create resolvin E1. Although the definite 
mode of action of E-resolvins has not been identified, it appears that the anti-
inflammatory properties of resolvins are largely based around the downregulation of the 
recruitment and function of polymorphonuclear leukocytes. 9 The effects of E-resolvins 
appear to arise from the actions on G-coupled protein receptors. As shown in figure 3, 
resolvins have an antagonistic relationship with type 1 leukotriene B4 receptor in 
neutrophils and dendritic cells. This antagonism leads to the suppression of leukocyte 
infiltration, intracellular signalling, and this leads to a reduction of biosynthesis and 
secretion of pro-inflammatory mediators. This was confirmed in an investigation by CN 
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Serhan et al who found that resolvin E1 was able to stop polymorphonuclear neutrophil 
migration in vitro and infiltration in vivo.7,10,11 
 Several biological tests have already been carried out using resolvin E1 to tests its 
effectiveness against various ailments. These findings are summarized in table 1. As 
shown in this table, the anti-inflammatory properties are potent in a wide range of 
illnesses.  
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Table 1. Examples of the biological testing results of anti-inflammatory lipids in recent 
literature. 
Mediator Disease Model  Action  Reference 
      
Resolvin Peritonitis  Limit neutrophil infiltration.  
 
   Increase apoptotic leukocyte engulfment.  12–15 
   Stimulate migration of macrophage to lymph   
   node.   
      
 Allergic airway  Activation of natural killer cells.  
 
 inflammation  
Dampening of the development of allergic 
 
16–18     
   airway inflammation.   
      
 
Ocular 
infection  Reducing the extent of angiogenesis.  
 
   Blocking the production of pro-inflammatory  19 
   cytokines.   
      
 Asthma  Inhibiting airway eosinophil and lymphocyte  
 
   recruitment.   
   Reducing Th2 cytokine and airway hyper-  20,21 
   responsiveness.   
      
 Inflammatory  Generation of pain hypersensitivity.  
 
 pain    3 
      
 Pneumonia  Decreasing lung neutrophil infiltration.  
 
   Enhancement of clearance of E.Coli.  22 
      
 
As shown in Table 1 resolvins have proven to be potent anti-inflammatory and pro-
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resolution compounds; however, an issue which must be addressed is why these 
compounds are of benefit over current anti-inflammatory remedies. Most anti-
inflammatory modes of function involve blocking key biochemical pathways and/or the 
signalling of pro-inflammatory mechanisms. However, this only provides symptomatic 
relief and does not effectively eradicate pathological conditions in most immune-
mediated inflammatory disorders.2 These compounds consist mainly of NSAID’s or 
opioidal drugs, and whilst these have been effective for most acute inflammation cases 
they have unwanted side effects and unfortunately it has been found that if a selective 
COX-2 inhibitor is administered at the peak of inflammation it will delay the resolution 
of inflammation.23 This has the potential to lead to aggravation of inflammation related 
symptoms by disturbing the endogenous pro-resolving mechanisms and obviously this is 
an extremely undesirable side-effect when trying to treat inflammation.  
New drugs designed to promote mediators in the resolving phase of inflammation will 
have a much smaller chance of being rejected by the body because they have homeostatic 
and modulatory capabilities. In the process of natural inflammation, after entering tissues, 
granulocytes promote the switch of arachidonic acid derived prostaglandins and 
leukotrienes to lipoxins, this initiates the termination sequence. At this point, neutrophil 
recruitment ceases and death by apoptosis is engaged. These events coincide with the 
biosynthesis from omega-3 polyunsaturated fatty acids of resolvins and protectins, except 
that they have the ability to substantially shorten the period of neutrophil infiltration by 
initiating apoptosis.24  
Another important factor which should not be ignored with regards to COX-inhibitors 
and opoidal treatments for inflammation are the numerous and well-known side effects. 
With regards to the most typically used NSAID’s, such as ibuprofen, the main issue is 
the formation of stomach ulcers through prolonged use of these drugs which is obviously 
a problem with chronic inflammation based diseases where inflammation is an underlying 
and constant problem. Opoidal drugs are also usually undesirable due to their numerous 
unfavourable side-effects and if used for prolonged periods of time then the physical 
dependence which is developed is also an enormous disadvantage in chronic 
inflammation based diseases. Given the potency of resolvins and the well-known side-
effects of opioids and COX-inhibitors, resolvins may now present new analgesics for the 
treatment of inflammatory pain. 
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2. Previous Syntheses of Resolvins and Related Compounds 
The analysis of resolvins which have been synthesised so far allow for the construction 
of a new and improved synthesis of resolvin for this project. It is important to weigh up 
the benefits and disadvantages of the methods used previously and take inspiration for a 
new synthesis of resolvin species. Given the potency of resolvins, the well-known side 
effects of opioids and COX 2 inhibitors and the limited availability of resolvins it is 
beneficial to keep exploring new methods of synthesis for this group of promising 
compounds. 
2.1 E Resolvins 
Resolvin E1 is an oxidative metabolite of EPA (eicosapentaenoic acid) which is produced 
by neutrophils from 18R-hydroxyeicosapentaenoic acid (18R-HEPE) through a 5-
lipoxygenase mediated pathway. 
 
Figure 5. Chemical Structure of 18R-HEPE. 
Resolvin serves as an on-demand negative feedback switch that can dramatically reduce 
inflammatory responses. Of particular importance, is the reduction of neutrophil and 
dendritic cell migration, and interleukin-12 production. Bearing this in mind, it is of 
interest to produce EPA to see if there are any functionalities within the structure which 
give the compound anti-inflammatory properties. A study conducted by Chaikof et al 
attempted synthetically to produce 18R-HEPE to determine the anti-inflammatory effects 
of this compound.13 The study was a success and the natural product was formed using 
the following key intermediates [5] and [6]. 
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Figure 6. Chemical structures of key intermediates. 
The total synthesis was achieved in a convergent manner using the terminal acetylene as 
a coupling point at which to join the two fragments using a Sonogashira coupling 
reaction. This method utilized Cu(I)-Pd(0) to obtain the desired E/Z conjugated diene 
system present in 18R-HEPE. The synthesis of this molecule was done efficiently with 
minimal steps to create each fragment and then the coupling being the main step to create 
the final compound; this paper shows a well thought out synthesis and claims to have 
produced the final product with an overall yield of 71%. Most importantly it was found 
that this compound was biologically active and has the ability to block neutrophil 
infiltration in a mouse peritonitis model.  
The total syntheses of several resolvins have already been published. Resolvin E1 has 
been synthesized using a number of different methods due to its limited availability in 
nature, it can be extracted at most on the microgram scale.25 The extraction is inefficient 
due to the complex nature of its extraction, as resolvins are metabolites of fish oils, the 
extraction was described by Masoodi et al.25 Brain, liver, and plasma samples were taken 
from male Wistar rats, and the tissue samples were homogenised in water. After further 
dilutions, the samples were centrifuged to remove precipitated proteins and the remaining 
samples were acidified. The samples were then washed with methanol, water and hexane 
to yield hydroxy acids. In order to determine the recovery of the metabolites, analysis 
was performed in parallel with brain, liver and plasma samples spiked with mixed 
hydroxy fatty acid, leukotriene, resolvin and protectin standard and un-spiked samples. 
These were analysed using LC/ESI-MS/MS.  
 Resolvin E1 can be characterised by three stereocentres, two cis double bonds and three 
trans double bonds. These characteristics present several synthetic challenges when 
embarking upon the total synthesis, however it has been synthesised in its entirety by four 
groups previously. The first total synthesis is described by Serhan et al and was 
completed in 2005.26  
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Scheme 2. Retrosynthesis of Resolvin E1. 
The authors claim that the starting materials were designed to be isomerically pure from 
starting materials with known stereochemistry. However, it does not state anywhere in 
the paper what these starting materials are, there is also no evidence confirming the 
absolute stereochemistry of any of these compounds. Indeed, there is a lack of data on all 
the compounds shown here. This may be since this is primarily a paper to discuss the 
biological results as opposed to a synthetic chemistry paper, however a little more 
information would be very useful.26 
A second total synthesis was described some years later in 2009, by Ogawa and 
Kobayashi.27 In this synthesis, the Suzuki-Miyaura coupling method was used to create 
the conjugated triene system, as this transformation is stereoselective and allowed for 
easy purification by silica column chromatography. It is also a method that has been 
developed in the group previously to synthesise conjugated triene systems in Leukotriene 
analogues.28 The synthesis of resolvin E1 was achieved using vinyl borane and vinyl 
iodide as requisite coupling partners.  
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Scheme 3. Total Synthesis of Resolvin E1 highlighting major disconnections and intermediates. 
The starting materials were each synthesised by a 6-step synthesis to create the 
enantiomerically pure starting materials [12] and [13]. These enantiomers were produced 
using a Noyori reduction and Sharpless epoxidations, whilst these are useful 
transformations, they can be capricious, and it might be worthwhile to consider using a 
starting material with known chirality for future syntheses. These compounds underwent 
a Wittig reaction to create the cis double bond in compound [11]. The total synthesis was 
achieved with a reasonable purity (>92%) which would be sufficient for biological 
analysis. While this is has proven an effective method, it may not be the most efficient, 
the six-step synthesis of both precursors is quite lengthy. Having considered this, it 
appears that it would be most beneficial to explore new synthetic routes which are not as 
lengthy to increase efficiency and therefore the overall yield. 
In 2011 another group completed the total synthesis of resolvin E1.29 Two routes are 
presented in this paper, with claims that routes are both modular and convergent in nature 
with an excellent control of all stereocentres. The synthetic disconnections suggested in 
this work are very compliant to analogue preparation and to further modifications. This 
has allowed for scale-up and consequently human testing was completed.  
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Scheme 4. Resolvin E1 total synthesis showing main disconnections and key intermediates. 
The scheme above shows the first retrosynthetic approach to the preparation of resolvin 
E1, this was designed after firstly trying the patented work by Petasis and co-workers, 
wherein a late stage bisalkyne was assembled from smaller fragments and subsequently 
reduced to form the pentene backbone.30  The route shown above was successful and 
produced several analogues, however the authors felt there were some major limitations 
to this approach. They agreed that: the synthesis of the allylic phosphonate was a 
relatively lengthy process; having to prepare the diene fragment highlighted in scheme 4 
was a several step syntheses; there was a modest 50% yield and only a 3:1 E/Z ratio for 
the Horner-Wadsworth-Emmons reaction, and that finally, the allylic phosphonate anion 
was shown to be highly unstable and therefore degradation pathways would compete with 
the desired pathway to the α-silyoxy aldehyde. The combination of all these negative 
factors led the group to begin devising a new route to resolvin E1.  
15 
 
 
Scheme 5. Second synthetic route towards resolvin E1. 
The new synthetic route presented an improvement upon the stereo-control, yields, and 
importantly, a shorter synthetic route towards the natural product. The chemistry 
described for scheme 5 was also able to provide access to scalable reactions which gave 
significant quantities of resolvin E1 for pharmacological evaluation, and flexibility for 
the design and synthesis of a range of analogues. Further modifications allowed for the 
large-scale preparation of resolvin E1 for preclinical development and subsequently this 
led to the first human clinical trial testing. This testing was described by Cholkar et al.31 
The compound shown in figure 7 is the fragment which has been tested by this group.  
 
Figure 7. Resolvin E1 fragment used for in vivo testing. 
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The aim was to entrap compound [26] within micelles and study in vivo ocular 
compatibility and tissue distribution following topical administration.31 The results from 
this study were promising, the micellar solution was well-tolerated and did not have any 
measurable tissue damage in rabbit ocular tissues. It is hoped that topical aqueous 
formulations may be employed to treat posterior ocular diseases. Such micellar topical 
formulations may be more patient acceptable over invasive routes of administrations such 
as intravitreal injection/implants. 31 
More recently, in April 2017 a patent application was published which described several 
routes towards resolvin E1.32 The first is summarized in scheme 6, this route utilizes a 
Wittig olefination to couple the two fragments together while achieving the desired trans 
double bond. 
 
Scheme 6. Retrosynthetic route towards resolvin E1. 
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Whilst this synthesis is successful in the sense that it achieved the natural product, it is a 
very long synthetic route. To form compounds [27] and [28] required a twelve-step 
synthesis from compound [32] and to create compound [31] required a four-step 
synthesis. Many possible routes were explored towards the synthesis of the intermediates 
shown above, however the scheme outlines the most important compounds in the 
synthesis. It can be seen that only one of the stereocentres is acquired from a fixed chiral 
pool starting material [32] which means that the remaining two stereocentres are 
dependent upon stereospecific reactions. This can prove a disadvantage in synthesis as 
these reactions can be capricious and enantiomers difficult to separate.  
 
Scheme 7. Alternate retrosynthetic route towards resolvin E1. 
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The alternative route towards resolvin E1 summarized in scheme 7 shows the utilization 
of the Sonogashira coupling to stitch together the main fragments and form the natural 
product. In this scheme, the synthesis of fragment [36] can be completed in four steps. 
However, the larger fragment [35] is more complicated and requires the same twelve-
step synthesis required for compound [27] in scheme 6. Several other similar routes are 
explored in this patent however none show any remarkable chemistry with clever use of 
chiral pools or simple couplings. The vast majority of the intermediate compounds 
require multi-step syntheses and whilst it is useful to utilize well-known, reliable 
reactions is it not always the most efficient way to devise a route towards a complex 
natural product such as resolvin E1.  
Resolvin E2 is another example of a lipid mediator derived from omega-3 fatty acids. 
Resolvin E2 can be characterised by its two stereocentres, three cis double bonds and two 
trans double bonds. These characteristics make it similar to resolvin E1 and a challenge 
to synthesise in its own respect.  
 
Figure 8. Chemical structure of resolvin E2. 
Resolvin E2 was first synthesised in 2009 by Inoue et al.33 The group decided it would 
be fruitful to take full advantage of the symmetry within the compound and devised a 
route with this in mind.  
19 
 
 
Scheme 8. Retrosynthetic route towards resolvin E2. 
This clever synthesis utilizes one main starting compound [46] to create the two 
symmetrical halves of the natural product. It was decided that compound [46] would 
prove a useful starting material as it could be chemoselectively reduced at either the 
carboxylic acid or the ester moieties to create the desired enantiomers in pleasing 
enantiomeric excess 87% ee for (+)-[47] and 64% ee for (-)- [45]. Whilst these 
enantiomeric excess values are not perfect, the team could not improve upon the results 
they gathered here so they left their compounds as a mixture of enantiomers deeming 
them sufficient for this synthesis.  This route ensures that the desired stereochemistry is 
retained throughout the entire synthesis which is a very efficient and effective way of 
ensuring enantiomeric purity in the natural product. The major disadvantage of this 
method is the requirement of three multi-step syntheses; of each symmetrical half, and a 
series of reactions with alkyne [48] to make the natural product. To synthesise compound 
[43] from (-)-[45] required a nine-step synthesis and to create [42] required a seven-step 
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synthesis. These are relatively long step-wise syntheses which would normally lead to 
low percentage yields and inefficiency however, the percentage yields that were stated 
were all reasonably high (>54%). In summary, an efficient route to resolvin E2 was 
devised and executed to deliver the natural product. A synthesis which utilized the 
intrinsic pseudoenantiomeric nature of the key fragments [41] and [42], and these 
fragments were subsequently assembled into the natural product in a convergent manner.  
Another synthesis of resolvin E2 was published a year later in 2010 by Kosaki et al. 34 
This group took note of the difficulty to achieve high enantiomeric excess values for the 
chiral centres, so decided to carry out alternative procedures that delivered the desired 
chiral alcohols with high enantiomeric excess.  
 
Scheme 9. Retrosynthetic route towards resolvin E2. 
 
This scheme was developed after trying to reproduce the work by Inoue et al, the group 
found that the resolvin E2 and the diastereoisomers derived from the racemic parts could 
21 
 
not be successfully separated using conventional silica chromatography techniques.33 
This prompted the use of reactions to deliver chiral alcohols. Overall, this paper shows 
the successful synthesis of resolvin E2 in which cis alkenes were constructed in an 
efficient and stereoselective route. The two chiral carbons in this compound are situated 
alpha to the hydroxyl groups, using the procedures carried out in this paper it was possible 
to construct these in highly pure enantiomeric forms (usually >95% pure). This was 
achieved using epoxidation/kinetic resolution of the ɣ-silylallylic alcohols using the 
Sharpless epoxidation and in the ozonolysis of the ɣ-silylallylic alcohol to the α-
alkoxyaldehyde, reduction with PPh3 was the choice method.  
Resolvin E3 was also found to be a potent anti-inflammatory by limiting the 
polymorphonuclear infiltration in zymosan-induced peritonitis. It has similar structure to 
previously described resolvins but is characterised by three cis double bonds and two 
trans double bonds. The stereochemistry the two chiral centres in this compound were 
unassigned until 2013, one year after the first total synthesis which described the 
synthesis of four possible stereoisomers.35,36 It was found that 17S,18S and 17R,18R gave 
the best biological results and managed to limit neutrophil infiltration both in vitro and 
in vivo whereas 17R,18S and 17S,18R gave poor results in comparison.  
 
Figure 9. Chemical structures of resolvin E3. Natural isomers highlighted in boxes. 
As mentioned previously, the absolute stereochemistry of the two chiral centres at carbon 
17 and 18 were unassigned, mainly due to the limited availability of resolvin E3 from 
eosinophils. The group set out to synthesize all four possible stereoisomers, so that they 
could be biologically tested and the absolute stereochemistry assigned.  
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Scheme 10. Retrosynthetic route towards four stereosiomers of resolvin E3. 
The four stereoisomers were successfully created by effectively utilizing the Horner-
Wadsworth-Emmons coupling and two copper(I) mediated SN2 reactions. The 
stereoselective total synthesis of resolvin E3 was successfully completed in a highly 
convergent method from the corresponding chiral aldehydes, these were developed by 
starting with Sharpless asymmetric dihydroxylation from starting material [60], followed 
by use of (DHQD)2PHAL or (DHQ)2PHAL chiral catalysts to provide enantiomeric diols. 
To create compounds [59c] and [59d] required three steps from [60] and [59a] and [59b] 
required and eight-step synthesis. This route towards the chiral centres is inventive, the 
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use of one starting material to all four stereoisomers was very successful and incredibly 
efficient. It was also achieved in a relatively small number of steps, and the late stage 
partial reduction was an advantageous route to take because it significantly reduced and 
simplified the overall route to the target compounds.  
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2.2 D Resolvins 
Protectin D1 is a metabolite of DHA and has been shown to possess high anti-
inflammatory and proresolving properties, almost as high as resolvin E1 mentioned 
previously. 37 Protectin D1 can be characterised by its four cis double bonds, two trans 
double bonds and two chiral centres. Interestingly, stereoisomers of this compound are 
formed in the differing biosynthetic pathways. Compound [63] is produced through the 
action of 15-lipoxygenase to form an epoxide intermediate followed by an enzymatic 
hydrolysis. Compound [63] was elucidated in 2011, showing that a stereoisomer of 
protectin D1 is formed through the metabolism of DHA but with aspirin triggered COX-
2. Under these conditions, COX-2 functions as a lipoxygenase-like enzyme, catalyzing 
the stereospecific formation of hydroxylated products with a 17R, rather than a 17S 
stereochemistry. 38 
 
Figure 10. Chemical structures of Protectin D1 [63a] and its aspirin triggered stereoisomer [63]. 
The first synthesis of protectin D1 was described by Serhan et al.37 They managed to 
successfully construct the unstable conjugated triene unit by utilizing the Sonogashira 
coupling method, followed by hydrogenation of the resulting dienylacetylene. However, 
unfortunately, the efficiency of the stereoselectivity and yields are not mentioned. In a 
later study by Ogawa and Kobayashi there were two approaches for the synthesis of 
protectin D1, these are summarized in scheme 11. 39  
25 
 
 
Scheme 11. Retrosynthetic route toward protectin D1. 
There were two main fragments required to create compound [63a], these are shown in 
the scheme above, [66] and [67]. The two fragments [64] and [65] were reacted in the 
presence of sodium hydroxide and a palladium catalyst to produce the desired natural 
product via a Suzuki cross coupling reaction. Overall, the completed natural product was 
formed under relatively mild conditions which the group suggest can be applied to the 
synthesis of analogues and other similar compounds. 
In 2013, the Petasis group devised a new way to synthesise both versions of protectin D1. 
38 In order to ensure the unambiguous total synthesis of the natural products, the group 
utilized a previously devised convergent strategy.37 This strategy involved starting with 
a protected glycidol and then forming z-alkenes via the selective reduction of the 
complimentary dienyne. The dienyne was generated using a standard Sonogashira 
coupling of the alkyne and dienyl iodide. The chiral moieties were produced via the initial 
epoxide opening of a glycidol derivative with a metallated 1-alkyne. This method is 
highly convergent, and it also leads to a predefined R/S chirality depending on the 
glycidol enantiomer used. Through this, it is also ensured that all the carbon double bonds 
adopt the desired Z/E geometry and therefore limits Z/E isomerisation, reducing the need 
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for separation techniques. The retrosynthetic scheme that was devised for this work is 
outlined in scheme 12. 
 
Scheme 12. Retrosynthetic route towards protectin D1. 
The synthetic strategy shown above is highly convergent and most importantly it offers 
a new route for stereocontrol of this compound. As can be seen, the stereochemistry of 
the epoxide groups is carried forwards through the steps, eradicating the need for 
separation of enantiomers. Following on from this, the Z/E alkenes were produced using 
selective hydrogenation techniques. 
Overall, the full synthesis of both protectins was successfully achieved and in high 
enough yields and scale that sufficient quantities were produced for biological testing 
against inflammation and neurodegenerative diseases. There was also product enough for 
development of lipid analysis with mass spectrometry. In addition to all this, they also 
managed to assign for the first time the R/S and E/Z stereochemistry of this potent lipid 
mediator. 
Resolvin D1 is another naturally found lipid mediator from the resolvin family of 
compounds, a natural metabolite of DHA. It has been shown to possess high anti-
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inflammatory activity under a variety of conditions including arthritis.3,40 It has also been 
found that resolvin D1 acts to promote the resolution of allergic airway responses in a 
similar fashion to the way that resolvin E1 promotes resolution phase of the inflammation 
response.41 Interestingly, it was reported by Chiang et al, that bacterial infections 
contribute to the active resolution of acute inflammation and resolvin D1 was identified 
as one of the self-resolving exudates in E. Coli in this study. Furthermore, it was found 
that resolvin D1 acted to promote phagocytosis of E.Coli in human macrophages and as 
a result, resolvin D1 accelerated the resolution phase which then led to enhanced survival 
towards gram positive and gram negative bacteria and lowered the requirement of 
antibiotic treatment. This offers a new potential therapeutic route for the ever-increasing 
problem of bacteria resistance to antibiotics. These discoveries would not have been made 
possible without the supply of synthetically produced resolvin D1 due to its extremely 
limited availability naturally.   
 
Figure 11. Chemical structure of Resolvin D1. 
In 2012, Rodriguez et al published a novel synthesis towards resolvin D1.42 Resolvin D1 
can be characterised by three trans double bonds, three cis double bonds and three chiral 
centres. The chiral hydroxyl groups were obtained using a chiral pool strategy from 2-
deoxy-ɒ-ribose, followed by Wittig reactions, a modified Sonogashira coupling and 
finally a Zn(Cu/Ag) cis-reduction to complete the total synthesis. The use of the chiral 
pool to obtain the correct stereochemistry is a desirable method as it eradicates the need 
for enantiomeric separation procedures, this was proven when they analysed with HPLC 
and found that this compound co-eluted with an authentic sample of resolving D1 
obtained from a commercial source. 
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Scheme 13. Retrosynthetic route towards resolvin D1. 
Resolvin D2 is another lipid mediator, metabolite of DHA which is known to be highly 
enriched in the brain, synapses and retina. It is also known for being a potent anti-
inflammatory like the other compounds mentioned here. The highly limited availability 
of this compound means that its total synthesis is required to be able to effectively analyse 
this interesting compound. Resolvin D2 can be characterised by three cis double bonds, 
three trans double bonds and three chiral centres.  
 
Figure 12. Chemical structure of resolvin D2. 
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The first total synthesis was published in 2004 by Rodriguez and Spur, they developed 
four key intermediates which were enantiomerically pure and would allow for the easy 
transfer of the chiral centres through the steps.43  
 
Scheme 14. Retrosynthetic route to resolvin D2. 
Unfortunately, the synthesis of compound [80] required a nine-step synthesis, however 
the remaining starting materials [81] [82] and [83] were all commercially available. This 
means that two stereocentres are fixed throughout the synthesis using compound [8] for 
its fixed chiral centre. For the remaining chiral centre, an epoxide was formed and then 
underwent hydrolytic kinetic resolution using Jacobsen’s (R,R)-(salen)Co(III)(OAc) 
catalyst to selectively produce the S-enantiomer which is then carried forwards through 
the synthesis. Once the main fragments were produced, a standard Sonogashira coupling 
was employed to complete the main skeleton, from this point another five-step synthesis 
was required to complete the natural product. Unfortunately, this paper provided no 
experimental procedures, which makes reproducing these results quite difficult. 
However, the data is present and confirms the findings in this paper, allowing biological 
testing of this synthetic compound for the first time. 
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After the total synthesis was completed in 2002, biological testing was conducted and it 
was found that resolvin D2 prevents the adherence of polymorphonuclear leukocytes 
(PMNs) to the blood vessel walls by promoting the shedding of L-selectin from the PMNs 
preventing binding to E-selectin on the endothelial cell lining of the blood vessel.44 44 It 
was also found to promote the influx and phagocytic activity of macrophages, allowing 
the clearance of all the dead cells and microbial pathogens and therefore promoting 
resolution of inflammation and infection. Having confirmed that resolvin D2 had 
fascinating biological properties, it became a higher priority to increase the efficiency of 
the total synthesis, and it was attempted a few years later in 2013, by M.A.Rizzacasa et 
al, after the group became frustrated at the lack of synthetic procedure information 
regarding this compound in previous literature.45 
 
Scheme 15. Retrosynthetic route towards resolvin D2. 
This group made use of the same chiral pool as previously seen in scheme 14, compound 
[82]. However, the synthetic route towards each fragment was completed in a more 
efficient manner, only requiring seventeen steps in total to reach the natural product in its 
free acid form. This paper also describes all synthetic procedures making this total 
synthesis reproducible and more reliable.  
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Resolvin D5 is another derivative of DHA, it is characterised by four cis double bonds, 
two trans double bonds, and two stereocentres.  
 
Figure 13. Chemical structure of resolvin D5. 
Resolvin D5 was produced synthetically for the first time in 2005.46 The chiral centres 
were generated via a Co-salen hydrolytic kinetic resolution of a terminal epoxide with 
more than 99% enantiomeric excess.  
 
Scheme 16. Retrosynthetic route towards resolvin D5. 
The key disconnections are shown in scheme 16, featuring a Sonogashira coupling, 
Yamaguchi coupling. Overall, this synthesis was completed making this novel anti-
inflammatory mediator available for biological evaluation. 
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Similarly, resolvin D6 is also a metabolite of DHA, characterised by four cis double 
bonds, two trans double bonds and two chiral centres.  
 
Figure 14. Chemical structure of resolvin D6. 
This compound was first synthesised in 2012, the chiral groups were introduced via a 
Noyori transfer hydrogenation and a Sharpless catalytic asymmetric epoxidation.  
 
Scheme 17. Retrosynthetic route towards resolvin D6. 
The synthesis of key intermediate [96] was achieved in six steps, [97] was produced in 
seven steps and the final fragment [95] was made in two steps. To piece together these 
fragments, Sonogashira couplings were used and to complete the natural product a 
Zn(Cu/Ag) reduction completed the natural product. This is a relatively simple synthesis 
which proved effective in producing the natural product in a surprisingly small number 
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of steps. This compound has now been produced in sufficient quantities for biological 
testing.47 
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3. MIDA-Boronates 
Inspired by the way natural products are biosynthesized via the iterative assembly of a 
defined set of building blocks, a platform for small molecule synthesis involving the 
iterative coupling of haloboronic acids protected as the corresponding N-
methyliminodiacetic acid (MIDA) boronates has been presented.48 In modern chemistry, 
the methods by which small molecules are brought together is being heavily developed 
to encourage more efficient synthetic routes. One method of particular interest is the 
“building-block” method, whereby small molecules are combined in an iterative fashion, 
retaining any oxidation states and stereochemistry the molecules may contain. This is 
clearly a very advantageous method which eradicates the need for lengthy syntheses and 
enantiomerically pure reactions. This is particularly useful in the synthesis of natural 
products, where a series of building blocks are usually created for this purpose.  
Resolvin E1 contains a considerable number of stereocentres, so, a method which allows 
for the retention of the stereochemistry would be very useful in this case. One such 
method is the use of MIDA boronates, as building blocks for small molecule synthesis. 
Practically, they are very useful with favourable chemical and physical properties. They 
are air stable, monomeric, highly crystalline, free flowing solids that have the ability to 
be stored indefinitely on the benchtop exposed to air. MIDA is also biodegradable.49 They 
are soluble in most organic solvents and compatible with silica gel chromatography. 
MIDA boronates are also stable to a wide range of other common reaction conditions 
making it possible to utilize multistep pathways to prepare complex organoborane 
building blocks from MIDA boronate starting materials.  
 
Scheme 18. MIDA boronate use as cross coupling tool.50 
This area of work has been explored extensively by Burke et al, who discovered that 
creating an ethynyl MIDA boronate would be useful in the synthesis of many natural 
products.50 The ethynyl moiety appears in a wide range of natural products, 
pharmaceuticals and materials. This moiety allows for a large range of substrates to be 
35 
 
coupled via Sonogashira reaction which opens up the opportunity for a wide variety of 
reactions. This was explored in a study by Burke et al, whereby a series of aromatic R-
groups were tested for their compatibility with MIDA-boronates presenting a very 
promising platform for this type of synthetic strategy, which has often been utilized in 
natural product synthesis.50  
 
Figure 15. Sonogashira coupling scope experiment (small number of examples).50 
It was shown in all these examples that the MIDA-boronate functionality was retained 
throughout the reaction to the product. Making these compounds potentially very useful 
building blocks for small molecule synthesis.  
Suzuki-Miyaura cross couplings with alkynyl boronic acids are very rare, this is thought 
to be due to the intolerance of the boronic acid group on the substrates, creating unstable 
intermediates. It has been established that this functional group is stable to anhydrous 
cross-coupling conditions as shown in figure 15. This is an important discovery as it 
opens the possibility of carrying out Suzuki-Miyaura type cross couplings with substrates 
which would have previously been unstable to the boronic acid functionality. To 
emphasize the scope of the use of the MIDA-boronate functional group, a study was 
conducted which tested the cross coupling a boronic acid substrate with a MIDA boronate 
substrate. As predicted, the MIDA-boronate was unchanged by the reagents in the 
reaction allowing for the boronic acid to selectively take part in the cross coupling. The 
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scope for this reaction was fairly diverse, testing a series of di- and tri- enyl boronic acids. 
51  
 
Scheme 19. Example of cross coupling reaction.50 
All the tests were successful, achieving pleasing yields (62-95%), showing that the MIDA 
boronate functional group enables these previously highly unstable boronic acids to 
undergo Suzuki-Miyaura cross coupling reactions. It also proved that these reactions are 
highly successful in terms of retaining stereochemistry, which is especially impressive 
considering the coupling is with encumbered MIDA boronates. This is particularly useful 
in terms of considering this as a method for the synthesis as resolvin E1, which contains 
several alkenes rendering it unstable to many reactions and functionalities. 
The MIDA boronate can be easily hydrolysed with mild aqueous base, which is actually 
advantageous as it enables controlled, iterative cross coupling of B-protected halo-
boronic acids. By having the ability to carry out the MIDA group hydrolysis and cross 
coupling in a one-pot reaction, the scope of this reaction is increased dramatically. 
Normally in these types of reactions it is essential to introduce a boronic acid functional 
group before the coupling. However, with the MIDA boronate a boronic acid is not 
required as it can be hydrolysed to the boronic acid with mild aqueous base and then 
immediately undergo the cross coupling in a one-pot reaction. This reaction was applied 
to the synthesis of the complex heptaene core of vacidin A [112].51  
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Scheme 20. Synthesis of complex heptaene core of vacidin A using novel one-pot MIDA boronate 
hydrolysis and cross coupling reaction.51 
This reaction is very interesting, particularly in terms of synthesising resolvin E1 which 
has a complex multi-ene sytem too. This provides opportunity to simplify the synthesis 
of resolvin E1 by utilizing this building blocks method. The yield of this reaction is also 
very pleasing, in a long step-wise synthesis it is very important to be aware of percentage 
yields; one inefficient reaction could prove catastrophic to finishing a complex synthesis.  
MIDA-boronates are becoming an increasingly general platform for organic synthesis 
given its diversity of substrates and versatile reaction conditions. However, it is also due 
to the varying rates of hydrolysis. It has been determined that there are two distinct 
mechanisms; base mediated and neutral.52 The former, is very fast and the rate is 
determined by a rate limiting hydroxide attack at the MIDA carbonyl carbon. The neutral 
mechanism does not require any base or acid and involves a rate limiting boron-nitrogen 
bond cleavage by a small water cluster.52 
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Figure 16. Differing outcomes of slow and fast MIDA boronate hydrolysis.52 
Overall, this paper determined that the rate of hydrolysis is determined by the pH, water 
activity and mass transfer rates between the phases. While the paper goes into great detail 
about the mechanistic studies of the rate determining steps and definitions between slow 
and fast rate hydrolysis, it is more important to note that in the context of this work, the 
control of the rate of hydrolysis is very important as it increases the scope of deprotection 
and coupling reactions that these MIDA boronate compounds are compatible with. 
However, these findings enable an even more effective and widespread utilisation of 
MIDA boronates in organic synthesis.  
The use of MIDA-boronates is of no use however, if the synthesis of the boronate itself 
is long and difficult. Fortunately, a simple synthesis for [98] is described by J.R.Struble 
et al.50  
 
Scheme 21. Synthesis of ethynyl MIDA boronate.50 
Unfortunately, the percentage yield for this reaction is 51% but given that the MIDA 
boronate can be formed in one step it is a very useful reaction, especially considering that 
the ethynyl MIDA boronate can be stored indefinitely on the benchtop without fear of 
degradation, meaning that [98] can be produced in bulk and stored for future reactions. 
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With respect to molecules found in living systems, nearly all biosynthetic systems are 
based on the iterative coupling of building blocks with bi-functionality. This is the same 
basic theory for the MIDA boronate mode of action. For example, polypeptides are built 
from amino acids, oligonucleotides are derived from nucleotide monomers and 
oligosaccharides are stitched together from individual sugar units.48 
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Figure 17. Iterative peptide coupling from protected amino acids (above) and iterative cross coupling 
platform for small molecule synthesis from MIDA boronate building blocks are analogous. (C=coupling 
and D=deprotection).53 
In relation to this, many small molecule natural products are constructed using iterative 
cross coupling of bifunctional building blocks. Also, in a similar fashion, many man-
made pharmaceuticals are also highly modular because they are constructed using 
different reactions to assemble collections of small building blocks.  
A review by Gillis and Burke describes how the group envisions an iterative cross-
coupling approach to most natural product syntheses. Building blocks having all of the 
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required functional groups preinstalled in the correct oxidation states with the correct 
stereochemical relationships are iteratively united using only a single cross-coupling 
reaction.53 In 2014, the group put the theory that most polyene natural products could be 
formed through an iterative cross coupling approach and were very succesfful.54 It was 
determined that polyene motifs found in more than 75% of all known polyene natural 
products can be synthesised using just twelve building blocks and one coupling reaction.  
As shown in figure 17, most molecules found in living systems are prepared naturally via 
the iterative assembly of a limited number of building blocks. Traditionally, in laboratory 
total syntheses, the synthesis of small molecule natural products has involved customised 
development of unique pathway and development of building blocks to access each 
target. As a result of this approach to natural products, despite many advances in 
accessing individual structures, the syntheses are generally inefficient, inflexible and 
normally only practised by specialists.  
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4.0 Conclusions 
The syntheses of most resolvins have been analysed here and something which strikes 
out as a particular problem, is the synthesis of numerous chiral centres and the 
stereochemistry of the double bonds. The literature syntheses which were the most 
efficient were those which employed the use of a compound with known and fixed 
stereochemistry. However, this was not the most commonly used method. Examples of 
compounds with fixed chirality are in figure 18.  
 
Figure 18. Chiral pool compounds used in resolvin synthesis. 
Using a chiral pool material is a very useful method for creating chiral centres, as it 
eradicates the need for enantioselective reactions which can sometimes prove to be 
unreliable or problematic. It also removes the need for any difficult separations of 
enantiomers at the end of the synthesis. However, it must not be forgotten that due to 
chiral centre being fixed at the beginning of the synthesis, special care must be taken in 
synthesis planning so as to take into account or avoid any reactions which would cause 
the stereocentre to invert. In 2012, Rodriguez and Spur used the chiral pool in their 
synthesis of RvD1 in 2012 for all three of the stereocentres present; 2-deoxy-ᴅ-ribose 
shown in figure 18 [78].42 Unfortunately, the use of this compound came with significant 
sacrifices in terms of reaction yield. The first reaction using 2-deoxy-ᴅ-ribose only 
yielded 43% which was quite modest, especially in a step-wise synthesis. The second 
reaction was a little more promising with a 60% yield, however it was necessary to further 
manipulate the compound to be left with the only one hydroxyl group. This reaction 
produced an undesired side product which accounted for 50% of the percentage yield and 
had to be discarded.  If a better chiral pool compound could be developed for these 
compounds it would be highly beneficial. The alternative to chiral pool compounds is the 
use of enantiomeric reductions, and a reaction which has been used previously in the 
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syntheses of similar compounds is the Noyori reduction. This is of importance due to its 
relevance in this project. 
 
Scheme 22.  Noyori asymmetric reduction reaction example.29  
The high enantiomeric excess values quoted here would make this a good choice for the 
production of chiral centres. However, if the reaction were to not work well with the 
required substrate then separating the enantiomers might be fairly difficult.  
All resolvins are similar in the way that they contain a carboxylic acid, chiral centres, 
hydroxyl groups and a series of cis and trans double carbon-carbon bonds. A selection of 
the many routes usually employed for the production of specific alkenes are: Wittig, 
Horner-Wadsworth-Emmons, Julia olefinations etc. However, these reactions often 
suffer from lack of stereocontrol. If isomers are produced, they can be potentially very 
difficult to separate and there is an obvious loss in yield due to the production of discarded 
isomer. Reactions involving transition metals and prebuilt building blocks have the 
advantage that they are stereospecific and carry the stereochemistry is faithfully 
transferred to the products however, the building blocks and/or the intermediates tend to 
suffer from instability and/or toxicity.  
An alternative solution to this is the use of MIDA-boronates as building blocks which are 
stable and enable the transfer of complex multi-ene systems to the products of coupling 
reactions. In this type of synthesis, bifunctional haloboronic acid building blocks with all 
the required functional groups, oxidation states, stereochemical geometries can be joined 
together through the stereospecific Suzuki-Miyaura reaction in an iterative manner. The 
inspiration for this functional group and reaction route is from the way an FMOC (9-
fluoroenyl-methoxy carbonyl) group enables the precise assembly of amino acids. 
Similarly, the MIDA ligand prevents random oligomerization via a reversible attenuation 
of reactivity of the borane terminus. The MIDA ligand is also biodegradable, which is 
always a major advantage.  
 
44 
 
5. Project Aims  
Previous sections have already highlighted the importance of resolvin compounds and 
the need for an efficient route towards resolvin E1 so that it might be tested for its anti-
inflammatory properties. The initial aim of this project was to synthesise a fragment of 
the natural product with varying R-groups so that tests may be conducted to determine if 
this fragment holds any significant anti-inflammatory properties.  
 
Figure 19. Target compound [115] with varying R-groups. 
It is hoped that once the tests have been conducted with varying R-groups, a trend in 
biological data can be discovered so that a new series of fragments can be synthesised 
and tested. The following retrosynthetic route towards the series of compounds is 
summarized in scheme 23.  
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Scheme 23. Retrosynthetic route towards target compound [115]. 
Following on from the fragment synthesis, the next part of the project will be to embark 
upon the natural product synthesis of resolvin E1. The aim of this synthesis is to make 
the route as simple, efficient, and reproducible as possible. The retrosynthetic route 
towards the natural product is summarised in scheme 24.  
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Scheme 24. Retrosynthetic route towards resolvin E1. 
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As can be seen in scheme 24, it is hoped that the MIDA-boronate building block method 
can be utilised to increase efficiency in this synthesis. Two more fragments will be 
required for this synthesis, which are summarised in scheme 25.  
 
Scheme 25. Retrosynthetic route towards target compounds [125] and [127]. 
The use of a chiral pool starting material should provide two chiral centres in the natural 
product, leaving only one requiring a stereospecific reaction in order to produce the 
correct enantiomer. It is hoped that by enabling the synthesis of the two fragments from 
one enantiomerically pure compound [129], the efficient of the synthesis will be 
increased.  
In order to create one of the intermediate compounds [125], it will be essential to develop 
a new reaction with the MIDA boronate building block. So that this reaction can be tested 
a trial compound will be developed so that precious amounts of intermediate compounds 
towards resolvin E1 are not wasted during the testing process.  
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Scheme 26. Retrosynthetic route towards trial compound [130]. 
It is hoped that by carrying out this reaction, the natural product can be made in an 
efficient manner but that the scope of reactions for the MIDA boronates can be diversified 
enabling even more reactions to be possible with this exciting new functional group. 
The overall aim is that once the synthesis of resolvin E1 is complete, then it can be tested 
for its biological activities in parallel to the commercially available extracted resolvin E1 
extracted from natural sources. 
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6. Results and Discussion 
6.1 Resolvin E1 Fragment Synthesis 
The aim of the synthesis of the resolvin fragment was to make the synthesis as efficient 
yet flexible as possible, as it is essential that it is compatible with a range of different R-
groups for future testing. The following scheme outlines the proposed route and reagents 
for the complete synthesis.  
 
Scheme 27 Proposed scheme for the synthesis of the resolvin E1 fragments. 
The beginning of the synthesis began with a standard Friedel-Crafts reaction using 
commercially available and relatively inexpensive, acyl chloride [124] and TMS-
protected actylene [133].  
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Scheme 28. Friedel-Crafts reaction to TMS-protected alkyne.55 
This reaction can be found in literature using similar substrates, and after minor 
adjustments to temperature and reaction time, it was possible to increase the yield of this 
reaction from 42%-70%.56 The procedure involved the use of bis(trimethylsilyl 
acetylene), glutaric acid monomethyl ester chloride, and aluminium chloride in 
dichloromethane at -15°C for 3 hours. The workup involved a quench with saturated 
aqueous citric acid and ice, extraction with ether and wash with brine to give the crude 
product, a brown oil. This was purified by silica gel column chromatography to give the 
pure product as a pale, yellow oil. The reaction could be scaled up to around 8g per 
experiment, and the TMS-protected alkyne [133] could be stored for several weeks in the 
freezer without degrading.  
After successfully scaling this reaction up, from a 0.1g to 8g scale, the next aim was to 
asymmetrically reduce the ketone at carbon 5.  
 
Scheme 29. Asymmetric reduction of ketone. 
For the reduction of the ketone to the secondary alcohol, there are a few options to 
perform this racemically, for example sodium borohydride, or DIBAL-H, are all viable 
options. For the selective reduction to the S-alcohol, a more sophisticated reduction was 
required. In literature, there are various methods which explore the use of the Noyori 
catalyst and those which make use of the Alpine-Borane method.13,29,47,56–59 Despite this 
transformation being well documented in literature, this reaction proved very capricious. 
The reaction was repeated many times with varying conditions, the starting material was 
the only result from every experiment.  
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Scheme 30. Noyori asymmetric reduction catalytic cycle. 60 
This type of reaction is a hydrogenation transfer, where the metal hydride is responsible 
for the reduction of the ketone and usually either isopropanol or formic acid are used as 
the hydrogen donor. As can be seen in the catalytic cycle, the hydrogen donor generates 
a ruthenium hydride species. The hydride is transferred to the substrate via a bifunctional 
mechanism related to the one that operates for hydrogenation. This means that in certain 
conditions, the reaction can be reversible or irreversible - depending on the desired 
outcome. A reversible reaction is usually obtained in the presence of isopropanol and 
base, whereas the irreversible reaction is usually carried in a mixture of triethylamine and 
formic acid. The activity and selectivity of the catalysts can also be modified to suit 
different systems by altering the diamine backbone or the sulfonyl substituent. In this 
work, both the reversible and irreversible conditions were attempted but were 
unsuccessful. 
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The first of these reactions was carried out with isopropanol under anhydrous 
conditions.13 Unfortunately, there was no change by TLC or in the 1H NMR taken of the 
reaction. Furthermore, the 1H NMR suggested that no reaction had taken place at all and 
the starting material was the only substance detected. Several attempts were made with 
isopropanol under the same conditions but at different time lengths (2, 6 and 18 hours), 
but the same results were observed. The reaction was also attempted with sodium formate 
and CTABr in ethyl acetate, and again with formic acid and triethylamine under 
anhydrous conditions, however no reaction was seen again.61  
Another method was attempted to achieve the reduction of compound [118] to the S-
alcohol. Alpine borane was previously used on this specific compound, however, when 
carried out in this study, unfortunately, the desired compound was not observed.62 TLC 
analysis showed many spots after following the reaction procedure and these proved very 
difficult to separate.  
 
Scheme 31. Mechanism of Alpine borane reduction. 
Having considered this mechanism, the product arises through the selective placement of 
the sterically undemanding alkyne close to the methyl substituent in the boat transition 
state, and it is because of this that the ketone can be reduced to a secondary alcohol with 
reasonable enantioselectivity. This reaction may not have worked because the TMS group 
on the end of the alkyne may be sterically hindering it too much to be able to position 
itself with the methyl group on the alpine borane. Bearing this in mind, the reaction was 
attempted again using compound [145], deprotected with no TMS group. However, 
despite this the reaction still refused to proceed.  
After spending some time attempting to reduce the ketone asymmetrically it was decided 
that the compound would be carried forwards in its racemic form. It is unknown why the 
asymmetric reduction could not achieved, however, it is thought that perhaps the reaction 
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was not dry enough or that trace amounts of moisture or oxygen were causing these 
reactions to fail. 
 
Scheme 32. Reaction scheme for the synthesis of the racemic alcohol. 
The first reducing agent to be trialled was DIBAL-H. However, this resulted in a mixture 
of the lactone and the desired product. When the reaction was monitored by TLC analysis, 
it was found that there were consistently three spots, and this did not change for the 
duration of the experiment. The three spots were assumed to be a mixture of the starting 
material, the desired product and possibly the fully cyclised lactone. It was hypothesised 
that by using camphorsulfonic acid (CSA), the mixture may be persuaded to complete 
conversion to the lactone, bypassing the alcohol and converting any alcohol made 
previously to the lactone.63 The reaction conditions have been summarized in scheme 31.  
 
Scheme 33. Conversion of mixture of [136a] and [118] to lactone [141]. 
The mixture of reduced ketone and lactone was stirred at room temperature and 1.0 
equivalent of camphorsulfonic acid was added to the reaction and monitored by TLC. It 
was found that this reaction did not push the solution to the desired lactone. The reaction 
was eventually quenched and purification by silica gel column chromatography was 
attempted. However, the mixture proved very difficult to separate and only the starting 
material was isolated. The reaction was repeated at varying temperatures and lengths of 
time, the longest being 48 hours. However regardless of this, the outcome of the reaction 
was never the desired product but starting material. 
After ascertaining that DIBAL-H would not work as well as hoped, a different reducing 
agent was tested - lithium aluminium hydride. This was initially carried out with two 
equivalents of LiAlH4, in diethyl ether under anhydrous conditions with an acidic 
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workup. This led to the production of a mixture of products. The 1H NMR indicated that 
the desired hydroxyl had been produced due to the triplet at δ 4.20 ppm, but that the 
alkyne had also been reduced to the alkene indicated by the peaks at δ 5.00 ppm and 6.00 
ppm, respectively. It was apparent that the ester had also been reduced to an alcohol due 
to the smaller integration seen on the ester peak at δ 3.60 ppm. So, 1.5 equivalents were 
tested, under the same conditions, which also led to a mixture of products. Finally, 1.0 
equivalent was tested under the same conditions. This appeared to work but still showed 
an untidy 1H NMR and the yield was found to be a moderate 40%. 
After finding that the reaction with LiAlH4 was not reliable, sodium borohydride was 
trialled. This was met with better results than the previous reducing agents. It was 
attempted in 2.0 equivalents in ethanol at 0°C, followed by an acidic workup, and it was 
found that the desired product had been produced. Confirmed by diagnostic peak in the 
1H NMR spectrum at δ 4.20 ppm.  Unfortunately, it was quite low yielding (30%) with 
an untidy 1H NMR spectrum. After repeating this reaction with differing conditions 
(reaction length, temperature, reducing agent equivalents), it was found that whilst the 
reaction was reliable, giving similar results each time, the yield could not be improved 
upon. Building on this, the Luche reduction was attempted.64 Knowing that sodium 
borohydride worked well with this substrate, this was attempted in an effort to increase 
the overall yield.  
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Scheme 34. Mechanism of Luche reduction. 
The Luche reagent (CeCl3) acts as a selective Lewis acid for the methanolysis of sodium 
borohydride in this reaction, meaning that a harder reducing agent is produced as shown 
in scheme 34. Sodium methoxyborohydrides are harder reducing agents and therefore 
can affect a 1,2-reduction with higher selectivity. This reaction has been completed many 
times, beginning on a small scale of 1 mmol up to 15 mmol. Firstly, yields were quite 
modest achieving only 32% but once optimized, by altering reaction time and temperature 
produced the pure product in up to 76% isolated yield. This compound was characterised 
using 1H NMR analysis, and clearly showed the indicative triplet peak at δ 4.20 ppm 
which corresponds to the hydroxyl group being formed.  
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Upon completion of the reduction to the racemic alcohol, it was decided that the hydroxyl 
group should be protected to ensure it was not interfered with later in the synthesis. This 
was completed using TBDMS-Cl with imidazole in dichloromethane under anhydrous 
conditions.65  
 
Scheme 35. TBS protection of hydroxyl group. 
This reaction was initially tried and achieved yields up to 50% but after scaling it up from 
5 mmol to 11 mmol, we managed to increase the yield up to 80% after purification. The 
characteristic 1H NMR peaks at δ 0.08 ppm for the two methyl groups on the silicon and 
the peak at δ 0.8 ppm corresponding to the remaining three methyl groups on the TBS 
protecting group indicate that the reaction was successful. This reaction repeated to 
ensure that the method was optimised, varying reaction length, temperature etc. for this 
substrate and to ensure that there was enough product to continue using in the next stage 
of the synthesis.  
After the successful protection of the hydroxyl group, it was necessary to attempt to 
selectively remove the TMS group.62  
 
Scheme 36. Selective deprotection of TMS group. 
Caesium carbonate was the first base trialled for the selective deprotection and this was 
successful when carried out in methanol under anhydrous conditions but was completed 
in a modest yield of 30%. After a few unsuccessful experiments under varying conditions 
(room temperature, length of reaction, solvents), it was found that the conditions in 
scheme 37 were the optimum conditions for this reaction. The desired product [143] was 
obtained and distinguished by 1H NMR, the loss of the trimethyl proton peaks from the 
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TMS made it obvious if that experiment had been successful. To increase the yield and 
the reliability of the reaction, more bases were experimented with.  
 
 Scheme 37. Deprotection of alkyne. 
Table 2. Alkyne deprotection reactions. 
Entry Base Yield (%) 
1 K2CO3 21 
2 Cs2CO3 34 
3 KF 5 
Ultimately, the best results were those gained using the original conditions (30%). This 
was not an acceptable yield in a reasonably lengthy stepwise synthesis such as this so the 
route towards the final product was revisited and an alternate route planned.  
After previously seeing the best results with caesium carbonate this was the first method 
to be attempted. The same conditions were used as previously, and this gave an untidy 
1H NMR before purification indicating the loss of the TMS proton peak at δ 0.10 ppm. 
However, the yield was still fairly low at 34%. Potassium carbonate was also attempted 
however this produced unreliable and sometimes unreproducible results, it also gave a 
lower yield than caesium carbonate (21%). After deciding that this route was also not 
going to suffice, an alternate route was devised.  
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Scheme 38. New scheme towards compound [143]. 
This route worked far better than the previous method. Unfortunately, the initial step of 
removing the TMS group was still quite modest in yield (40%) but, the reaction was 
reliable, worked every time and could be easily purified by silica gel column 
chromatography. TBAF, K2CO3 and Cs2CO3 were all tested for this reaction in an attempt 
to improve the yield, however, the experiment with TBAF proved to be the most suitable, 
giving the highest yield and being reproducible every time.  
A trial experiment for the Sonogashira reaction was conducted to optimize the conditions 
for this key step in the synthesis.  
 
Scheme 39. Sonogashira coupling trial reaction. 
This method used a palladium source, PdCl2(PPh3)2, copper (I) iodide, and 
diisopropylamine, in THF, at 65°C under reflux to promote the coupling between the 
alkyne and iodobenzene. This reaction was successful by analysis of 1H NMR spectra. 
Of particular importance, were the aromatic peaks featured in the 1H and 13C NMR 
spectra and the loss of the terminal alkyne C-H peak at δ 3.00 ppm but unfortunately the 
yield was quite modest at 45%.  Considering this, it was thought that the hydroxyl group 
could be playing a part in the reaction and causing unwanted side products which would 
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explain the lower yield. So, the hydroxyl group was protected with TBS-Cl and the 
reaction trialled again.  
 
Scheme 40. Sonogashira trial with protected hydroxyl group. 
Unfortunately, the yield was not much improved in the protected version. It was decided 
that as the protected version did not improve the yield significantly, the unprotected 
compound [144] would be used for the Sonogashira couplings. The mechanism of action 
of the sonogashira coupling is outlined in figure 21.  
 
Scheme 41. Sonogashira coupling reaction mechanism. 
This mechanism shows the route of action of the Sonogashira reaction. This mechanism 
does not indicate anywhere that the unprotected hydroxyl group will have an effect on 
the reaction and this is also backed in literature, whereby similar compounds have been 
used without protection of hydroxy groups.66,67 However, this did not solve the problem 
of the poor yield so a series of reactions with varying conditions were trialled to attempt 
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to increase the yield. These experiments are summarized in table 3. All experiments were 
carried out using the same substrates as shown in scheme 39.  
Table 3. Summary of Sonogashira conditions trialled. 
Entry Solvent Setup Time (h) Temp. (°C) Yield (%) 
1 THF (a) 6 50 45 
2 THF (a) 6 50 45 
3 THF (b) 12 50 55 
4 THF (c) 18 50 55 
5 DMF (d) 12 60 55 
6 DMF (d) 18 70 70 
7 DMF (d) 18 80 80 
8 DMF (d) 24 80 80 
Reagents and conditions:     (a) Water reflux condenser, Ar bubbler. 
             (b) Air condenser, Ar balloon. 
             (c) Water reflux, N2 bubbler. 
             (d) Water reflux condenser, N2 bubbler. 
It was found that the optimum solvent for this reaction is DMF. Moderate results with 
THF were observed after leaving the reaction for a longer time, however, it was hoped 
that higher yields could be achieved. Using DMF, entries 5-8, along with an increase in 
temperature, worked well and an increase to a total of 80% yield was observed once the 
temperature had been brought up to 80°C. After optimising this important coupling 
reaction, it was used in the actual synthesis.  
 
Scheme 42. Sonogahira coupling reaction with iodobenzene. 
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This reaction proceeded better than anticipated with 91% yield. The reaction was carried 
out under the optimum conditions devised previously, to give a crude oil which was then 
purified by silica gel column chromatography to give the product as a yellow oil. The 
compound was characterised by 1H, important peaks were situated at δ 7.25 and 7.40 
ppm, respectively which were indicative of the aromatic protons.  
After the success of the first Sonogashira reaction, the following reactions were 
completed successively to form a series of alkyl fragments which were tested for their 
biological activities.  
 
Scheme 43. Sonogashira coupling of substrate and iodotoluene. 
 
Scheme 44. Sonogashira coupling of substrate and 4-tert-butyliodobenzene. 
The reactions in scheme 40 and 41 proceeded without any further modifications needed 
and the percentage yields were very pleasing. In the interest of compound stability, a 
short study was conducted using compound [149] to test how long compounds of this 
type could be stored before they began to degrade. Compound [149] was left in a sealed 
container (not flushed with inert gas) and placed in the freezer for six months, the proton 
NMR after this time was collected and compared with the original proton NMR, which 
showed no changes. This suggests that these fragment compounds can withstand storage 
for moderately long periods of time without degrading, this is useful knowledge to have 
if these compounds were to be presented for further biological testing.  
The remaining two fragments needed coupling partners which were not commercially 
available. To make the desired vinyl iodides it was decided that the Takai olefination 
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reaction would be employed. The first vinyl iodide coupling partner could be synthesised 
from benzaldehyde using the Takai olefination reaction. The advantage of these reactions 
is their generally high selectivity for the E-alkene, normally ratios are 4:1 (trans:cis).68 
 
Scheme 45. Takai olefination reaction.68 
The vinyl iodide was characterised by NMR spectroscopy, the 1H NMR showing two 
doublets for the alkene at δ 6.80 and 7.40 ppm and a multiplet at δ 7.30 ppm for the 
aromatic system. The proton peaks for the alkene protons gave a J-coupling value of 14.8 
Hz. It was also completed in a good yield, 81%. The reaction procedure involved 
dissolving chromium (II) chloride in THF at 0°C for 15 minutes before adding the 
iodoform and benzaldehyde dissolved in THF dropwise. The mixture was stirred for 10 
minutes at 0°C before being taken out of the ice bath and stirred at room temperature 
overnight. The reaction was quenched with water, extracted with diethyl ether, washed 
with sodium thiosulfate and brine. This gave the crude oil which was quickly purified on 
a short silica gel column to give the pure product as a pale, yellow oil. 
It was soon realised that this compound would degrade on a silica gel column if the 
column was too long or ran too slowly, it would also degrade if left in the freezer too 
long. The ideal use of this compound would be to use it the same day that it is made after 
having spent a couple of hours on the hi-vac to remove any trace solvents. It was hoped 
that the diene version of this compound could be synthesised using the same reaction.  
 
Scheme 46. Takai reaction of cinnamaldehyde. 
Unfortunately, this reaction did not work, the 1H NMR were inconclusive, such that it 
was not possible to confidently confirm if the reaction had occurred. Analysis by TLC 
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indicated a large mixture of compounds, six rather faded spots were on the TLC plate. In 
an attempt to understand why this reaction had not worked an NMR and TLC plate of the 
cinnamaldehyde bottle used was taken. This showed three spots on the TLC and it was 
clear on the NMR that despite the bottle claiming to be trans-cinnamaldehyde, there was 
a mixture of cis and trans. To try and rectify this, the cinnamaldehyde was purified by 
column chromatography using 100% petroleum ether. trans-Cinnamaldehyde was 
isolated and characterised by NMR, confirming that there was only one product in there. 
At this point the purified cinnamaldehyde was used in the Takei olefination, unfortunately 
the same inconclusive results were observed. Varying conditions were attempted to make 
this reaction work, temperature changes, order of adding chemicals to reaction mixture, 
length of reaction but they all ended with the same unfortunate result of no product. In 
order to explore why this would not work the mechanism of reaction is outlined in scheme 
47.  
 
Scheme 47. Takai olefination reaction mechanism.68 
The mechanism proposed by Takai suggests that chromium (II) is oxidised to chromium 
(III) when replacing two iodide atoms. The carbodianion complex then reacts at the back 
of the aldehyde carbonyl in a 1,2-addition type reaction forming an important 
intermediate shown in scheme 44. The chromium groups then engage in an elimination 
reaction, to form the trans-alkene. It is important to note that this geometry is due to the 
64 
 
steric bulks of the alkyl and halogen groups encouraging an anti-elimination reaction. In 
terms of using this reaction with cinnamaldehyde, it may not have worked because double 
bond adjacent to the aldehyde may be changing the reactivity of the carbonyl group 
meaning that the chromium complex was unable to attack. So, after discovering that it 
was not going to be possible to simply make this substrate, it was decided that it would 
be left until after the biological results had been conducted. If the results showed 
extremely promising activities for compound [156] then the substrate synthesis would be 
revisited.  
Meanwhile, compound [153] was used in the Sonogashira coupling reaction to create 
compound [156] 
 
Scheme 48. Sonogashira coupling to form compound [156]. 
This reaction proceeded with moderate yield (50%). Compound [156] was characterised 
by 1H NMR spectroscopy, key doublets were observed at δ 6.93 ppm and 6.15 ppm 
respectively, which indicated the formation of the double bond to the compound. The J-
coupling value of this double bond was 16.8 Hz, which suggested the formation of a trans 
double bond. This was a big indicator of the formation of the product, because the double 
bond protons in compound [153] looked very different by 1H NMR spectroscopy, 
forming one doublet at δ 6.86 ppm.  
The final stage of the synthetic route was the Lindlar hydrogenation reaction to reduce 
the triple bonds to cis-alkenes. A trial reaction was conducted firstly to ensure that 
conditions were optimum for these compounds.  
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Scheme 49. Lindlar hydrogenation trial reaction. 
Unfortunately, after carrying this out, it was found that a mixture of products was 
produced. The reaction was carried out using Pd/CaCO3/Pb (Lindlar catalyst) with 1.0 
equivalent of quinoline in anhydrous toluene under a hydrogen atmosphere. When the 
reaction had completed it was diluted with ethyl acetate and an acidic workup was 
conducted. After purification by column chromatography it was found that a mixture of 
cis:trans product was observed in a 1:1 ratio.  
In the hope of solely creating the cis-alkene differing conditions were tried, firstly it was 
attempted with differing equivalents of quinoline. With 1.0 and 2.0 equivalents of 
quinoline, there was a mixture of cis/trans alkene again. With no equivalents of 
quinoline, it was found that there was a mixture of cis/trans alkene (1:1 ratio), and also, 
there was evidence that alkyne [136a] was hydrogenated all the way down to an alkane 
due to additional peaks in the δ 1.00 ppm to 2.00 ppm region of the 1H NMR spectrum.  
It may be possible that the acidic workup used to remove the quinoline, may have been 
the reason for the loss of selectivity. So, instead of a 1M HCl workup, a 2M copper 
sulphate workup was used. This produced far better results than seen for the acidic 
workup, producing the cis-alkene selectively. It was via this method that the final 
fragments were created. These are summarized below in figure 20.  
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Figure 20. Products of Lindlar hydrogenation reactions. 
The yields of these reactions varied from 46-63%, however as this was the final stage of 
the synthesis, the reactions were not further optimised to increase yield. The priority was 
placed upon having enough product to conduct all characterisation and biological 
analyses, and fortunately, there was enough product produced in order to complete this 
for each fragment. As can be seen in figure 20, not all the alkyne fragments were 
hydrogenated to create cis-alkene products. The hydrogenation of alkyne [156] was not 
conducted due to the difficulty of making this compound. However, if the biological 
results came back suggesting that the alkene system was having a hugely positive effect 
on the anti-inflammatory activity, then this hydrogenation would have been revisited in 
order to gather further biological results.  
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Table 4. Summary of main compounds submitted for testing including percentage yields. 
Entry Compound Percentage Yield (%) Overall Reaction Yield (%) 
1 149 81 17 
2 150 80 17 
3 151 90 19 
4 156 50 12 
5 158 48 10 
6 159 46 10 
7 160 63 13 
 
 
Figure 21. Chemical structures of main compounds submitted for biological testing. 
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6.2 Biological Testing 
The series of fragments that were synthesised in chapter 6 were produced for the purpose 
of biological testing. It was the aim that this testing would indicate some form of 
structure-activity relationship and present more analogues with hopefully increasing 
biological effects. 
 
Figure 22. Structure of Resolvin E1, highlighting fragment synthesised for biological testing. 
This section of the compound was chosen to test due to the inclusion of the carboxylic 
acid and the cis-alkene double bond. It was hoped that this fragment would show 
promising biological results due to these functionalities and that by manipulating the R-
group, a trend in biological data could be established.  
The biological testing was carried out using skeletal muscle mouse cells by another 
member of the mini-CDT in the biology department. A detailed description of the method 
is outlined in the appendix. Inflammation was induced using LPS (lipopolysaccharide) 
which initiates the inflammatory response and then IL-6 gene expression was measured 
using an alamar assay (if the gene is expressed, then resazurin will fluoresce). This 
enabled a quantitative method for metabolic activity. This works because when pro-
inflammatory cytokines are produced, the IL-6 gene is expressed. The extent to which 
this is expressed can be measured using the assay. It was hoped that these compounds 
would reduce the IL-6 gene expression, as this would be indicative of a reduction in pro-
inflammatory cytokines being produced, which would be an anti-inflammatory response.  
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Figure 23. Summary of compounds submitted for biological testing. 
The initial testing would determine if the compounds were compatible with the assay. It 
was found that compounds containing a ketone functional group were not compatible due 
to causing cell death. These compounds caused cell death and evidence of this can be 
seen in figure 24.  
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Figure 24. Left image shows compound [145] at high dose, centre image is the control and right image is 
the low dose. 
The tube-like structures shown in the centre image are indicative of healthy cells. The 
image to the left shows that these structures have entirely broken down and the image to 
the right shows partial breakdown. These images show that compound [145] is having a 
negative effect on the cell culture and is killing the cells. The collapse of the tube-like 
structures is indicative of cell death. The similarity between the compounds which caused 
cell death is the presence of a ketone. Ketones can undergo Michael addition reactions 
and Michael acceptors are not compatible with biological systems due to causing cell 
death.69 
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Table 5. Biological results. 
 
These results show that the compounds containing a ketone functional group are not 
viable in the cell culture. The most interesting information that was gathered from the 
data is the trend that can be seen in compounds [149], [150], and [151]. Racemic 
compounds were tested with the intention that if any showed promising biological results 
they would be separated using chiral HPLC and tested again. 
In these compounds, there was an increase in the IL-6 gene expression as the compounds 
became more lipophilic, which meant that the anti-inflammatory effect is best in the least 
lipophilic compounds compared with the more lipophilic compounds. The compounds 
containing the cis-double bond also show the same trend as their triple bond counter-
parts. Interestingly, they show an overall decrease in activity in comparison with the triple 
bond compounds. This is an unexpected result as it was anticipated that the compounds 
would increase in activity the more similar in structure they became to the natural 
product. Despite this being an unexpected result, the structure-activity relationship is such 
that more lipophilic R-groups are potentially better anti-inflammatory agents. This means 
that more compounds could be created with this characteristic for further biological 
testing in an attempt to increase the biological activity and refine a fragment with 
significantly increased anti-inflammatory properties.  
 
Entry Compound Cell viability IL-6 gene expression 
1 136a Good No effect 
2 144 Good No effect 
3 149 Good 30% reduction 
4 150 Good 25% reduction 
5 151 Good 15% reduction 
6 156 Good 25% reduction 
7 158 Good 25% reduction 
8 159 Good 16% reduction 
9 160 Good 11% reduction 
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6.3 MIDA Boronate Epoxide ring opening 
MIDA-boronates have been shown to be useful building blocks in natural product 
syntheses. However, these are relatively new class of compounds and they still hold 
potential for further manipulation. It was hoped that a new reaction using MIDA 
boronates could be explored so that their scope could be expanded. Specifically, using 
the ethynyl MIDA boronate, it was hoped that it could be selectively deprotonated, and 
used as a nucleophile for an SN2 reaction.  
 
Scheme 50. Deprotonation of ethynyl MIDA-boronate ester, leading to epoxide ring opening reaction. 
It was hoped that the alkyne could be deprotonated using a non-nucleophillic base whilst 
leaving the MIDA protecting group intact, so that it could then ring open the epoxide and 
in the process, add an alkyne group onto the end of the molecule which could be readily 
removed using the iterative cross coupling method previously described in chapter 3. It 
was ultimately hoped that this reaction could be utilized in the synthesis of resolvin E1.  
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Scheme 51. Proposed utilization of epoxide ring opening reaction in natural product synthesis. 
By using the MIDA-boronate building block, the trans double bond at carbon 16 could 
be introduced, and also the triple bond included at the desired position at carbon 14. In 
order to test this reaction and optimise the conditions without wasting precious amounts 
of compound [166], it was proposed that a relatively simple to produce compound would 
be synthesised in order to test the reaction. The retrosynthetic scheme to producing this 
compound is outlined in scheme 52. 
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Scheme 52. Retrosynthetic route towards compound [130] showing use of new epoxide ring opening 
reaction. 
Scheme 52 shows how compound [130] would be produced. The aim was to use the 
protected version of D-Mannitol, which has fixed stereochemistry that can be transferred 
through the reaction sequence and retained through to the final compound [130]. The first 
reaction was to produce the protected version of D-Mannitol from D-Mannitol.  
 
Scheme 53. Synthesis of protected D-Mannitol. 
This reaction proceeded well after minor adjustments to the method, resulting in a 
pleasing 90% yield. This reaction was also very efficient as it did not require any 
purification. The only variation in the method to this reaction was to increase the 
temperature. The boiling point of acetone is 56°C, so initially this reaction was tested at 
55°C, however, unfortunately at this temperature the solution did not fully dissolve and 
therefore the reaction did not go to completion. A series of repeat reactions were trialled 
at increased external temperatures, 60°C, 70°C and 80°C. The findings of these reactions 
are summarized in table 6.  
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Table 6. D-Mannitol protection reaction conditions summary. 
Reaction Time (h) Temp. (°C) Percentage Yield (%) 
1 24 24 25 
2 24 55 30 
3 24 60 55 
4 5 70 60 
5 18 70 75 
6 5 80 80 
7 1 80 80 
This reaction has been conducted previously, however it is carried out at room 
temperature.70 In this study, the reaction at room temperature resulted in a very low yield 
regardless of reaction time. The product to this reaction was confirmed and characterised 
by NMR spectroscopy. The characteristic peaks were observed by 1H NMR spectroscopy 
at approximately δ 1.30 ppm and 1.40 ppm respectively, these peaks were indicative of 
the methyl groups on the acetonide protecting group and the integrations of these peaks 
suggested that the reaction had gone to completion. This was coupled with the fact that 
only one spot was observed on a TLC plate. Using this compound as a starting material 
was very useful because it had fixed stereochemistry which could hopefully be 
transferred through the synthetic route. It is also useful because D-Mannitol is 
commercially available, and relatively inexpensive.  
After optimising the conditions for D-mannitol, the next reaction involved using sodium 
periodate to produce aldehyde [169].71 
 
Scheme 54. Synthesis of aldehyde [169]. 
This reaction proceeded well without any modifications required. This reaction gave a 
very pleasing 90% yield, which was deemed sufficient for use in this step-wise synthesis. 
The formation of the aldehyde was confirmed by 1H NMR analysis by the characteristic 
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peak at δ 9.60ppm which is indicative of the aldehyde proton. It is further indicated by 
the loss of the doublet of doublets at δ 3.70 ppm. The specific rotation of aldehyde [169] 
was recorded and found to be [α]D
20 = +56.94 (c 1.0, CH2Cl2).
71 
Following the assurance of the retainment of the stereochemistry, the next step in the 
synthesis required the introduction of the trans double bond. This was achieved using a 
Wittig reaction as the aldehyde was set in position for this transformation.  
 
Scheme 55. Wittig reaction. 
The Wittig reaction allows for the preparation of an alkene by the reaction of an aldehyde 
with the ylide generated from a phosphonium salt. This reaction is very reliable and is 
used to create stereospecific carbon-carbon double bonds. The driving force of the 
reaction is the production of triphenylphosphine oxide as the phosphorus-oxygen bond is 
very strong and the geometry of the resulting alkene depends on the reactivity of the 
ylide. The cis alkene is favoured with an unstabilised phosphonium ylid. However, a 
trans alkene is formed by stabilised ylides whereby the substituents on the carbon are 
conjugating or anion stabilising and it is this geometry that is required for alkene [168]. 
The initial yield of this reaction was a modest 40%, however, after adjusting the reaction 
setup, the yield was increased to a moderate 62%.  
Unfortunately, the stereoselectivity of this reaction was not as pleasing, a mixture of 
cis:trans was observed in a 1:3 ratio.  Furthermore, it was not possible to separate these 
isomers. The trans isomer was confirmed as the major isomer due to the calculated J-
coupling values. The major peaks have a J-coupling value of 11.6 Hz and the minor peaks 
have a J-coupling value of 7.6 Hz. It is typical of trans-alkenes to have a greater J-
coupling value than cis-alkenes. The formation of the alkene was confirmed by 1H NMR, 
specifically by the peaks at; δ 5.70 ppm and 6.70 ppm resectively, and the loss of the peak 
at 9.60 ppm, suggesting the loss of the aldehyde proton. The optical rotation of this 
compound was recorded and found to be [α]D
20 = +36.42 (c 1.0, CH2Cl2).
72  
77 
 
The next reaction was the deprotection of the acetonide to yield the diol. This was 
acheived using 2M HCl. The yield of this reaction was a moderate 62% after purification.  
 
Scheme 56. Deprotection of acetonide. 
This reaction was initially produced a modest yield of 40%. However, after modifying 
the setup of the reaction and increasing the reaction time, the yield was increased to a 
more adequate 62%. The formation of the diol was confirmed by 1H NMR spectroscopy, 
specifically by the loss of the methyl peaks at δ 1.40 ppm. It was also possible to confirm 
that the trans double bond was isolated in diol [132], The shift of the split peaks for carbon 
1 suggests that the environments around these protons has been transformed. The specific 
rotation of this compound was recorded as [α]D
20 = +47.68 (c 1.0, CH2Cl2).
73  
After confirming the retainment of the stereochemistry, the next step of the synthesis was 
to prepare the compound for ring closing to form the epoxide. This was achieved by 
introducing a tosylate group selectively onto the primary alcohol.  
 
Scheme 57. Tosylation of primary alcohol. 
This reaction proceeded without any significant issues and after purification gave a 
moderate 53% yield. This was a satisfactory outcome and so therefore, the procedure was 
not optimised any further. The production of compound [171] was confirmed by 1H NMR 
analysis, specifically by the multiplet of peaks at δ 7.70 ppm indicating the aromatic 
protons of the tosylate group. The specific rotation of this compound was obtained and 
found to be [132], [α]D
20 = +38.52 (c 1.0, CH2Cl2). Unfortunately, there are no literature 
values to compare this with, however the specific rotation has the same sign as the 
previous compounds in this synthesis. Whilst this does not definitively mean that the 
stereochemistry has been retained, it does suggest that it has.  
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The next step in the synthesis was to ring close to the epoxide. This was attempted using 
1M sodium hydroxide in diethyl ether creating an ethereal solution and this reaction was 
successful.  
 
Scheme 58. Epoxide ring closing reaction. 
This reaction proceeded well and yielded a very pleasing 88% of epoxide [131]. The pure 
product was characterised by indicative peaks in the 1H NMR spectrum at δ 2.77 ppm 
and 3.07 ppm, which corresponded to protons attached to carbon 1 in compound [131]. 
The full conversion of the tosylate to the epoxide was confirmed by the loss of 1H NMR 
peaks at δ 4.01 ppm and 4.10 ppm, which were indicative of protons at position 1 in 
compound [171]. The specific rotation value was found to be, [α]D
20  = +43.34 (c 1.0, 
CH2Cl2). Unfortunately, there were no literature values for this compound, but the 
specific rotation sign was retained from the previous compound. This does not 
definitively mean that the stereochemistry was retained but it does suggest so. The likely 
confirmation of the stereochemistry at this stage indicated that it was possible to retain 
the stereochemistry of the D-Mannitol starting material through to the final product of 
the six-step synthesis. While knowledge of this is not hugely advantageous in this 
circumstance, it is important to bear in mind that resolvin E1 contains three stereocentres, 
and reagents and specific reactions which make the formation of these stereocentres 
easier is always an advantage.  
After successfully characterising compound [131], it was time to begin testing the 
epoxide ring opening reaction with ethynyl MIDA-boronate ester. To begin determining 
a set of conditions to use, a similar reaction was researched, so that inspiration might be 
gained from this.  
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Scheme 59. Simplified epoxide ring opening reaction. 
The reaction in scheme 59 has been found in other publications, with very similar 
conditions.74–78  
Table 7. Summary of literature reactions of scheme 55. 
Entry Reference Base (eq.) Lewis Acid (eq) Yield (%) 
1 74 1.1 1.2 81 
2 75 1.1 1.2 78 
3 76 1.1 1.2 81 
4 77 1.0 1.2 81 
5 78 1.0 1.1 71 
Reagents and conditions:  
All reactions were carried out using n-BuLi as the base, BF3.OEt2 as the Lewis acid and 
1.5 eq. of epoxide [172]. Freshly distilled anhydrous THF was used as the solvent for 
every reaction. Each reaction began by stirring the base and alkyne [171] at -78°C for 1 
hour. This was followed by the addition of epoxide [172] and continued stirring at -78°C 
for 3 hours.  
Table 7 summarizes the findings of this research, it was found that in these substrates, 
the most commonly used base was butyl lithium to deprotonate the acetylene proton. 
Following the deprotonation, boron trifluoride diethyl etherate was used as a Lewis acid 
to facilitate the opening of the epoxide ring. After some time, the epoxide was added and 
compound [173] was formed. The reactions in the literature above show excellent yields 
and the repeated use of the same conditions suggest that this reaction is very reliable.  
The MIDA-boronate system is obviously more complex than the benzyl group. In the 
MIDA-boronate there are formally two B-O covalent bonds, and also a dative bond which 
forms from donation from the basic lone pair on the nitrogen to the boron atom. This 
donation hybridises boron from sp2 to sp3 while weakening the B-O bond and forcing the 
tetrahedron geometry observed.79 Furthermore, with regards to the intended epoxide-ring 
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opening reaction, it was important to ensure that a non-nucleophilic base was selected 
which would not interfere with the integrity of the MIDA-functionality.80,81 
 
Scheme 60. Trial experiment for epoxide ring opening reaction. 
This reaction was trialled multiple times, unfortunately, with no promising results. The 
first experiment to be trialled used conditions based on the research summarized in table 
7. The first step of this reaction was to dissolve 1.0 equivalent of MIDA-boronate [98] in 
anhydrous THF. This is where the first potential issue was encountered because [98] 
would not dissolve in THF. The solution was cooled to -78°C and 1.0 equivalent of n-
BuLi was added; this was stirred for 30 minutes. The reduced time was chosen because 
in MIDA-boronate compound [98], the ester groups are susceptible to base catalysed 
hydrolysis, it is widely known that MIDA-boronate esters are hydrolysed in the presence 
of aqueous base.79 After 30 minutes, 1.0 equivalent of the Lewis acid BF3.OEt2 was 
added, this was stirred for five minutes before adding 1.0 equivalent of epoxide [131] in 
anhydrous THF. An attempt to monitor the reaction by TLC was then conducted at this 
point, however this was quite difficult because there were five spots and there was no 
way of telling which of the additional spots were undesired side products or the desired 
product.  
The experiment was quenched with saturated ammonium chloride, extracted with ethyl 
acetate, and washed with brine. A crude 1H NMR spectrum was gathered which indicated 
a mixture of compounds. The separation of compounds was attempted using silica gel 
column chromatography, however, none of the isolated compounds were identifiable as 
the desired product, or indeed as compounds of any interest. The distinctive MIDA-
boronate ester peaks at δ 3.80 ppm and 3.95 ppm were missing from all the isolated 
compounds which suggests that MIDA-boronate [98] was being hydrolysed. The 
experiment was repeated a further five times using epoxide [131], the conditions of these 
repeats are summarized in table 8.  
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Table 8. Summary of conditions of experiments trialled for reaction in scheme 60. 
Entry Solvent Base Time (h) Temp. (°C) Results 
1 THF n-BuLi  1 -78 Unsuccessful 
2 THF n-BuLi  2 -78 Unsuccessful 
3 THF LDA  5 -78 Unsuccessful 
4 DMF n-BuLi  1 -40 Unsuccessful 
5 DMF LDA 3 -40 Unsuccessful 
 
Reagents and Conditions: 
All reactions were carried out under a nitrogen atmosphere. 1.0 equivalent of MIDA-
boronate and 1.0 equivalent of epoxide were used in every reaction. 1.0 equivalent of 
base was used in every entry except entry 2 which was 2.0 equivalents. Lewis acid used 
was 1.2 equivalents of BF3.OEt2. Workup conditions were, saturated aqueous NH4Cl 
quench, ethyl acetate extraction, brine wash.  
After conducting these series of experiments, there were no positive results and therefore, 
it was decided that a more thorough investigation of this reaction needed to be conducted. 
This would save time making epoxide [131] by a step-wise synthesis. It was decided that 
in order to do this, a simpler epoxide would be trialled, racemic styrene oxide was chosen 
to be used for these reactions.  
 
Scheme 61. Simpler epoxide ring opening experiment. 
Styrene oxide was chosen for these trials because it was a simple epoxide which was 
commercially available and relatively cheap to purchase. The method of reaction was the 
same as previously tested but the reagents were varied, these are summarized in table 9.  
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Table 9. Summary of experiments using styrene oxide [174]. 
Entry Epoxide (eq.) Base (eq.) Lewis acid (eq.) Time (h) Results 
1 1.0 n-BuLi 1.0 1.0 1 Unsuccessful 
2 1.0 n-BuLi 2.0 1.5 2 Unsuccessful 
3 1.5 n-BuLi 1.0 1.0 5 Unsuccessful 
4 1.5 n-BuLi 1.2 1.5 1 Unsuccessful 
5 1.5 LDA 1.2 1.5 3 Unsuccessful 
6 1.5 LDA 1.0 1.0 3 Unsuccessful 
7 1.5 LDA 1.2 1.5 3 Unsuccessful 
 
Reagents and Conditions:  
The solvent in all entries was freshly distilled, anhydrous THF. The Lewis acid used in 
all entries was BF3.OEt2. The workup conditions used in each entry was saturated aqueous 
ammonium chloride quench, ethyl acetate extraction, and brine wash. One equivalent of 
MIDA-boronate was used in every entry. All entries were carried out at -78°C and under 
an inert atmosphere (either argon or nitrogen).  DMPU (1 cm3) was used in entries 5-7.  
Unfortunately, these series of experiments did not yield any promising results. This was 
evident in the 1H NMR spectra, the loss of the peaks at δ 3.80 and 3.95 ppm were 
indicative of the hydrolysis of the MIDA- group. The strong peaks which were observed 
in many of the spectra at δ 2.78 ppm and 3.07 ppm respectively, corresponded to epoxide 
protons, which suggested that much of the epoxide was not reacting. To begin solving 
the problem of the MIDA-group hydrolysing, a more appropriate base must be found for 
this system. n-BuLi is appropriate for compound [171] which only contains an aromatic 
group, however the MIDA-group is more complicated and includes ester protons which 
are susceptible to attack by base. Another problem is that the boron could be susceptible 
to nucleophilic attack, it is due to this reason that non-nucleophilic, bulky bases were 
trialled specifically for the MIDA-boronate.  
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Figure 25. MIDA-Boronate with predicted pKa values for acidic protons.82 
The pKa of the ester and acetylene protons are particularly important when choosing the 
correct base to selectively deprotonate acetylene proton [1]. The pKa values stated here 
were predicted using pKa predicting software, this software has been cited and while 
results may not be completely accurate, it provides an estimate which can be used to 
judge which base should be used.82,83 Unfortunately, this prediction suggested that the 
acetylene and ester protons have very similar pKa values, this makes choosing a base 
more difficult. However, it was hoped that ester hydrolysis would occur more slowly than 
acetylene deprotonation.  
Table 10. Summary of commonly used strong non-nucleophilic bases. 
Base pKa 
t-BuLi 53 
n-BuLi 50 
LDA 36 
NaH 35 
NaHMDS 26 
LiHMDS 26 
Of the bases shown in table 9, the most suitable are either NaHMDS or LiHMDS. These 
both have a suitable pKa for the deprotonation of the acetylene proton and due to their 
steric bulk, they are both less nucleophilic and therefore less likely to hydrolyse the esters. 
In order to ensure that MIDA-boronate [98] was deprotonated in the correct position, a 
series of quench studies were conducted. Initially these were conducted using deuterium 
oxide however, after using up the labs supply, simple alkyl iodide compounds were used. 
The use of DMPU was to encourage MIDA-boronate [98] to dissolve in THF, however 
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it was very difficult to remove DMPU from the reaction mixture and therefore would be 
the dominant compound observed in 1H NMR spectra. This made it difficult to determine 
the products of reactions, so after attempting to remove DMPU from reaction mixtures, 
it was eventually omitted from experiments.  
The findings of these quench studies are summarised in table 11. 
Table 11. Summary of quench study experiments. 
Entry Substrate Base Base eq. Result 
1 D2O  n-BuLi  1.2 Unsuccessful 
2 D2O  n-BuLi  1.2 Unsuccessful 
3 D2O  NaHMDS  1.2 Unsuccessful 
4 D2O  NaHMDS  1.2 Unsuccessful 
5 CH3I  LDA  1.0 Unsuccessful 
6 CH3I  LDA  1.0 Unsuccessful 
7 CH3I  NaHMDS  1.0 Unsuccessful 
8 CH3I  NaHMDS  1.0 Unsuccessful 
9 CH3I  NaHMDS  1.0 Unsuccessful 
10 EtI  NaH  1.0 Unsuccessful 
11 EtI  NaH  2.0 Unsuccessful 
12 EtI  NaHMDS  1.0 Product observed in crude 
1H NMR 
but could not isolate 
13 EtI  NaHMDS  2.0 Product observed in crude 
1H NMR 
but could not isolate 
14 EtI  NaHMDS  1.0 2% yield but not reproducible 
Reagents and conditions:  
All entries were carried out in freshly distilled anhydrous THF and used one equivalent 
of MIDA-Boronate [98]. Reactions ran for one hour, under an inert argon atmosphere 
and at -78°C. The entries had workup conditions of ethyl acetate extraction, and brine 
wash. Entries 1-8 were quenched with saturated aqueous ammonium chloride and entries 
9-14 were quenched with distilled water. DMPU was included in entries 2,4,6,8-11. 
Substrates were used in 1.0 equivalents for entries 1-10, and 12. Substrates in entries 11, 
and 13 were 1.5 equivalents and entry 14 in 2.0 equivalents. 
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Analysis by 1H NMR suggested the desired product was observed in entry 14, to produce 
these results, two equivalents of ethyl iodide, and one equivalent of NaHMDS were 
required. It was important during this reaction to time how long the base and MIDA-
boronate [98] were reacted together as this had an effect on the selective deprotonation 
of the acetylene proton. It was also suspected that the saturated aqueous ammonium 
chloride quench may have been the cause of the MIDA group hydrolysis, despite 
literature claiming MIDA-boronates to be compatible with this common workup 
reagent.81  
 
Figure 26. Structure of product [176] from quench reactions. 
 Unfortunately, the low yield of this reaction meant that full characterisation was not 
possible however characteristic peaks which strongly suggest the formation of compound 
[176] was successful. The retention of the important peaks in the 1H NMR at δ 3.86 ppm 
and 3.98 ppm were indicative that the MIDA-group remained intact and peaks at δ 1.90 
ppm and 2.45 ppm were thought to correspond to the ethyl group.  
Following characterisation by 1H NMR, the 13C NMR spectrum was collected. The low 
yield of this reaction meant that it was not possible to confirm the presence of the 
important ethyl peaks. It was hoped that this reaction could be repeated on a larger scale 
and the data collected again but despite repeating this reaction several times using the 
same conditions. However unfortunately, the reaction was not reproducible. So, whilst 
the data collected thus strongly suggests the formation of the desired product, it cannot 
be confidently confirmed because it was not possible to repeat. Despite this, it presents 
an interesting area to explore in future. If it was possible to develop a procedure to carry 
out this type of reaction reliably and in good yield, then the scope of MIDA-boronate 
building blocks would be increased significantly. They would no longer be limited by 
coupling reactions alone.  
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6.4 Resolvin E1 Natural Product Substrate Synthesis 
In order to complete the synthesis of resolvin E1, two substrates were required. As seen 
previously in chapter 2, it is more efficient if stereocentres can be introduced at this stage 
so that there is no need for asymmetric reactions. It was hoped that the two substrates 
required for the synthesis of resolvin E1 could be created using much of the chemistry 
already established in this work so far. The following scheme outlines the methods used 
to produce the required substrates. The advantages of being able to make both substrates 
from the same reaction series was invaluable. It reduced the time spent synthesising 
compounds, it also saved cost in resources and it was especially useful to create both 
enantiomeric centres with no additional reactions which would have undoubtedly 
required optimisation.  
 
Scheme 62. Natural product substrate synthesis – proposed scheme. 
It was decided that this would be the most efficient way of forming vinyl iodide [178] 
due to previous optimisations of these reactions. There is another route towards 
compound [178] that can be found in literature however the starting material is expensive 
in comparison to D-mannitol.29 
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Scheme 63. Synthetic route towards compound [178] found in literature.29 
This synthetic route is six steps long and results in vinyl iodide [178], similarly the route 
proposed in this project was six steps long (four shown of these steps shown in scheme 
63), however the main advantage is that D-mannitol is substantially cheaper than S-
glycidol. (According to Sigma Aldrich, D-mannitol (100g) is £18.50, and S-glycidol (5g) 
is £72.80). 
 The proposed route outlined in scheme 62, utilises D-mannitol as a starting material. 
This synthetic route was devised to be similar to the synthetic route towards epoxide 
[131] in chapter 6.3 so that many of the same reactions could be used again. The synthesis 
of this and optimisation of the method is outlined in chapter 6.3. Following the protection 
of D-mannitol, the aldehyde was produced using sodium periodate, also covered in 
chapter 6.3. The next step involved making use of the Takai olefination reaction, whereby 
the aldehyde is converted to a vinyl iodide using chromium (II) chloride.  
 
Scheme 64. Takai Olefination reaction. 
The Takai reaction shown in scheme 59 was conducted under the same conditions as 
benzaldehyde to form vinyl iodide [128] in chapter 6.1. Aldehyde [169] did not require 
any modifications to these conditions to form compound [128] in a good yield of 80%. 
The production of vinyl iodide [128] was confirmed by 1H NMR analysis. Characteristic 
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peaks were observed between δ 6.41-6.56 ppm which corresponded to the double carbon-
carbon bond. Unfortunately, a J-coupling value could not be obtained to test the E:Z 
selectivity because there were more peaks here than expected. It was generally found that 
for the vinyl iodide compounds, the peaks for the double bonds were not clear and 
contained overlapping. However, this reaction was used to successfully produce the trans 
isomer selectively previously in the project. This does not necessarily mean that this 
product has the same selectivity as previous compounds, but it does suggest that 
selectivity for the trans isomer should be fairly, reliable. Previous specific rotation data 
was collected by dissolving compounds in CH2Cl2 however, these vinyl iodide 
compounds do not dissolve very well in dichloromethane, so ethanol was used. The 
observed value was [α]D
20 -7.34 (c 1.0, EtOH).84 
Following the formation of the vinyl iodide, the acetonide needed to be cleaved to give a 
diol.  
 
Scheme 65. Acid catalysed diol formation. 
The formation of the diol proceeded without any need for method modification. The 1H 
NMR spectrum from this experiment suggested that a cis:trans ratio of 1:4 was present, 
this was gathered by comparing the alkene protons. An attempt to separate these isomers 
was made but unfortunately, it was found that the vinyl iodide compounds in this series 
tend to degrade on a silica gel column. So, the ratio of isomers was deemed sufficient for 
use as the first substrate in the natural product synthesis and sufficient for carrying 
forwards to make substrate II. The specific rotation value was found to be [α]D
20 -8.48 (c 
1.0, EtOH). The sign of specific rotation was retained from the starting material which 
suggests the retention of the chiral centre.  
The next step of this synthesis was to add a tosylate group to the terminal alcohol. This 
was achieved using the same conditions outlined in chapter 6.3 on compound [132].  
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Scheme 66. Tosylation reaction. 
This reaction proceeded fairly well, without any modifications to the previously used 
method, giving a modest yield of 46%. The specific rotation was analysed, and it was 
found to be [α]D
20 -15.82 (c 1.0, EtOH). The characterisation of this compound was 
confirmed by 1H NMR analysis. Specific peaks which indicated the successful formation 
of this product were found in the 1H NMR spectra between δ 7.63-7.76 ppm for the 
aromatic ring and a large singlet at δ 2.39 ppm which corresponded to the methyl group 
of the tosylate group. The E:Z ratio was difficult to determine because the peaks were 
overlapping making it difficult to obtain J-coupling values.  
The next reaction was the formation of the epoxide ring.  
 
Scheme 67. Ring closing to form epoxide [126]. 
 Unfortunately, this reaction did not proceed as planned. To begin, the same conditions 
were attempted as used previously on compound [171] to form epoxide [131]. However, 
it was found that whilst these conditions worked to a certain extent, they did not provide 
complete conversion of the tosylate to the epoxide. 
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Figure 27. 1H NMR for mixture after reaction shown in scheme 67. 
 By comparing the 1H NMR spectra peaks for protons found at carbon 1 and carbon 5 and 
carbon 2 and carbon 6, it was possible to deduce from the integrations of these peaks that 
around a 50% conversion was taking place.  
 
Figure 29. Compound [177] and compound [126] including carbon numbers. 
The epoxide peaks are clearly visible at δ 2.69 ppm and 2.95 ppm respectively in the 1H 
NMR spectrum. However, the dominant peaks are visible for the protons at carbon 1 at δ 
3.99 and 4.01 ppm respectively. This suggests that there has been partial conversion to 
the epoxide. After discovering that separating these compounds by silica gel column 
chromatography would not be an option due to compound degradation, a series of trials 
were conducted to attempt to push the reaction to completion.  
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Table 11. Summary of ring closing to epoxide conditions trialled. 
Entry Solvent Base 
Base 
equivalents 
Time (h) Result 
1 Diethyl Ether NaOH (2M) 5.0 18 No completion 
2 Ethyl acetate KOH (2M) 2.0 18 No completion 
3 Diethyl Ether NaOH (5M) 5.0 18 No completion 
4 THF (anhydrous) NaH 1.0 18 No completion 
5 THF (anhydrous) NaH 2.0 18 No completion 
6 CH2Cl2/ MeOH K2CO3 1.0 0.5 No completion 
7 THF (anhydrous) NaH 5.0 0.5 No completion 
Reagents and Conditions:  
All entries had a workup which included a diethyl ether or ethyl acetate extraction, and a 
saturated aqueous ammonium chloride or brine wash. All entries were carries out at room 
temperature (20°C), except for entries 4,5 and 7 which began at 0°C before being allowed 
to warm up to room temperature. Sodium and potassium hydroxide were used as aqueous 
solutions. 
The conditions trialled for this reaction were chosen due to being commonly used 
procedures in literature for epoxide ring closing reactions.85–89 The varying solvents were 
trialled because it proved difficult for compound [177] to fully dissolve into a suitable 
solvent for the reaction. Unfortunately, varying the conditions and the workup procedures 
had little effect on the conversion of the tosylate to the epoxide.  
Whilst trialling conditions for the ring closing epoxide reaction, the next step in this 
synthesis towards substrate II was using methyl magnesium bromide and copper iodide 
to ring open and form compound [179].  
 
Scheme 68. Epoxide ring opening to form compound [179].90 
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This reaction proceeded well and produced compound [179] in a good yield of 75%. This 
method involves using methylmagnesium bromide and copper (I) iodide to facilitate the 
ring opening of the epoxide. The product was characterised by 1H NMR by the peaks at 
δ 0.90 and 1.79 ppm respectively, which correspond to the ethyl group. Another large 
indicator of the success of the reaction was the loss of the epoxide 1H NMR peaks at 
approximately δ 3.00 ppm. The success of this reaction meant if it was possible to form 
epoxide [126], then it was hoped that this method would successfully form one of the 
final compounds in the synthetic route, compound [120].  
After discovering that the method outlined in scheme 68 was successful with styrene 
oxide, it was decided that it would be attempted with the mixture of tosylate [177] and 
epoxide [126]. It was hoped that it would be possible to convert the epoxide in the mixture 
and then isolate compound [178] using column chromatography. However, after trying 
this, it was found that there were several spots observed in the TLC analysis and these 
also proved very difficult to separate. This meant that it was not possible to isolate 
compound [178] successfully from the mixture. It was difficult to determine if the desired 
compound had been formed at all. So, with this in mind, it was decided that rather than 
spend time attempting to optimise these reactions, one of the previously synthesised vinyl 
iodide compounds would be used as coupling partner for the natural product synthesis. 
Options for coupling partners are shown below in figure 31.  
 
Figure 28. Potential compounds for coupling reaction in natural product synthesis. 
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6.5 Resolvin E1 Natural Product Synthesis 
The synthesis of resolvin E1 has been achieved previously, and these syntheses were 
reviewed in chapter 2.1. The synthetic route proposed for resolvin E1 utilizes MIDA-
boronates as versatile building blocks. However, after determining that it would not be 
possible to ring-open the epoxide using acetylide MIDA-boronate [98] another route had 
to be devised to open the epoxide ring and form the acetylene. The reaction was first 
tested using styrene oxide.  
 
Scheme 69. Trial epoxide ring opening reaction.88 
This reaction was successful and produced alkyne [180] in a good 76% yield. Alkyne 
[180] was characterised by 1H NMR spectroscopy; key peaks were observed at δ 2.06 
ppm and 4.83 ppm respectively, which corresponded to protons at position 3 and 1 
respectively (in red). It was also confirmed by 13C NMR spectroscopy, peaks indicating 
the formation of alkyne carbons at position 1 and 2 (in blue) were observed at δ 71.10 
ppm and 80.89 ppm respectively. Another key indicator was the IR spectrum which gave 
a distinctive peak at 2119.52 cm-1 for the alkyne carbon triple bond and the peak at 3292 
cm-1 which indicated the C-H bond from the alkyne.  
 
Figure 29. Lithium acetylide - ethylene diamine complex [181]. 
Following the success of this trial experiment, it was decided that this would be a suitable 
method for use in the natural product synthesis. This method would replace the route 
using ethynyl MIDA-boronate [98] to ring open the epoxide and form the important 
alkyne so that the product is ready to be used for a Sonogashira coupling.  
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The route towards resolvin E1 natural product involved continuing the synthetic route 
towards the RvE1 fragments developed in chapter 6.1. However, due to the desire to make 
sure that the natural product did not have any racemic stereocentres, efforts to reduce the 
ketone in compound [118] was revisited.  
 
Scheme 70. Asymmetric reduction of ketone. 
After repeating many of the same conditions outlined in chapter 6.1 for this reaction, the 
same results as before were observed – no reaction. It was decided that the catalyst would 
be prepared separately before adding to the alkyne [118]. It was by using this method that 
positive results were first observed.  
The first reaction saw a very low percentage of conversion to the alcohol (10%) after 48 
hours. The reaction progress was monitored by TLC. The ketone starting material [118] 
was a very strong green spot with an Rf value of 0.7 and the desired alcohol product [136] 
gave a distinctive blue spot with an Rf value of 0.6. The coloured spots were observed 
using a vanillin dip. This was an enormous improvement on previous attempts which 
yielded no alcohol whatsoever but was not sufficient to make this method suitable for use 
in the natural product synthesis. In an attempt to increase the yield, the reaction time was 
increased from 48 hours to 3 days (over weekend) and also to a full week. However, this 
had no significant effect on the yield.  
The temperature was the next variable to be assessed, as the reactions at room temperature 
had yielded very little alcohol. The first temperature to be trialled was 40°C, this reaction 
was also monitored by TLC until no further change was observed. The yield at 40°C was 
not significantly different from the reaction at room temperature. The temperature of 
these reactions was then increased by 10°C for each trial and monitored by TLC. The 
results of these experiments are summarised in table 12.  
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Table 12. Summary of reaction temperatures effect on product yield for scheme 70 (compound [136]). 
Entry Temperature (°C) Yield of alcohol (%) 
1 40 15 
2 50 25 
3 60 50 
4 70 75 
5 80 95 
As table 12 highlights, increasing the temperature to 80°C had a significant effect on the 
percentage yield. The temperature also affected the reaction time; entry 3, 4 and 5 were 
monitored for 3 days each before quenching to ensure that the reaction had converted as 
much of the ketone to the alcohol as possible. However, it was possible to observe by 
TLC, that the reactions were reaching their endpoints faster than they were previously, at 
room temperature. It was found that at 80°C, the reaction showed no trace of ketone by 
TLC after an hour of stirring at this temperature. So, increasing the temperature had a 
positive effect on the yield of the reaction and on the reaction time. After optimising this 
reaction, the specific rotation of this reaction was gathered, however as there are currently 
no literature values for this compound, Mosher ester analysis was performed to confirm 
the R/S arrangement of the chiral centre.  
 
Scheme 71. Mosher ester reactions. 
Mosher ester analysis relies on the fact that the protons in diastereomeric α-methoxy-α-
trifluoromethylphenylacetic acid (MTPA) esters, display different arrays of chemical 
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shifts and their 1H NMR spectra. These differing chemical shifts are because the phenyl 
group of the Mosher ester will shield part of the molecule – this is different depending on 
which enantiomer of the Mosher ester being looked at. This shielding results in an upfield 
chemical shift for the spacially proximal protons. Figure 33 illustrates the relationship 
between the phenyl group from the Mosher ester and the proximal R groups. For the R-
ester shown on the left, protons near R2 will experience a chemical upshift, and for the S-
ester shown on the right the R1 substituent will experience shielding from the phenyl 
group and subsequent upward field shift will be observed on a 1H NMR spectrum.  
 
Figure 30. R and S esters, highlighting interaction with R-groups and phenyl group. 
This analysis has been used on known chiral compounds in order to validate the method.91 
An example of this was (-)-Menthol.  
 
Scheme 72. (-)-Menthol Mosher ester analysis.91 
The peaks of the two Mosher esters were tabulated and the ΔδSR values calculated. This 
indicated that the protons with positive values were all on the front facing side of the 
compound and the protons with negative values were on the back facing side of the 
compound. Using this method, it was confirmed that this was the R chiral centre that was 
expected.  
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Table 13. Mosher ester analysis of (-)-Menthol. 
S-ester (ppm) R-ester (ppm) ppm (ΔδSR) Hz (500 MHz) 
1.12 0.98 +0.14 +70 
2.13 2.08 +0.05 +25 
0.94 0.91 +0.03 +15 
1.54 1.52 +0.02 +10 
4.90 4.88 +0.02 +10 
0.87 0.86 +0.01 +5 
1.70 1.70 0.00 0 
1.04 1.06 -0.02 -10 
1.67 1.69 -0.02 -10 
1.42 1.45 -0.03 -15 
0.67 0.77 -0.10 -50 
0.74 0.87 -0.13 -65 
1.56 1.88 -0.32 -160 
Transferring this knowledge across to fit in with compound [184], it was expected that 
for the desired S chiral centre, there would be a chemical upshift on the 1H NMR for 
protons on carbon 2. Unfortunately, there are no protons immediately attached the other 
R-substituent because it features a triple carbon-carbon bond with a TMS group on the 
end. The closest protons are attached to the TMS group and these protons were taken into 
consideration for the Mosher ester analysis. Fortunately, it has been suggested that the 
shielding effect can extend a further distance within the molecule so that even remote 
protons within each R-group can be shielded.91 
 
Figure 31. Compound [136a] showing assignment of substituent priorities about the chiral centre. 
Referring to figure 30, in this commonly encountered representation of rotational 
isomers, a consequence of the shielding affect means that the signs of ΔδSR values for the 
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protons residing in R1 will be positive and R2 will be negative. By knowing which protons 
have positive and negative ΔδSR values, one can deduce the structures of R1 versus R2 and 
hence the absolute configuration of the secondary carbinol centre. So, considering all of 
this, the Mosher esters of compound [136a] were produced. The data collected from these 
diastereoisomers are tabulated in table 13.  
 
Figure 32. Chemical structure of compound [184] highlighting the important protons to consider in the 
Mosher ester analysis. 
Table 14. Mosher ester analysis, summary of peaks of each Mosher ester. 
Proton S - Ester R- Ester ΔδSR (ppm) ΔδSR (Hz) 
n/a 2.372 2.351 + 0.021 + 8.4 
1 0.153 0.139 + 0.014 + 5.6 
n/a 3.666 3.662 + 0.004 + 1.6 
n/a 4.369 4.377 - 0.008 - 3.2 
2 1.748 1.814 - 0.0665 - 26.6 
3 1.748 1.814 - 0.0665 - 26.6 
 
The important peaks to consider when conducting this Mosher analysis were those 
directly connected to the chiral centre, (highlighted in figure 36 and in table 13). Two 
peaks have been considered at positions 2 and 3 in compound [184] due to the heavy 
overlapping of these peaks. As mentioned earlier, the shielding effect can stretch further 
than expected so it should not affect the analysis to include the adjacent protons too. As 
can be observed in the table, protons at position 1 gave a positive value for ΔδSR and at 
position 2 and 3, a negative value has been calculated. Referring to figure 33, which 
indicated that the protons residing in R1 will be positive and R2 will be negative. Another 
way to consider this is that whilst the conformation of the chiral centre in compound 
[184] is unknown, it is fixed in position. The R ester will force the outward facing group 
upfield and the S-ester will force the backward facing group upfield. Table 14 clearly 
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indicates that the protons in position 2 and 3 are shifted upfield in the R-ester, and the 
protons at position 1 are shifted upfield for the S- ester. This suggests that protons in the 
2 and 3 positions are outwardly facing and protons at position 1 are backward facing. 
This means that the observed absolute configuration of the chiral centre is S, as predicted 
in figure 35.  
After determining that the correct enantiomer was being created using the S,S-Noyori 
catalyst, this method was applied to compound [118].  
 
Scheme 73. Noyori asymmetric reduction reaction. 
The conditions for this reaction which were previously optimised (summary in table 12), 
were utilized and fortunately, the conditions were equally effective for this substrate. This 
allowed for the production of alcohol [136] in excellent yield and in the desired chirality. 
The enantiomeric excess was not calculated but it is generally considered that the Noyori 
reduction can give excellent ee% values.92 Similar compounds have also previously been 
analysed using Mosher ester analysis and an enantiomeric excess of more than 95% was 
achieved using the same Noyori conditions that have been used in this project.47 The 
specific rotation value was also found to be [α]D
20 = -24.74 (c 1.0 CH2Cl2).  
Following this success, the same conditions to remove the TMS-group which were used 
in chapter 6.1 for the fragment synthesis were also used here. TBAF proved to be a good 
choice for this, and alkyne [144] was produced in a good yield of 70%, this reaction also 
required no purification step which meant that time was saved.  
 
Scheme 74. TMS removal reaction. 
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A specific rotation value for this compound was found to be [α]D
20  = -39.81 (c 1.0 
CH2Cl2). The sign remained the same as compound [136] which suggested that the 
stereochemistry had been retained. This reaction was not further optimised. The 
following step involved the protection of the alcohol with a silyl protecting group. The 
natural product synthesis was longer and therefore it was decided that the protection of 
this hydroxyl group was important to protect it against reactions further along in the 
synthesis.  
 
Scheme 75. TBS protection of secondary hydroxyl group. 
The TBS-protection was achieved by simply stirring alcohol [144] in dichloromethane at 
room temperature and adding imidazole and tert-butyldimethylsilyl chloride 
successively. The formation of a white precipitate indicated the progression of this 
reaction. This was then stirred overnight, filtered and the solvent removed under vacuum 
to give TBS-protected compound [143]. This reaction proceeded with excellent yield and 
was not further optimised. The specific rotation of this compound was also collected and 
found to be, [α]D
20 = -27.83 (c 1.0 CH2Cl2).  
The next step in the synthesis was to couple a vinyl MIDA-boronate to compound [143]. 
The ideal option for this coupling would be to use the same Sonogashira coupling 
conditions optimised for the fragment synthesis in chapter 6.1. In order to determine if 
the MIDA-boronate functionality would be compatible with these conditions, a couple of 
trial reactions were conducted with simple substrates. This was done so that compound 
[143] was not used up, as it is created via a 4-step synthesis and therefore more difficult 
to acquire than a commercially available compound. The reactions that were trialled are 
outlined in scheme 76 and 77.   
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Scheme 76. Sonogashira trial reaction. 
 
Scheme 77. Sonogashira trial reaction. 
The purpose of carrying out these reactions was simply to ensure that the MIDA-boronate 
group would remain intact in the Sonogashira reaction conditions. Fortunately, it was 
found that the previously optimised Sonogashira coupling conditions developed in 
chapter 6.1 were suitable for use with the MIDA-boronate compounds. The MIDA-
boronate moiety is characteristically observed in a 1H NMR spectrum with peaks at δ 
3.86 ppm - 3.90 ppm and δ 3.98 ppm - 4.02 ppm respectively. These peaks were also 
observed in the product 1H NMR spectrum, so it can be confidently stated that the MIDA-
boronate group was unaffected by the conditions in the Sonogashira coupling, making it 
a versatile functional group in the synthesis of resolvin E1 natural product. Following the 
confirmation that the MIDA-boronate would remain unaffected, the ethynyl MIDA-
boronate was synthesised using literature procedure.51 Unfortunately, the yield was not 
quite as good as presented in literature and it was due to this reason that it turned out to 
be more cost efficient to purchase compound [98] rather than synthesize it.  
 
Scheme 78. Synthesis of Ethynyl MIDA-boronate [98]. 
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The synthesis of compound [98] was confirmed by NMR analysis. The 1H NMR 
spectrum showed two doublets at δ 3.83 ppm - 3.87 ppm and δ 3.95 ppm - 4.00 ppm 
which are characteristic of this compound and correspond to the two CH2 protons at 
positions 1 and 2 in compound [98]. The synthesis of this compound was fairly lengthy 
and the yield was low in comparison to literature so, as mentioned above, it was decided 
that this compound would be bought commercially rather than synthesised.  
 
Scheme 79. Synthesis of vinyl iodide [107]. 
Following the procurement of compound [98] the next reaction involved converting the 
alkyl group to a vinyl iodide. This method was outlined in the same literary reference as 
compound [98].51 However, after following this method, there was no product observed. 
It was decided that it was important to try and make this reaction work as the cost of 
synthesising this compound would be far less than purchasing the commercially available 
vinyl iodide. According to Sigma Aldrich, vinyl iodide [107] (1g) is £111, and alkyne 
[98] (5g) is £138. This experiment was repeated using various conditions and varying 
setups to try and produce a positive result from this reaction. The findings of these studies 
are summarised in Table 15. 
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Table 15. Summary of reactions to create vinyl iodide [107]. 
Entry AIBN (equiv.) Bu3SnH (equiv.) I2 (equiv.) Yield (%) 
1 0.1 1.5 2.0 No reaction 
2 0.1 1.5 2.0 No reaction 
3 0.1 1.5 2.0 No reaction 
4 0.1 1.5 2.0 20 
5 0.1 0.5 2.0 10 
6 0.1 1.5 1.5 10 
7 0.1 1.5 2.0 40 
8 0.2 1.5 2.0 50 
9 0.3 1.5 2.0 70 
10 0.5 1.5 2.0 99 
Reagents and conditions: 
Entry 1 used a nitrogen bubbler, entry 2 used a nitrogen balloon and entry 3 used an argon 
balloon. Entries 4-10 were evacuated of air and carried out under an inert atmosphere 
(either nitrogen or argon). Entries 1-6 used a syringe and needle to introduce the iodine 
solution to the reaction, entries 7-10 transferred the iodine solution via cannula.  
The studies began by using the same equivalents of reagents and similar setup conditions, 
unfortunately this yielded no product. The first breakthrough with this reaction occurred 
when a vacuum pump was attached to the system so that the reaction vessel could be fully 
evacuated of oxygen – Schlenk conditions. This suggested that the reaction was more 
sensitive to air than previously assumed so extra care was taken when setting this reaction 
up to ensure that all air was removed, and glassware thoroughly dried before use. After 
this, the equivalents of tributyl tin hydride and iodine were altered to test what would 
happen, and it seemed that by doing this the yield decreased. However, soon afterwards, 
it was decided to return to the prescribed equivalents and try adding the iodine via 
cannula, it was expected that this would further ensure that the system remained as dry 
as possible. This had a positive effect on the yield and the product was isolated at a 40% 
yield. Whilst this was a vast improvement and showed substantial progress, further tests 
were conducted to test if the yield could be increased. Interestingly, it was found that 
increasing the equivalents of AIBN rapidly increased the yield of the reaction to a very 
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pleasing 99%. The completion of these studies ensured that there was enough vinyl iodide 
to try the Sonogashira coupling with alkyne [143].  
 
Scheme 80. Sonogashira coupling to produce compound [190]. 
This reaction proceeded well the first time producing a moderate 55% yield of pure [190]. 
The formation of this product was confirmed by characteristic peaks on the 1H NMR 
spectrum. Peaks at δ 6.00 ppm - 6.11 ppm corresponded to the alkene protons in this 
compound which suggested that the coupling reaction had been successful. These peaks 
are shown in figure 33.  
 
Figure 33. Alkene protons from compound [190]. 
The specific rotation value was found to be [α]D
20 = -43.78 (c 1.0 CH2Cl2). After repeating 
this reaction several times, it was found that the yield originally achieved of 55% was not 
a consistent yield to expect from this reaction. The yield would occasionally drop as low 
as 15-20% and at other times would increase to approximately 70%. Despite carrying out 
meticulous tests to pin point the conditions that were causing the greater change in yield, 
the exact cause could not be identified. After discovering that the reaction yield was 
somewhat capricious, another drawback was an unexpected sudden formation of an 
unwanted product in some experiments. After some time, the reaction mixture was tested 
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by 1H NMR and an unusual set of peaks were observed, different from those expected 
after this reaction.  
 
Figure 34. 1H NMR spectrum of unknown compound from Sonogashira reaction (scheme 75). 
As observed in figure 38, the peaks seen in this product do not match those previously 
observed for this compound. Of particular interest, was the change in the coupling pattern 
of the alkene protons. This product was observed consistently and until it was possible to 
either convert it to the desired product or fix the reaction so that it produced the desired 
product, progress with the natural product synthesis had to be halted. Through TLC 
analysis, only one spot was observed which suggested that this solution was pure, but 
looking at the 1H NMR spectrum suggested a mixture of compounds. It was originally 
thought that the unusual splitting was observed due to a mixture of cis and trans double 
bond proton peaks overlapping. To determine if there was just one compound in the 
mixture a GC-MS was collected. One peak was observed for this, however due to the 
high polarity of the compound the results of this may not be conclusive.  
A set of reactions were conducted to test the reagents and conditions of this reaction to 
ensure that the reason for the loss of product [192] was not due to faulty catalysts or other 
reagents used in the Sonogashira reaction. The first reaction to be performed, used vinyl 
iodide [107] and phenylacetylene [191].  
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Scheme 81. Sonogashira reaction to create compound [192]. 
This reaction was carried out using the same conditions used for all of the previous 
Sonogashira reactions. This reaction proceeded well and gave the product with a 
moderate 55% yield. The product was easily isolated using column chromatography and 
was fully characterised using NMR analysis. There were no unusual peaks observed for 
this compound. So, from this it was deduced that the reaction conditions and reagents 
were still viable. Alkyne [143] was tested rigorously for its purity to ensure that it was 
not a contaminant in this oil which caused the unusual peaks observed in figure 34. GC-
MS analysis indicated that this compound was >95% pure.  
After discovering very little to explain the observed spectrum in figure 34, a series of 
NMR experiments were carried out to determine if the desired product was in the solution 
at all. nOe experiments were carried out which hit specific peaks and gathered 
information about protons within the vicinity.  
 
Figure 35. Compound [190] structure. 
The proton at position 5 (in figure 35) was hit, in an attempt to see what was happening 
with the alkene protons. The alkene peaks were picked up in both experiments, however 
the expected coupling for the alkene protons were not observed in either of these spectra. 
This result suggested that the overlapping theory was not correct because neither of the 
spectra contained the expected coupling previously observed in pure compound [190] 
observed in figure 33. Following this, a series of 1H NMR experiments at different 
temperatures were trialled in order to determine if changing the temperature would have 
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an effect on observed spectrum for this compound. So, the 1H NMR was repeated at 30°C, 
40°C and 50°C.  
 
Figure 36.  1H NMR spectra of varying temperature. 
(a) 30°C 
(b) 40°C 
(c) 50°C 
Figure 40 shows that changing the temperature had no significant effect on the observed 
1H NMR spectra. Following this, it was decided that solvent effects would be tested to 
see if this had any effect on the spectrum. The sample was evaporated, separately 
dissolved in deuterated, acetone and methanol and the 1H NMR was tested again.  
Changing the solvent system did little to change the peaks observed in the 1H NMR 
spectra. This may mean that changing the deuterated solvent might have no effect on this 
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system when carrying NMR testing. However, if the solvent is causing an adverse effect, 
it might be that this sample was already “damaged” by the stock bottle of deuterated 
chloroform. In order to confirm this, another sample of compound [190] was prepared 
which could be tested with different deuterated solvents, whilst the rest of the 
characterisation tests were carried out.  
Following no positive results from the previous tests, it was decided that a simple IR 
would be taken in order to determine if the expected alkene was present in the sample at 
all. A test was ran using Gaussian-03 to determine the predicted IR spectrum for 
compound [190], by comparing this predicted value with the experimental data collected 
from an IR spectrum, it might be possible to confirm if the alkene is present in compound 
[190]. This test was kindly conducted by Dr Mark Edgar. The structure was optimised 
using the Density Functional Theory method B3LYP and the basis set 6-31G*, this 
optimised structure was then used as an input geometry for a frequency calculation using 
the same method ( B3LYP/6-31G* ) to provide the infra-red vibrations to compare to the 
experimentally derived data. 
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Figure 37. 3D image of compound to be tested using Gaussian 03. Calculation of IR spectrum of 
compound [190]. IR spectrum has been turned upside down to closer resemble a conventional IR 
spectrum93. 
By carrying out this test, the predicted alkene stretch should be observed at 1645 cm-1. 
The closest stretch the prediction was observed at 1671 cm-1. These values are moderately 
close, which suggests that there is an alkene stretch, however the slight difference in the 
structure of the computed IR and the actual sample tested may account for some of the 
difference. Whilst this analysis was useful to confirm the presence of an alkene of some 
form, it did not really help in identifying a structure of the sample.  
While the analysis was being performed on the sample from figure 39, a fresh supply of 
[190] was prepared. The crude product was collected from the Sonogashira coupling 
reaction and split into three separate NMR tubes, containing; base-washed chloroform, 
acetonitrile, and DMF. In all the samples, the correct, product was observed in the 1H 
NMR spectra. This suggests that the problem originated from the bottle of deuterated 
chloroform, and the solvent tests that were carried out earlier using NMR were not 
successful in identifying this problem because compound [190] had already been altered 
by the original chloroform that it was in before. This was particularly unusual as this 
transformation had not been seen previously with standard deuterated chloroform, and 
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the same batch was used to analyse other samples without these adverse effects. 
Regardless, this was the outcome of the situation, so, from this point onwards, compound 
[190] was always analysed using base-washed chloroform. This was done using a small 
glass Pasteur pipette with a bud of cotton wool near the base and a short column of 
potassium hydroxide which the chloroform could pass through. Unfortunately, the 
precise transformation that occurred using the standard chloroform was never identified. 
However, after discovering a fix to this problem it was decided that the synthesis would 
be continued. 
The next reaction was a one-pot hydrolysis and cross coupling reaction. This reaction 
required the Pd/SPhos to be prepared beforehand, and this was always completed directly 
before carrying out the reaction. The preparation of this catalyst involved adding 
Pd(OAc)2 as a source of palladium, and the SPhos ligand. This was then sealed and 
purged with argon before adding anhydrous toluene. It was then left to stir for 
approximately 1 hour at room temperature, during which time a colour change could be 
witnessed, from a light orange to a deep red solution.  The inspiration for this reaction 
was taken from literature visited in chapter 3.51 Following on from chapter 6.4, it was not 
possible to create vinyl iodide [126]. So, instead the diol [127] was used for this reaction.  
 
Scheme 82. MIDA hydrolysis and cross coupling reaction. 
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The MIDA hydrolysis and cross coupling reaction was performed using vinyl iodide 
[127]. This was decided because it was the purest available compound to use at the time 
that compound [190] was made in sufficient mass to try this reaction. It was important to 
use a newly made, fresh batch of vinyl iodide compound because it would degrade with 
exposure to air and at room temperature. It was also possible to freeze compound [127] 
in the lab freezer and convert it from an oil to a solid, this made it considerably easier to 
weigh out accurately and reuse for each reaction. This reaction was successful; however, 
its yield was not sufficient (25%). The pure product had to be isolated using column 
chromatography, and following this purification step, the pure yield was not usually 
found to be above 30%.  
Compound [193] was characterised by 1H NMR, peaks found at δ 3.52 ppm corresponded 
to the protons found at position 6, and the most significant peaks were found between δ 
5.61 ppm - 6.54 ppm which corresponded to the diene system in compound [193]. The 
low yield of this reaction was a drawback in the natural product synthesis, and at this 
stage it was essential to ensure that every step was giving the highest yield possible so 
that mass could be preserved through the steps.  
After looking more closely at the components of this reaction, it was hypothesised that a 
boron could sit between the two alcohols, forming an unwanted side product. This side 
product could be isolated using column chromatography. The 1H NMR of this side 
product looked similar to the spectrum collected for compound [193], however, a major 
difference was the loss of the distinct peaks indicating the splitting of protons at position 
6. Unfortunately, boron NMR was not possible with the NMR instruments available. 
However, an IR spectrum could be taken, and as predicted, there were no O-H stretches 
observed. This suggested that either the diol had disappeared, or that something was 
blocking the OH groups – like a boron chelating in the middle. If the yield of this 
compound had suggested that this was the major product made then efforts would have 
been made to remove the boron and reinstate the diol, however the yield of this was also 
not worthwhile pursuing.  
In an attempt to increase the reaction yield, other vinyl iodide compounds within figure 
28 were tried. It was thought that if a compound further along in the synthesis could be 
used then that would be beneficial, so, compound [177] was trialled firstly.  
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Scheme 83. MIDA group hydrolysis and cross coupling reaction using compound [177]. 
Scheme 83 outlines how the tosylated vinyl iodide [177] was used in the MIDA 
hydrolysis and cross coupling reaction. It was not possible to determine if this reaction 
had produced any of the desired product due to an untidy 1H NMR. Vinyl iodide [177] 
was difficult to work with during this reaction due to its susceptibility to degradation. The 
purification of compound [177] was fairly difficult too. It could be purified using column 
chromatography but it would bring some of the impurities through the column despite 
appearing as one spot on the TLC plate. The suspected compromised purity of compound 
[177] could have contributed to the failure of this reaction.  
Another option was to try using compound [128]. This compound had its disadvantages 
because it would mean that more steps are required in the main synthesis to achieve the 
natural product however, it was thought that because the diol is protected in this version, 
that the unwanted side product previously seen would not be able to form.  
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Scheme 84. MIDA hydrolysis and cross coupling reaction with compound [128]. 
Scheme 84 outlines the reaction that was tried using compound [128] as the vinyl iodide 
substrate. It was difficult to determine if this reaction was successful as the 1H NMR 
spectrum was complex and the identifying peaks between δ 6.00 ppm – 7.00 ppm which 
would have confirmed the diene system was not distinct enough to make a confident 
decision either way. It was difficult to pinpoint the reason for the failure of this reaction, 
but it may be associated with the purity of the starting material, compound [127].  
This vinyl iodide [127] was also challenging to purify, after purification through a silica 
gel column, one would frequently find that iodoform had been carried through the column 
with the product and this would obviously have the potential to be very problematic with 
future reactions using that batch of compound. Also, again, it would degrade very quickly 
after being synthesised, which made it tricky to use. Ideally, these compounds would be 
used the same day they are synthesised. These effects were not seen so dramatically in 
the synthesis in chapter 6.4 because the vinyl iodide compounds were never left for more 
than a day in the freezer without being put into the next reaction to make the diol. When 
having two starting materials compound [143] and compound [127] which both tended 
to degrade, the timing of making these had to be perfect in order to be able to carry out 
the MIDA hydrolysis and cross coupling reaction. So, while the reaction looked as though 
it had worked, the quality of the product at the end, even after purification, was not as 
high as when diol [127] was used as a substrate.  
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The MIDA hydrolysis and cross-coupling reaction could be made easier by using the diol 
version of the vinyl iodide [127] since it was stable for longer periods of time and would 
form an easy to handle solid when kept cold in the lab freezer. So, it was for this reason 
that diol [127], was used as the substrate for this reaction despite the unwanted side-
product that was formed every time this reaction was performed. It was decided that the 
quality of the sample was more important than the yield, and the diol gave the highest 
quality sample.  
After synthesising a sufficient amount of compound [193], the next step in the synthesis 
was to tosylate the terminal hydroxyl group. This was an essential transformation in the 
synthesis because it would facilitate the ring closing and epoxide formation.  
 
Scheme 85. Tosylation of diol [193]. 
The tosylation of compound [193] proceeded well with a sufficient 55% yield. This was 
helpful at this stage of the synthesis, where reactions were performed using less than 
20mg of compound [193]. The conditions for the tosylation were reused from previous 
syntheses found in chapters 6.3 and 6.4. Compound [194] was not purified at this stage 
and was carried forwards crude. The product was characterised using 1H NMR, important 
peaks were observed at δ 7.30 ppm and 7.70 ppm respectively, which corresponded to 
the aromatic protons on the tosylate section of the compound. Of equal importance, the 
peaks indicating the protons at position one in compound [194], have shifted up-field in 
the spectrum due to the presence of the tosyl-group. These peaks were observed at δ 3.52 
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ppm for diol [193] and upon conversion to the tosylate, these peaks were observed at δ 
3.91 and 4.02 ppm respectively. The shift of these protons was an important indicator in 
confirming the success of this reaction, and it was decided again that this product would 
be carried through to the next stage of the synthesis crude. The next step was to ring close 
compound [194] to the epoxide. This reaction used the same conditions to form an 
epoxide as previously used in chapter 6.3 and 6.4.  
 
Scheme 86. Epoxide formation reaction. 
This reaction yielded the desired epoxide, and this was achieved with an adequate yield 
of 45%. This epoxide [196] was characterised by 1H NMR spectroscopy; the key peaks 
which confirmed the formation of the epoxide were the protons situated at position 1. 
These two protons split to form two multiplets at δ 2.67 ppm and 3.00 ppm, and this has 
been observed for all epoxides formed in this project.  
At this point in the synthesis the mass of compound [196] was very small (8mg) and 
ideally it would have been useful to have more time to make more of this compound to 
carry forward to the next step of the synthesis. The epoxide was not purified by column 
chromatography due to the mass that was available and due to the time left of the project, 
so was carried forward to the next stage crude. The next step was to open to the epoxide 
ring and introduce the alkyne on the end of the compound. This reaction would be 
completed with lithium acetylide ethylene diamine complex and this reaction was trialled 
previously and discussed previously in this chapter.  
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Scheme 87. Synthesis of alkyne [197]. 
This reaction was attempted toward the end of the project with 7mg of epoxide [196] 
gained from the previous epoxide reaction. The loss of 1 mg was due to collecting all the 
data for epoxide [196]. It could not be definitively said whether the alkyne was 
successfully formed in this reaction. The small mass of product made it difficult to 
analyse using NMR spectroscopy. Although, there was a loss of the epoxide peaks 
observed for protons at position one in compound [196] which suggested that the reaction 
might have been successful. The mass given at the end of this reaction was approximately 
1mg, which made collected the data and characterising this compound quite challenging. 
Due to the small amount of product, the NMR spectra were polluted with grease, very 
untidy, and there was too little compound to attempt to purify using column 
chromatography. Due to time constraints, unfortunately the repetition of this reaction was 
not feasible, so, the synthesis of the natural product had to end at this stage.  
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7. Conclusions and Future Work 
Overall, the synthesis of a series of resolvin E1 fragments were synthesised and tested 
for their anti-inflammatory effects. A general trend was observed in the biological results 
suggesting that the least lipophilic compounds were the most effective anti-
inflammatories. Following this, studies were conducted to attempt to manipulate alkynyl 
MIDA-boronates to ring-open epoxides. Unfortunately, this was unsuccessful, however 
the work does show promise for further study. The synthesis of resolvin E1 natural 
product was attempted, the synthesis was nearly completed with only three steps in the 
synthetic route left. This also shows promise for future work.  
The priority of future work must focus on finishing resolvin E1 natural product. The route 
proposed is very promising and if more time were available then the natural product it is 
entirely possible that the natural product could have been completed. This synthesis 
encountered many obstacles, however with reaction optimisations, many of these were 
resolved or another way found to continue the work. Although the natural product was 
not quite finished in this work, the route towards the natural product is plausible, using 
previously trialled reactions that should work for this system. There are three remaining 
reactions in the synthesis to complete the natural product. The next reaction after that 
shown in scheme 82, is a Sonogashira coupling using the same conditions as used 
previously with these compounds. Then, an epoxide ring-opening reaction, and it was 
hoped that copper iodide and methyl magnesium bromide could be used to achieve this 
transformation. This ring opening reaction was trialled in chapter 6.4 using styrene oxide 
and was successful, so, it is hoped that it would be successful for this compound too. 
Following this, a Lindlar hydrogenation, which has been previously used in chapter 6.1, 
and finally, a deprotection reaction to remove any silyl protecting groups. One of the 
largest obstacles in this synthesis is introducing the required stereocentres, and this 
synthetic route provided the tools to create these centres with relative ease.  
Once the natural product has been synthesised, it is also hoped that with future work, 
more fragments could be evaluated for biological activity. There is currently one 
fragment of resolvin E1 in clinical trials, and it would be very interesting to carry out 
preliminary tests to ascertain if similar compounds could produce promising results.31 
Possible fragments which could be explored in this work are summarised in figure 44.  
118 
 
 
Figure 38. Possible fragments for future biological testing. 
These compounds would be of interest because they are the precursors to the natural 
product. The results from the biological testing discussed in chapter 6.2 suggested that 
the compounds with the alkyne functional group provided better anti-inflammatory 
affects and all of these compounds contain the alkyne functionality. Furthermore, it 
would also be interesting to test any diastereoisomers of these compounds to ascertain if 
the conformation of the stereocentres have any effect on the anti-inflammatory activity.  
In addition to the work on the E-series of Resolvins, it would also be advantageous to 
explore the D-series of Resolvins. This series are also known for their significant anti-
inflammatory effects, and they are also known to have anti-microbial properties which 
might be an interesting route to explore. The use of the MIDA-boronate functional group 
would also be of great use in the synthesis of any other Resolvins due to their great ability 
to construct complex polyenes.  
With regards to future work using MIDA boronates, it would be intriguing to revisit the 
work discussed in chapter 6.3 whereby an ethynyl MIDA-boronate is used to open an 
epoxide ring followed by addition of the ethynyl MIDA-boronate onto the substrate. This 
would have exciting implications for broadening the use of these new MIDA-boronate 
compounds.  
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8. Experimental 
8.1 General  
Anhydrous conditions were obtained through the use of oven dried glassware purged with 
either nitrogen or argon (method specifies) prior to the addition of the chemical reagents. 
The inert atmosphere was maintained either by nitrogen bubbler or nitrogen or argon 
balloon. Commercially available solvents were used and not subjected to further 
purification, except THF and DMF. THF was distilled over benzophenone and sodium 
when needed and DMF was distilled over magnesium sulphate. Other anhydrous solvents 
were purchased dry from commercial suppliers. Light petroleum ether refers to fractions 
with a boiling point between 40-60°C.  
NMR spectra were recorded using either a JEOL 400 MHz or a Bruker 400 MHz NMR 
machine. Chemical shifts are reported in ppm for both 1H and 13C NMR spectra. 1H was 
recorded at 400 MHz and 13C spectra were recorded at 100 MHz. DEPT was used to 
assign environment (CH, CH2, CH3) to each carbon atom in the 
13C spectra. The solvent 
system used for NMR spectroscopic measurements is specified with the applicable data 
set. 
NMR nOe spectra were obtained on a Bruker ultra-shield Av-400 spectrometer operating 
at 400.13 MHz for protons, employing a 5 mm high-resolution broad-band ATMA 
gradients probe. Spectra were recorded using the selnogp pulse program with P90 = 15.25 
μs covering a sweep with 20.7 ppm (8278 Hz) with 64k time domain data points giving 
an acquisition time of 3.95 seconds, selective shaped-pulses (Gauss5, 40 ms, 70 dB) were 
used to irradiate individual signals and a mixing time of 0.6 seconds allows nOe 
enhancements to build-up, FIDs were Fourrier transformed using 64k data points and 
references to an internal TMS standard at 0.00 ppm.  
A Thermofisher Exactive (orbi) mass spectrometer was used to obtain high resolution 
mass spectra, with ESI as the ionisation mode. The solvent used for all samples was 
methanol. 
A Perkin-Elmer spectrum 65 FT-IR spectrophotometer was used to obtain infrared 
spectra. Spectra obtained from liquid samples were acquired using a thin film on a sodium 
chloride 116 disc. Spectra obtained from solid samples were dissolved in a small amount 
of dichloromethane before being applied as a thin film on a sodium chloride disc.  
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Optical rotation measurements were recorded on an Optical Acitivity polar 2001 
automatic polarimeter at room temperature. The solvent system used is a specified with 
the applicable data set. 
TLC analysis was carried out on Sigma Aldrich TLC silica gel 60 F254 aluminium backed 
plates and were visualised by vanillin, or potassium permanganate stain or using a UVP 
chromate-vue cabinet model CC-60.  
Column chromatography used Apollo Scientific ZEOprep 60 silica with a particle size of 
40-63 microns. The eluent and concentration used is specified with the relevant methods.  
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8.2 Resolvin E1 Fragment  
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate55 
 
Scheme 88. 
A solution of bis(trimethylsilyl)acetylene [124] (5.00 g, 29.34 mmol, 1.1 equiv.) and 
glutaric acid methyl ester chloride in 100 mL dichloromethane (4.38 g, 26.64 mmol, 1.0 
equiv.) was produced and added dropwise to a solution of aluminium chloride (4.70 g, 
35.21 mmol, 1.2 equiv.) in dichloromethane. This was done at -15°C and stirred for 3 
hours. After this time, the reaction was quenched using a saturated solution of citric acid 
and ice. It was then extracted using diethyl ether (3 x 50 mL) and washed with brine (3 
x 50 mL). The organic extracts were then dried over anhydrous magnesium sulphate, 
filtered and concentrated on the rotary evaporator to yield a dark brown oil. This was 
then purified by column chromatography using a solvent mixture of petroleum ether and 
ethyl acetate (8:2) as eluent (Rf = 0.62). The final product was isolated as a yellow oil 
(1.99 g, 8.80 mmol, 67%). δH (400 MHz, CDCl3) 3.62 (s, 3H), 2.60 (q, 2H, J=7.2 Hz), 
2.29-2.39 (m, 2H), 1.90 (tq, J=7.2 Hz, 2H), 0.13 (s, 9H). δc (100MHz, CDCl3) 186.83, 
173.54, 101.7, 98.23, 51.69, 44.31, 32.94, 19.82, 0.11. IR (NaCl) v 2958, 2150, 1740 cm-
1. HRMS (ESI) m/z 227.1098 (C11H18O3SiNa
+ requires 227.1098). 55 
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Methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate94 
 
Scheme 89. 
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate [118] (0.22 g, 1.00 mmol, 1.0 equiv.) was 
dissolved in methanol (2.5 mL) at 0°C. The Luche reagent cerium(III) chloride 
heptahydrate (0.37 g, 1.00 mmol, 1.0 equiv.) was added and stirred for 1 hour. After this 
time, sodium borohydride (0.08 g, 2.00 mmol, 2.0 equiv.) was added slowly and the 
solution left to stir for a further hour. Then, if necessary, the solution was adjusted to pH 
neutral using dilute HCl acid. It was then extracted using diethyl ether (3 x 10 mL), dried 
over sodium sulphate and the solvent removed in vacuo to yield the crude product as a 
yellow oil. The crude product was then purified by flash column chromatography using 
petroleum ether and ethyl acetate (8:1) as eluent to give the title compound as a pale, 
yellow oil (Rf = 0.52). (0.10g, 0.44 mmol, 53%).  δH (400 MHz, CDCl3) 5.28 (s, 1H), 
4.37 (t, 1H, J=6.2 Hz), 3.66 (s, 3H), 2.35-2.46 (m, 2H), 1.95 (quin, 2H, J=7.2 Hz), 1.69-
1.83 (m, 2H), 0.08 (s, 9H). δc (100MHz, CDCl3) 174.13, 106.43, 89.67, 62.70, 51.75, 
36.92, 33.60, 20.46, 0.19. IR (NaCl) v 3442, 2957, 2171, 1736 cm-1.  HRMS (ESI) m/z 
229.1255 (C11H21O3Si
+ requires 229.1256).94 
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Methyl 5-((tert-butyldimethylsilyl)oxy)-7-(trimethylsilyl)hept-6-ynoate95 
 
Scheme 90. 
Methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate [136a] (0.58 g, 2.57 mmol, 1.0 
equiv.) was dissolved in dimethylformamide (anhydrous) (20 mL) at room temperature 
under nitrogen atmosphere. Imidazole (0.43g, 6.43 mmol, 2.5 equiv.) was added and 
followed by TBDMSCl (0.50 g, 3.34 mmol, 1.3 equiv.) was added dropwise. This was 
left to stir overnight. The reaction was quenched with n-hexanes, washed with brine, 
and distilled water. It was dried over sodium sulphate, filtered, and concentrated under 
vacuum. The crude product was then purified by column chromatography using 
petroleum ether and ethyl acetate (8:1) as eluent (Rf = 0.83). This gave the pure title 
compound as a pale, yellow oil (0.32g, 0.93 mmol, 55%). δH (400 MHz, CDCl3) 4.36 
(t, 1H, J=18.4 Hz). 3.66 (s, 3H), 2.35 (t, 2H, J=7.2 Hz), 1.74-1.78 (m, 2H), 1.70-1.72 
(m, 2H), 0.89 (s, 9H), 0.16, (s, 9H), 0.08 (s, 6H). δc (100 MHz, CDCl3) 174.17, 106.64, 
89.60, 62.38, 51.76, 37.01, 33.69, 29.51, 25.81, 18.13, 0.28, -3.44. IR (NaCl) v 2171, 
1740, 1438, 1250 cm-1. HRMS (ESI) m/z 342.2041 (C17H34O3Si2 requires 342.1322). 
95 
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Methyl 5-hydroxyhept-6-ynoate55 
 
Scheme 91. 
To a stirred solution of methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate [136a] (0.05 g, 
0.14 mmol, 1.0 equiv.) in dry methanol (20 mL) was added caesium carbonate (0.10 g, 
0.29 mmol, 2.0 equiv.) and the mixture was stirred for 25 minutes. After this time, the 
reaction was diluted with water, and extracted with diethyl ether (3 x 15 mL). The 
combined organic layers were dried over magnesium sulphate, filtered, and concentrated 
under vacuum to yield the crude product. This was then purified by column 
chromatography using petrol and ethyl acetate (8:1) (Rf = 0.47) as eluent, to yield the 
pure product. (0.03 g, 0.21 mmol, 67%). δH (400 MHz, CDCl3) 4.34 (s, 1H), 3.64 (s, 3H), 
2.44 (s, 1H), 2.32 (t, 2H, J=10.4 Hz), 1.73-1.80 (m, 2H), 1.66-1.72 (m, 4H). δc (100 
MHz, CDCl3) 174.10, 84.70, 73.07, 61.68, 51.77, 36.82, 33.56, 20.41. IR (NaCl) v 3443, 
3304, 2954, 2253, 1729, 1438, 1245, 1201 cm-1. HRMS (ESI) m/z 179.0680 (C8H12O3Na
+ 
requires 179.0679).55 
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Methyl 5-((tert-butyldimethylsilyl)oxy)hept-6-ynoate96 
 
Scheme 92. 
To a stirred solution of 6-heptynoic acid, methyl 5-((tert-butyldimethylsilyl)oxy)-7-
(trimethylsilyl)hept-6-ynoate [142] (0.05 g, 0.15 mmol, 1.0 equiv.) in dry methanol (10 
mL) under an inert atmosphere was added caesium carbonate (0.10 g, 0.29 mmol, 2.0 
equiv.), and the mixture was stirred at room temperature for 25 minutes. After this time, 
the reaction was diluted with water and extracted with diethyl ether (3 x 5 mL). The 
combined organic layers were dried over magnesium sulphate, filtered, and concentrated 
under vacuum to give the crude product. This was then purified by column 
chromatography using petrol and ethyl acetate (8:1) (Rf = 0.75) to yield the pure product 
as a yellow oil (0.01g, 30%). δH (400 MHz, CDCl3) 4.31-4.37 (m, 1H), 3.66 (s, 3H), 2.32-
2.38 (m, 2H), 1.63-1.72 (m, 4H), 0.88 (s, 9H), 0.12 (s, 6H). δc (100 MHz, CDCl3) 174.06, 
85.22, 76.78, 62.43, 51.61, 37.80, 33.73, 29.78, 25.82, 20.68, -0.12. HRMS (ESI) m/z 
293.1543 (C14H26O3SiNa
+ required 293.1544).96 
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(But-3-yn-1-yloxy)(tert-butyl)dimethylsilane 97 
 
Scheme 93. 
3-Butyn-1-ol [201] (0.50 g, 7.13 mmol, 1.0 equiv.) was dissolved in DMF (anhydrous) 
(40 mL) at room temperature under an inert atmosphere. The solution was then treated 
with imidazole (1.40g, 9.27 mmol, 1.3 equiv.), followed by TBDMS-Cl (1.21 g, 17.83 
mmol, 2.5 equiv.). This reaction mixture was left to stir overnight. The reaction was 
diluted with n-hexanes, washed with brine (4 x 30 mL) and distilled water (3 x 30 mL), 
dried over sodium sulphate, filtered, and concentrated under vacuum to give the crude 
product. This was then purified by column chromatography using petrol and ethyl acetate 
(8:2) (Rf = 0.65) to yield the pure product as a yellow oil (0.54g, 2.93 mmol, 41%). δH 
(400 MHz, CDCl3) 3.71 (t, 2H, J=7.2 Hz). 2.34-2.37 (m, 2H), 1.92 (s, 1H), 0.86 (s, 9H), 
0.04 (s, 6H). δc (100 MHz, CDCl3) 78.17, 62.05, 30.9, 26.01, 24.16, 3.93, -2.41.97 
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Tert-butyldimethyl((4-phenylbut-3-yn-1-yl)oxy)silane 
 
Scheme 94. 
To a degassed solution of iodobenzene (0.20 g, 0.98 mmol, 0.7 equiv.), 
bis(triphenylphosphine) palladium(II)chloride (0.04 g, 0.06 mmol, 0.04 equiv.), copper 
(I) iodide (0.01 g, 0.05 mmol, 0.03 equiv.), and diisopropylamine in DMF (25 mL) (0.40 
g, 3.92 mmol, 2.7 equiv.) was added (but-3-yn-1-yloxy)(tert-butyl)dimethylsilane [147] 
(0.25 g, 1.47 mmol, 1.0 equiv.). The reaction mixture was heated to 85°C and left to stir 
for 18 hours. The reaction mixture was then diluted with ethyl acetate (15 mL), washed 
with brine (3 x 15 mL), dried over sodium sulphate, filtered, and concentrated under 
vacuum to give the impure product. This was then purified by flash column 
chromatography using petroleum ether and ethyl acetate (8:1) (Rf = 0.32) to give the pure 
product as an orange oil (0.18g, 0.73 mmol, 49%). δH (400 MHz, CDCl3) 7.37-7.40 (m, 
2H), 7.25-7.29 (m, 3H), 3.81 (t, 2H, J=7.0 Hz), 2.47 (t, 2H, J=7.0 Hz), 0.91 (s, 9H), 0.01 
(s, 6H). δc (100 MHz, CDCl3) 131.66, 128.80, 127.75, 123.85, 87.27, 81.64, 62.05, 26.02, 
23.92, 18.46, -5.14. IR (NaCl) v 3583, 2928, 1440 cm-1.  
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4-Phenylbut-3-yn-1-ol 78 
 
Scheme 95. 
To a degassed solution of iodobenzene (0.20 g, 0.98 mmol, 0.7 equiv.), bis 
(triphenylphosphine) palladium (II) chloride (0.04 g, 0.06 mmol, 0.04 equiv.), copper (I) 
chloride (0.01 g, 0.05 mmol, 0.03 equiv.), and diisopropylamine (0.40 g, 3.92 mmol, 2.7 
equiv.) in anhydrous DMF (20 mL) was added 3-butyn-2-ol [145] (0.10 g, 1.47 mmol, 
1.0 equiv.). The mixture was heated to 85°C and stirred for 18 hours. After this time, the 
mixture was diluted with ethyl acetate, washed with brine (3 x 10 mL), dried over sodium 
sulphate, filtered, and concentrated under vacuum to give the crude product. This was 
then purified with flash column chromatography using petroleum ether and ethyl acetate 
(6:1) (Rf = 0.43) as the eluent to yield the pure product as an orange oil (0.12 g, 0.82 
mmol, 55%). δH (400 MHz, CDCl3) 7.44-7.53 (m, 3H), 7.29-7.35 (m, 2H), 3.83 (t, 2H, 
J=5.0 Hz), 2.71 (t, 2H, J=5.0 Hz). δc (100MHz, CDCl3) 131.61, 128.24, 127.98, 123.23, 
86.35, 82.31, 61.07, 23.78. IR NaCl v 3355, 2940, 1490, 1042, 755 cm-1.78 
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 (E)-(2-Iodovinyl)benzene98 
 
Scheme 96. 
Anhydrous chromium (II) chloride (0.74 g, 6.00 mmol, 6.0 equiv.), was suspended in dry 
THF (40 mL) under nitrogen and stirred for 10 minutes. A solution of benzaldehyde [152] 
(0.11 g, 1.00 mmol, 1.0 equiv.) and iodoform (0.79 g, 2.00 mmol, 2.0 equiv.) was added 
dropwise at 0°C and stirred overnight at room temperature. The reaction mixture was 
added to distilled water and the product extracted with diethyl ether (3 x 20 mL). The 
organic extracts were dried over magnesium sulphate, filtered and the solvent removed 
by evaporation under reduced pressure. This was then purified by column 
chromatography using petroleum ether as eluent (Rf = 0.85). The title compound was 
isolated as a yellow oil (0.17g, 0.79 mmol, 74%). δH (400 MHz, CDCl3) 7.46 (d, 1H, 
J=14.8 Hz), 7.29-7.37 (m, 5H), 6.86 (d, 1H, J=14.8 Hz). δc (100 MHz, CDCl3) 145.01. 
137.69, 128.74, 128.40, 126.02, 60.45. IR NaCl v 3057, 1569, 1524, 1494, 1469, 1444, 
1170, 1070, 983, 688 cm-1.98 
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Methyl (Z/E)-5-hydroxy-7-(trimethylsilyl)hept-6-enoate 
 
Scheme 97. 
5-Hydroxy-7-(trimethylsilyl)hept-6-ynoate [136a] (1.50 g, 6.59 mmol, 1.0 equiv.), and 
quinoline (0.85 g, 6.59 mmol, 1.0 equiv.) were dissolved in toluene (50 mL) (anhydrous). 
The solution was stirred vigorously in the presence of Pd/CaCO3/Pb (0.70 g, 6.59 mmol, 
1.0 equiv.) under H2 for 3 hours at room temperature. The mixture was then filtered, and 
the filtrate concentrated under vacuum. The remaining residue was diluted with ethyl 
acetate (30 mL) and then washed with 1M HCl. The organic extracts were dried over 
sodium sulphate, filtered, and concentrated under vacuum to give the crude product. This 
was then purified by column chromatography using petroleum ether and ethyl acetate 
(8:2) (Rf = 0.45) to give the products as a yellow oil (0.50g, 2.17 mmol, 33%). δH (400 
MHz, CDCl3) 6.23 (d, 1H, J=8.0 Hz). 6.27 (d, 1H, J=8.0 Hz), 5.71 (s, 1H), 4.23-4.26 (m, 
1H), 3.69 (s, 3H), 2.38 (t, 2H, J=7.2 Hz), 1.60-1.79 (m, 2H), 1.50-1.59 (m, 2H), 0.08 (s, 
9H). δc (100 MHz, CDCl3) 174.26, 148.18, 129.47, 73.64, 51.56, 36.13, 33.93, 21.06, -
1.31. (Data of cis isomer only given). 
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Methyl 5-oxohept-6-ynoate 
 
Scheme 98. 
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate [118] (1.00 g, 3.31 mmol, 1.0 equiv.) was 
dissolved in dry THF (50 mL) under N2 at -78°C and TBAF (1M in THF) (2.59 mL, 0.8 
equiv.) was added. This stirred for 30 mins before being added to 1M HCl (25 mL) and 
ice. This was then transferred to a separating funnel and extracted with diethyl ether (4 x 
40 mL) and washed with brine (3 x 40 mL). Dried over magnesium sulphate, filtered, and 
evaporated under vacuum to yield a dark, brown oil. This was then purified using column 
chromatography using petroleum ether and ethyl acetate (7:1) (Rf = 0.40) as the eluent to 
give the pure product as a pale, yellow oil (0.23g, 1.49 mmol, 45%). δH (400 MHz, 
CDCl3) 3.61 (s, 3H), 3.22 (s, 1H), 2.65 (t, 2H, J=7.6 Hz), 2.36 (t, 2H, J=7.6 Hz), 1.95 
(quin, 2H, J=7.6 Hz). δc (100 MHz, CDCl3) 18.83, 32.75, 44.39, 51.75, 78.79, 81.33, 
173.32, 186.38. IR (NaCl) v 3252. 2954, 2093, 1735, 1682 cm-1. HRMS (ESI) m/z 
177.0522 (C8H10O3Na
+ requires 177.0524).  
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Methyl 5-hydroxyhept-6-ynoate99 
 
Scheme 99. 
Methyl 5-oxohept-6-ynoate [145] (0.55 g, 3.62 mmol, 1.0 equiv.) was dissolved in 
methanol (35 mL) and stirred at room temperature for 5 minutes. The Luche reagent, 
cerium III chloride (2.02 g, 5.43 mmol, 1.5 equiv.) was added and the reaction cooled to 
0°C. This was left to stir for an hour before the slow addition of sodium borohydride 
(0.13 g, 3.62 mmol, 1.0 equiv.) and then the reaction was left to stir for an additional hour 
at 0°C. After this time, the reaction was quenched with the addition of saturated aqueous 
ammonium chloride. The aqueous layer was extracted with diethyl ether (3 x 20 mL) and 
the combined organic layers were washed with brine (3 x 20 mL), dried over magnesium 
sulphate and concentrated under vacuum to yield a pale, yellow oil (0.35g, 2.24 mmol, 
61%). δH (400 MHz, CDCl3) 4.34 (s, 1H), 3.64 (s, 3H), 2.44 (s, 1H), 2.32 (t, 2H, J=10.4 
Hz), 1.73-1.80 (m, 2H), 1.66-1.72 (m, 4H). δc (100 MHz, CDCl3) 174.10, 84.70, 73.07, 
61.68, 51.77, 36.82, 33.56, 20.41. IR (NaCl) v 3443, 3304, 2954, 2253, 1729, 1438, 1245, 
1201 cm-1. HRMS (ESI) m/z 179.0680 (C8H12O3Na
+ required 179.0679).99 
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Methyl 5-hydroxy-7-phenylhept-6-ynoate 
 
Scheme 100. 
To a three necked flask equipped with reflux condenser and nitrogen bubbler was added 
methyl 5-hydroxyhept-6-ynoate [144] (0.14 g, 0.63 mmol, 1.0 equiv.), iodobenzene (0.08 
g, 0.42 mmol, 0.7 equiv.), Pd[PPh3]2Cl2 (0.02 g, 22.15μmol, 0.04 equiv.), and CuI (36.00 
mg, 18.99 μmol, 2.7 equiv.) and anhydrous THF (30 mL). The reaction was then heated 
up to 80°C and diisopropylamine (0.17 g, 1.69 mmol, 2.7 equiv.) added which resulted 
in a temporary colour change to yellow and then gradually turned to a deep brown. This 
was left under N2 atmosphere, heating at 80°C and stirred overnight. The next day, the 
reaction was taken off the heat and diluted with ethyl acetate. This solution was 
transferred to a separating funnel and washed with distilled water (3 x 15 mL), before 
being washed with brine (3 x 15 mL). The organic extract was then dried over magnesium 
sulphate and reduced under vacuum to yield the crude product as a dark, brown oil, this 
was purified by column chromatography using petroleum ether and ethyl acetate (6:1) 
(Rf = 0.32). to give the product as a yellow oil. (0.13 g, 0.56 mmol, 81%). δH (400 MHz, 
CDCl3) 7.40-7.42 (m, 2H), 7.25-7.32 (m, 3H), 4.61 (t, 1H, J=11.6 Hz), 3.66 (s, 3H), 2.38-
2.42 (m, 2H), 1.82-1.89 (m, 4H). δc (100 MHz, CDCl3) 174.03, 131.77, 131.54, 128.54, 
128.38, 122.56, 89.72, 85.19, 51.71, 37.15, 33.67, 20.69, IR (NaCl) v 3453, 2922, 1731 
cm-1. HRMS (ESI) m/z 255.0987 (C14H16O3Na
+ requires 255.0992).  
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Methyl 5-hydroxy-7-(p-tolyl)hept-6-ynoate 
 
Scheme 101. 
To a three-necked flask equipped with reflux condenser and nitrogen bubbler was added 
methyl 5-hydroxyhept-6-ynoate [144] (0.17 g, 1.11 mmol, 1.0 equiv.), iodotoluene (0.16 
g, 0.75 mmol, 0.7 equiv.), Pd[PPh3]2Cl2 (0.03 g, 0.04 mmol, 0.04 equiv.), and CuI (0.01 
g, 0.03 mmol, 0.03 equiv.) and anhydrous THF (30 mL). The reaction was then heated 
up to 80°C and diisopropylamine (0.30 g, 2.98 mmol, 2.7 equiv.) added which resulted 
in a temporary colour change to yellow and then gradually turned to a deep brown. This 
was left under N2 atmosphere, heating at 80°C and stirred overnight. The next day the 
reaction was taken off the heat and diluted with ethyl acetate. This solution was 
transferred to a separating funnel and washed distilled water (3 x 15 mL), before being 
washed with brine (3 x 15 mL). The organic extract was then dried over magnesium 
sulphate and reduced under vacuum to yield the crude product as a dark, brown oil. This 
was purified by column chromatography using petroleum ether and ethyl acetate (6:1) 
(Rf = 0.35) to give the product as a yellow oil. (0.22 g, 0.89 mmol, 80%). δH (400 MHz, 
CDCl3) 7.26 (d, 2H, J=8.4 Hz), 7.09 (d, 2H, J=8.4 Hz), 4.59 (s, 1H), 3.66 (s, 3H), 2.39 
(t, 2H, J=14.0 Hz), 2.33 (s, 3H), 1.79-1.89 (m, 4H). δc (100 MHz, CDCl3) 174.06, 138.62, 
131.66, 129.14, 119.46, 89.04, 85.31, 62.59, 51.72, 37.19, 33.69, 21.57, 20.71. IR (NaCl) 
v 3583, 2951, 17364, 1509 cm-1. HRMS (ESI) m/z 269.1150 (C15H18O3Na
+ requires 
269.1148). 
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Methyl 7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-ynoate 
 
Scheme 102. 
To a three necked flask equipped with reflux condenser and nitrogen bubbler was added 
methyl 5-hydroxyhept-6-ynoate [144] (0.11 g, 0.73 mmol, 1.0 equiv.), 4-tert 
butyliodobenzene (0.13 g, 0.49 mmol, 0.7 equiv.), Pd[PPh3]2Cl2 (0.02 g, 0.24 μmol, 0.04 
equiv.), and CuI (4.00 mg, 0.22 μmol, 0.03 equiv.) and anhydrous THF (30 mL). The 
reaction was then heated up to 80°C and diisopropylamine (0.19 g, 1.95 mmol, 2.7 equiv.) 
added which resulted in a temporary colour change to yellow and then gradually turned 
to a deep brown. This was left under N2 atmosphere, heating at 80°C and stirred 
overnight. The next day the reaction was taken off the heat and diluted with ethyl acetate. 
This solution was transferred to a separating funnel and washed distilled water (3 x 15 
mL), before being washed with brine (3 x 15 mL). The organic extract was then dried 
over magnesium sulphate and reduced under vacuum to yield the crude product as a dark, 
brown oil. This was purified by column chromatography using petroleum ether and ethyl 
acetate (6:1) (Rf = 0.31) to give the pure product as a yellow oil (0.19 g, 0.66 mmol, 
90%). δH (400 MHz, CDCl3) 7.34-7.36 (m, 2H), 7.29-7.32 (m, 2H), 4.61 (t, 1H, J=5.6 
Hz), 3.67 (s, 3H), 2.40 (t, 2H, J=7.2 Hz), 1.83-1.92 (m, 4H), 1.29 (s, 9H). δc (100 MHz, 
CDCl3) 174.03. 151.82, 131.49, 125.38, 119.51, 89.04, 85.31, 62.61, 51.69, 37.19, 34.85, 
33.69, 31.23, 20.71. IR (NaCl) v 3400, 2954, 2869.04, 1736 cm-1. HRMS (ESI) m/z 
311.1621 (C18H24O3Na
+ requires 311.1618).  
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Methyl (E)-5-hydroxy-9-phenylnon-8-en-6-ynoate 
 
Scheme 103. 
To a three necked flask equipped with reflux condenser and nitrogen bubbler was added 
methyl 5-hydroxyhept-6-ynoate [144] (0.12 g, 0.54 mmol, 1.0 equiv.), (E)-(2-
iodovinyl)benzene  (0.08 g, 0.36 mmol, 0.7 equiv.), Pd[PPh3]2Cl2 (0.0 1 g, 0.019 mmol, 
0.04 equiv), and CuI (4 mg, 0.016 mmol, 0.03 equiv.) and anhydrous THF (30 mL). The 
reaction was then heated up to 80°C and diisopropylamine (0.15 g, 1.43 mmol, 2.7 equiv.) 
added which resulted in a temporary colour change to yellow and then gradually turned 
to a deep brown. This was left under N2 atmosphere, heating at 80°C and stirred 
overnight. The next day the reaction was taken off the heat and diluted with ethyl acetate. 
This solution was transferred to a separating funnel and washed distilled water (3 x 15 
mL), before being washed with brine (3 x 15 mL). The organic extract was then dried 
over magnesium sulphate and reduced under vacuum to yield the crude product as a dark, 
brown oil. This was purified by column chromatography using petroleum ether and ethyl 
acetate (6:1) (Rf = 0.54) to give the pure product as a yellow oil.  (0.07 g, 0.27 mmol, 
50%). δH (400 MHz, CDCl3) 7.30-7.37 (m, 5H), 6.93 (d, 1H, J=16.8 Hz), 6.15 (d, 1H, 
J=16.8 Hz), 4.55-4.65 (m, 1H), 3.67 (s, 3H), 2.39 (t, 2H, J=7.2 Hz), 1.62-1.89 (m, 4H). 
δc (100 MHz, CDCl3) 174.01, 141.94, 136.12, 128.83, 128.81, 126.37, 107.42, 91.86, 
84.41, 62.68, 51.72, 37.15, 33.66, 20.67. IR (NaCl) v 3418, 3028, 2951, 1733, 1437 cm-
1. HRMS (ESI) m/z 281.1152 (C16H18O3Na
+ required 281.1148).  
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Methyl (Z)-5-hydroxy-7-phenylhept-6-enoate 
 
Scheme 104. 
Methyl 5-hydroxy-7-phenylhept-6-ynoate [149] (0.19 g, 0.82 mmol, 1.0 equiv.) was 
dissolved in methanol (10 mL), and quinoline (0.01 g, 0.08 mmol, 0.1 equiv.) and Lindlar 
catalyst (0.09 g, 0.82 mmol, 1.0 equiv.) were added. The reaction vessel was evacuated 
of air and flushed with nitrogen three times before being flushed with hydrogen 3 times. 
The reaction was then left under hydrogen with very rigorous stirring overnight. The 
reaction mixture was then filtered and put back into the reaction flask with a fresh load 
of catalyst. It was evacuated of air and flushed and left overnight again. The next day, the 
reaction was filtered and concentrated under vacuum. The residue was then diluted with 
ethyl acetate (15 mL) and washed with 2M copper sulphate (3 x 10 mL) and brine (3 x 
10 mL). The organic extract was then dried over magnesium sulphate and concentrated 
under vacuum to give the crude product. This was then purified using column 
chromatography using petroleum ether and ethyl acetate (3:1) (Rf = 0.43) as eluent. The 
pure product was isolated as a pale, yellow oil. (0.09 g, 0.38 mmol, 46%). δH (400 MHz, 
CDCl3) 7.23-7.35 (m, 5H), 6.56 (d, 1H, J=11.6 Hz), 5.66 (dd, 1H, J=11.6 Hz), 3.66 (s, 
3H), 2.31-2.36 (m, 2H), 1.58-1.78 (m, 4H). δc (100 MHz, CDCl3) 174.12, 136.60, 134.27, 
131.39, 128.80, 128.49, 127.39, 67.49, 51.65, 36.93, 33.85, 20.97. IR (NaCl) v 3421, 
3024, 2950, 1735 cm-1. HRMS (ESI) m/z 257.1151 (C14H18O3Na
+ required 257.1148).  
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Methyl (Z)-5-hydroxy-7-(p-tolyl)hept-6-enoate 
 
Scheme 105. 
Methyl 5-hydroxy-7-(p-tolyl)hept-6-ynoate [150] (0.20 g, 0.91 mmol, 1.0 equiv.) was 
dissolved in methanol (10 mL), and quinoline (0.01 g, 0.09 mmol, 0.1 equiv.) and Lindlar 
catalyst (0.09 g, 0.91 mmol, 1.0 equiv.) were added. The reaction vessel was evacuated 
of air and flushed with nitrogen three times before being flushed with hydrogen 3 times. 
The reaction was then left under hydrogen with very rigorous stirring overnight. The 
reaction mixture was then filtered and put back into the reaction flask with a fresh load 
of catalyst. It was evacuated and flushed the same as before and left overnight again. The 
next day, the reaction was filtered and concentrated under vacuum. The residue was then 
diluted with ethyl acetate (15 mL) and washed with 2M copper sulphate (3 x 10 mL) and 
brine (3 x 10 mL). The organic extract was then dried over magnesium sulphate and 
concentrated under vacuum to yield the crude product. This was then purified by column 
chromatography using petroleum ether and ethyl acetate (3:1) (Rf = 0.51) to give the pure 
product as a pale, yellow oil. (0.09, 0.36 mmol, 40%). δH (400 MHz, CDCl3) 7.13-7.18 
(m, 4H), 6.52 (d, 1H, J=11.6 Hz), 5.61 (d, 1H, J=11.6 Hz), 4.56-4.61 (m, 1H), 3.67 (s, 
3H), 2.36 (s, 3H), 2.32-2.34 (m, 2H), 1.58-1.77 (m, 4H). δc (100 MHz, CDCl3) 174.12, 
137.23, 132.07, 131.38, 128.76, 128.65, 128.52, 67.56, 51.63, 36.94, 33.88, 21.26, 20.90. 
IR (NaCl) v 3437, 2950, 1735, 1511, 1437 cm-1. HRMS (ESI) m/z 271.1309 
(C15H20O3Na
+ required 271.1305).  
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Methyl (Z)-7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-enoate 
 
Scheme 106. 
Methyl 7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-ynoate [151] (0.21 g, 0.71 mmol, 1.0 
equiv.) was dissolved in methanol (10 mL), and quinoline (0.01 g, 0.07 mmol, 0.1 equiv.) 
and Lindlar catalyst (0.11 g, 1.06 mmol, 1.5 equiv.) were added. The reaction vessel was 
evacuated of air and flushed with nitrogen three times before being flushed with hydrogen 
3 times. The reaction was then left under hydrogen with very rigorous stirring overnight. 
The reaction mixture was then filtered and put back into the reaction flask with a fresh 
load of catalyst. It was evacuated and flushed the same as before and left overnight again. 
The next day, the reaction was filtered and concentrated under vacuum. The residue was 
then diluted with ethyl acetate (15 mL) and washed with 2M copper sulphate (3 x 10 mL) 
and brine (3 x 10 mL). The organic extract was then dried over magnesium sulphate and 
concentrated under vacuum to yield the crude product. This was then purified by column 
chromatography using petroleum ether and ethyl acetate (3:1) (Rf = 0.52). (0.13 g, 0.45 
mmol, 63%). δH (400 MHz, CDCl3) 7.36 (d, 2H, J=8.0 Hz), 7.2 (d, 2H, J=8.0 Hz), 6.52 
(d, 1H, J=11.6 Hz), 5.5 (dd, 1H, J=11.6 Hz), 4.59-4.65 (m, 1H), 3.67 (s, 3H), 2.40 (t, 2H, 
J=7.2 Hz), 1.59-1.79 (m, 4H), 1.31 (s, 9H). δc (100 MHz, CDCl3) 174.14, 150.4, 133.71, 
131.22, 128.60, 126.95, 125.36, 67.56, 51.64, 36.94, 34.65, 33.92, 31.37, 20.94. IR 
(NaCl) v 3413, 2954, 1735, 1436. HRMS (ESI) m/z 313.1777 (C18H26O3Na
+ required 
313.1774).  
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8.3 MIDA-Boronate Epoxide Ring Opening 
(1R,2R)-1,2-Bis((S)-2,2-dimethyl-1,3-dioxolan-4-yl)ethane-1,2-diol100 
 
Scheme 107. 
Acetone (50 mL) was saturated with zinc chloride to form a milky solution. This was 
allowed to settle down before being transferred to a separate 3-necked flask containing 
D-mannitol [170] (5 g, 27.45 mmol, 1.0 equiv.). The contents were heated at 80°C until 
the solution turned clear and colourless, this took approximately 1 hour. After this time, 
the heat was turned off and the reaction mixture quenched with saturated aqueous 
potassium carbonate (50 mL). This was stirred for a further 30 minutes at room 
temperature. The mixture was then filtered, and the filtrate transferred to a separating 
funnel so that it could be extracted with dichloromethane (3 x 50 mL). The organic 
extracts were then dried over sodium sulphate, filtered, and reduced under vacuum. The 
crude product was recrystallized using hot hexane to yield the title compound as a white 
solid. (5.76 g, 21.96 mmol, 80%). Melting point 119-123°C. δH (400 MHz, CDCl3) 4.06-
4.19 (m, 4H), 3.92-3.98 (m, 2H), 3.72-3.74 (m, 2H), 1.34-1.41 (m, 12H). δc (100 MHz, 
CDCl3) 109.38, 76.28, 71.21, 66.74, 26.72. IR (NaCl) v 1217, 2874, 2938, 3306 cm
-1. 
HRMS (ESI) m/z 285.1309 (C12H22O6Na
+ required 285.1297). [α]D
20 = +3.2.100 
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2,2-Dimethyl-1,3-dioxolane-4-carbaldehyde101 
 
Scheme 108. 
Protected D-Mannitol [129] (0.05 g, 0.19 mmol, 1.0 equiv.) was added to 
dichloromethane and stirred for 10 minutes. Saturated NaHCO3 (0.01 mL, 0.02 mmol, 
0.1 equiv.) was added, followed by sodium metaperiodate (0.09 g, 0.38 mmol, 2.0 equiv.) 
slowly over 5 minutes whilst ensuring that the reaction temperature does not exceed 35°C 
using water bath cooling. The reaction was then stirred at room temperature for 2 hours 
before magnesium sulphate was added and stirred for an additional 20 minutes. The 
reaction mixture was then filtered, and the filtrate collected. The filter cake was then 
added to dichloromethane and stirred for 10 minutes before being filtered again. The filter 
cake was discarded, and the filtrate added to that collected previously. The solvent was 
removed by evaporation under reduced pressure to yield the product. (0.04 g, 0.31 mmol, 
81%). δH (400 MHz, CDCl3) 9.71 (s, 1H), 3.68-4.18 (m, 3H), 1.46 (s, 3H), 1.47 (s, 3H). 
δc (100 MHz, CDCl3) 201.98, 108.64, 91.97, 65.60, 26.59, 25.29. IR (NaCl) v 2987, 
1736, 1456, 1381 cm-1. HRMS (ESI) m/z 153.0522 (C6H10O3Na
+ required 153.0518). 
[α]D
20 = +56.94 (c 1.0, CH2Cl2).
101 
 
 
 
 
 
 
 
 
 
 
 
142 
 
(E)-2,2-Dimethyl-4-styryl-1,3-dioxolane72 
 
Scheme 109. 
To a suspension of [PPh3CH3]Br (0.13 g, 0.29 mmol, 1.0 equiv.) in anhydrous THF (25 
mL)  was added n-BuLi (2.5M in hexanes, 0.11 mL) at 0°C and stirred for 15 minutes. A 
solution of 2,2-dimethyl-1,3-dioxolane-4-carbaldehyde [169] (0.04 g, 0.29 mmol, 1.0 
equiv.) in anhydrous THF (10 mL), was added dropwise and allowed to stir at 0°C for an 
additional hour. The reaction mixture was then quenched with saturated aqueous 
ammonium chloride (30 mL) and extracted with diethyl ether (3 x 15 mL). The organic 
extracts were dried over magnesium sulphate, filtered and the solvent removed under 
reduced pressure to give the product. (0.08 g, 0.39 mmol, 62 %). δH (400 MHz, CDCl3) 
7.99-7.59 (m, 5H), 6.73 (d, 1H, J=11.6 Hz), 5.71 (q, 1H, J=11.6 Hz), 4.92 (q, 1H, J=7.6 
Hz), 3.66-3.71 (m, 2H), 1.39 (s, 6H). δc (100 MHz, CDCl3) 136.22, 134.10, 129.27, 
128.80, 128.67, 128.10, 127.63, 126.79, 109.55, 69.79, 69.61, 26.85, 26.04. IR (NaCl) v 
3382, 3024, 2935, 1593, 1246 cm-1. LCMS (m/z) 227 [M+ + Na]. [α]D
20  = +36.42 (c 1.0, 
CH2Cl2).
72 
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 (S,E)-4-Phenylbut-3-ene-1,2-diol73 
 
Scheme 110. 
(E)-2,2-dimethyl-4-styryl-1,3-dioxolane [168] (0.18 g, 1.90 mmol, 1.0 equiv.), 2M HCl 
(0.93 mL) and ethanol (3 mL) were added together and allowed to stir at room 
temperature for 5 hours. The reaction mixture was quenched by the addition of sodium 
bicarbonate (5 mL). The insoluble material was filtered, and the solvent removed by 
evaporation under reduced pressure yielding the crude product. The title compound was 
isolated by column chromatography using petroleum ether: ethyl acetate as eluent (2:1) 
(Rf = 0.32). (0.19 g, 1.18 mmol, 62 %). δH (400 MHz, CDCl3) 7.22-7.39 (m, 5H), 6.61 (d, 
1H, J=11.6 Hz), 5.62 (q, 1H, J=11.6, J=9.4 Hz), 4.64-4.69 (m, 1H), 3.53-3.70 (m, 2H). 
δc (100 MHz, CDCl3) 136.32, 133.57, 129.73, 128.72, 128.51, 127.68, 68.76, 66.34. IR 
(NaCl) v 3368, 1643, 1590, 1437 cm-1. HRMS (ESI) m/z 187.0730 (C10H12O2Na
+ 
required 187.0723). [α]D
20 = +47.68 (c 1.0, CH2Cl2).
73 
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(S,E)-2-Hydroxy-4-phenylbut-3-en-1-yl 4-methylbenzenesulfonate 
 
Scheme 111. 
A flask was charged with (S,E)-4-phenylbut-3-ene-1,2-diol [132] (0.50 g, 3.05 mmol, 1.0 
equiv.) and dichloromethane (50 mL). The resulting solution was cooled to 0°C and 
triethylamine (2.12 mL, 15.23 mmol, 5.0 equiv.), 4-toluenesulfonyl chloride (0.75 g, 3.96 
mmol, 1.3 equiv.) and DMAP (approx. 10 mg) were added. The reaction was stirred at 
room temperature for 3 hours. After this time, the mixture was poured into a separating 
funnel containing HCl (1M, 20 mL). The layers were separated, and the organic layer 
washed with saturated aqueous sodium bicarbonate (3 x 20 mL) and brine (3 x 20 mL). 
The organic layers were dried over sodium sulphate, and the solvent removed under 
vacuum to give the crude product. This was purified by column chromatography using 
petroleum ether and ethyl acetate (6:1) (Rf = 0.45). (0.21 g, 0.66 mmol, 21%). δH (400 
MHz, CDCl3) 7.76-7.80 (m, 4H), 7.29-7.32 (m, 5H), 6.65 (d, 1H, J=12.0 Hz), 5.56 (q, 
1H, J=12.0, 9.2 Hz), 4.74-4.78 (m, 1H), 3.90-4.10 (m, 2H), 2.43 (s, 3H). δc (100 MHz, 
CDCl3) 145.22, 134.54, 130.06, 128.73, 128.58, 128. 08, 127.88, 127.56, 126.72, 125.66, 
73.01, 66.16, 21.77. IR (NaCl) v 3400, 1645, 1597, 1437, 1360 cm-1. HRMS (ESI) m/z 
341. 0818 (C17H18O4SNa
+ required 341.0825). [α]D
20 = +38.52 (c 1.0, CH2Cl2).  
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(S,E)-2-Styryloxirane102 
 
Scheme 112. 
A flask was charged with (S,E)-2-hydroxy-4-phenylbut-3-en-1-yl 4-
methylbenzenesulfonate [171] (0.11 g, 0.29 mmol, 1.0 equiv.) and diethyl ether (5 mL). 
An aqueous solution of NaOH (2M, 3 mL) was added to the ethereal solution and the 
resulting biphasic mixture was stirred vigorously at room temperature for 24 hours. The 
layers were separated and extracted with diethyl ether, washed with saturated aqueous 
sodium bicarbonate (3 x 5 mL) and brine (3 x 5 mL). The organic layers were dried over 
magnesium sulphate and reduced under vacuum to give the product. (0.1 g, 0.68 mmol, 
88%). δH (400 MHz, CDCl3) 7.25-7.37 (m, 5H), 6.78 (d, 1H, J=11.6 Hz), 5.35 (q, 1H, 
J=11.6, 8.8 Hz), 3.76-3.78 (m, 1H), 2.77-3.08 (m, 2H). δc (100 MHz, CDCl3) 136.19, 
129.41, 128.48, 128.72, 128.86, 126.54, 52.76, 49.17. IR (NaCl) v 3034, 2991, 1953, 
1685, 1253 cm-1. MS (m/z, %): 146 (32, MC); 117 (100); 115 (76); 102 (11); 90 (48); 50 
(16). [α]D
20 = +43.34 (c 1.0, CH2Cl2).
102 
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8-(But-1-yn-1-yl)-4-methyldihydro-4l4,8l4-[1,3,2]oxazaborolo[2,3-
b][1,3,2]oxazaborole-2,6(3H,5H)-dione 
 
Scheme 113. 
8-Ethynyl-4-methyldihydro-4l4,8l4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborole-
2,6(3H,5H)-dione [98] (0.05g, 0.28 mmol, 1.0 equiv.) was dissolved in anhydrous THF 
(2 mL) and cooled the -78°C. NaHMDS (1.0 M in THF, 0.28 mL, 1.0 equiv.) and ethyl 
iodide (0.09 g, 0.56 mmol, 2.0 equiv.) were added successively. The mixture was stirred 
for 15 minutes at -78 °C. The reaction was then quenched with water, extracted with ethyl 
acetate, dried over magnesium sulphate and reduced under vacuum to give the crude 
product as a pale, yellow oil. This was then purified by column chromatography using 
ethyl acetate and petroleum ether (3:1) (Rf = 0.3) to give the product as a colourless oil. 
(1.0 mg, 4.78 μmol, 2%). δH (400 MHz, CDCl3) 3.96 (d, 2H, J=17.0 Hz), 3.84 (d, 2H, 
J=17.0 Hz), 3.00 (s, 3H), 2.43-2.2.41 (m, 2H), 1.93-1.90 (m, 3H). It was not possible to 
collect the remaining data so full characterisation could not be completed and therefore 
confident confirmation of the product could not be achieved.  
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8.4 Resolvin E1 Natural Product Substrate Synthesis 
(S,E)-4-(2-Iodovinyl)-2,2-dimethyl-1,3-dioxolane103 
 
Scheme 114. 
Anhydrous chromium (II) chloride (1.45 g, 11.80 mmol, 6.0 equiv.), was suspended in 
dry THF under nitrogen and stirred for 10 minutes. A solution of the aldehyde [169] (0.25 
g, 11.80 mmol, 1.0 equiv.) and iodoform (1.55 g, 3.93 mmol, 2.0 equiv.) was added 
dropwise at 0°C and allowed to stir overnight at room temperature. The reaction mixture 
was added to distilled water and the product extracted with diethyl ether. The organic 
extracts were dried over magnesium sulphate, filtered and the solvent removed by 
evaporation under reduced pressure. The crude product was purified by column 
chromatography using petroleum ether (100%) as eluent. (2.40 g, 9.44 mmol, 80%).  δH 
(400 MHz, CDCl3) 6.51-6.52 (m, 2H), 4.46 (q, J=6.4 Hz, 1H), 4.08 (q, 1H, J=6.4 Hz), 
3.67 (q, 1H, J=6.4 Hz), 1.41 (s, 3H), 1.38 (s, 3H). δc (100 MHz, CDCl3) 143.50, 109.84, 
65.51, 26.66, 25.84. IR (NaCl) v 2985, 2932, 2872, 1609, 1060 cm-1. [α]D
20 -7.34 (c 1.0, 
EtOH).103  
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(S,E)-4-Iodobut-3-ene-1,2-diol 
 
Scheme 115. 
(S,E)-4-(2-iodovinyl)-2,2-dimethyl-1,3-dioxolane [128] (1.36 g, 5.35 mmol, 1.0 equiv.), 
2M HCl (7.36 mL, 2.8 equiv.) and ethanol (10 mL) were added together and allowed to 
stir at room temperature for 5 hours. The reaction mixture was quenched by the addition 
of sodium bicarbonate. The insoluble material was filtered, and the solvent removed by 
evaporation under reduced pressure yielding the crude product which was carried forward 
without further purification. (0.89 g, 4.01 mmol, 75%). δH (400 MHz, CDCl3) 6.45 (d, 
1H, J=8.0 Hz), 6.28 (d, 1H, J=8.0 Hz), 4.19 (t, 1H, J=7.8 Hz), 3.71-3.64 (m, 1H), 3.53-
3.46 (m, 1H). δc (100 MHz, CDCl3) 144.22, 84.54, 79.58, 65.51. IR (NaCl) v 3400, 1639, 
1401, 1074 cm-1. HRMS (ESI) m/z 236.9383 (C4H7O2INa
+ required 236.9386). [α]D
20 -
8.48 (c 1.0, EtOH).  
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 (S,E)-2-Hydroxy-4-iodobut-3-en-1-yl 4-methylbenzenesulfonate 
 
Scheme 116. 
A flask was charged with (S,E)-4-iodobut-3-ene-1,2-diol [127] (0.18 g, 0.82 mmol, 1.0 
equiv.) and  of dichloromethane (25 mL). The resulting solution was cooled to 0°C and 
triethylamine (0.57 mL, 4.09 mmol, 5.0 equiv.), 4-toluenesulfonyl chloride (0.20 g, 1.06 
mmol, 1.3 equiv.) and DMAP (approx. 10 mg) were added. The reaction was stirred at 
room temperature for 3 hours. After this time, the mixture was poured into a separatory 
funnel containing HCl (1M, 5 mL). The layers were separated, and the organic layer 
washed with saturated aqueous sodium bicarbonate (3 x 15 mL) and brine (3 x 15 mL). 
The organic layers were dried over sodium sulphate, and the solvent removed under 
vacuum to give the crude product. This was purified by column chromatography using 
petroleum ether and ethyl acetate as eluent (10:1) (Rf = 0.31) to give the product as a pale, 
yellow oil. (0.14 g, 0.38 mmol, 46%). δH (400 MHz, CDCl3) 7.76-7.70 (m, 2H), 7.68-
7.63 (m, 2H), 6.48-6.33 (m, 1H), 6.23-6.17 (m, 1H), 4.32-4.28 (m, 1H), 4.04-3.91 (m, 
1H), 3.88-3.84 (m, 1H), 2.39 (s, 3H). δc (100 MHz, CDCl3) 145. 60, 142.41, 137.04, 
130.20, 128.07, 85.34, 71.78, 68.50, 21.85. IR (NaCl) v 3401, 1922, 1728, 1597, 1449, 
1358, 1178 cm-1. HRMS (ESI) m/z 390.9471 (C11H13O4ISNa
+ required 390.9480). [α]D
20 
-15.82 (c 1.0, EtOH).  
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(S,E)-2-(2-Iodovinyl)oxirane 
 
Scheme 117. 
A flask was charged with (S,E)-2-hydroxy-4-iodobut-3-en-1-yl 4-
methylbenzenesulfonate [177] (0.11 g, 0.36 mmol, 1.0 equiv.) and diethyl ether (5 mL). 
An aqueous solution of NaOH (2M, 5 mL|) was added to the ethereal solution and the 
resulting biphasic mixture was stirred vigorously at room temperature for 24 hours. The 
layers were separated and extracted with diethyl ether (3 x 5 mL), washed with saturated 
aqueous sodium carbonate (3 x 5 mL) and brine (3 x 5 mL). The organic layers were 
dried over magnesium sulphate and reduced under vacuum to give the crude product. The 
epoxide could not be separated from compound [177] so, percentage yield cannot be 
given. δH (400 MHz, CDCl3) 6.59 (d, 1H, J=15.2 Hz), 6.50 (d, 1H, J=15.0 Hz), 4.95-4.93 
(m, 1H), 2.96-2.94 (m, 1H), 2.67-2.69 (m, 1H). δc (100 MHz, CDCl3) 143.44, 85.19, 
53.34, 48.45. Further data was not collected on this mixture due to the difficulty in 
separating product from starting material.  
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1-Phenylpropan-1-ol104 
 
Scheme 118. 
An oven dried round bottomed flask was charged with CuI (0.04g, 0.21 mmol, 0.1 
equiv.), gently heated (40-50°C) under vacuum for 5 minutes. After this time, the flask 
was cooled with a flow of nitrogen and anhydrous THF (5mL) was added. This 
suspension was cooled to -20°C and vigorously stirred. CH3MgBr 3.0 M in diethyl ether 
(1.39mL, 2.0 equiv.) was injected and styrene oxide [174] (0.25 g, 2.08 mmol, 1.0 equiv.) 
dissolved in anhydrous THF (1 mL) was added dropwise. This mixture was stirred at -
20°C for 18 hours. The reaction was quenched with saturated aqueous ammonium 
chloride and extracted with diethyl ether (5 mL) three times. The organic extracts were 
washed with brine (5 mL), dried over magnesium sulfate, filtered, and reduced under 
vacuum to give the crude product as a dark, yellow oil. This was purified using silica gel 
column chromatography using petroleum ether and ethyl acetate (9:1) (Rf = 0.56) as 
eluent. This isolated the title compound as a clear oil. (0.20 g, 1.50 mmol, 72%). δH (400 
MHz, CDCl3) 7.24-7.36 (m, 5H), 4.59 (t, 1H, J=6.8 Hz), 1.71-1.87 (m, 2H), 0.91 (t, 3H, 
J=7.4 Hz). δc (100 MHz, CDCl3) 144.67, 10.25, 128.50, 127.59, 126.06, 76.13, 31.98. 
IR (NaCl) v 3368, 3029, 2965, 1453 cm-1.104 
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8.5 Resolvin E1 Natural Product Synthesis 
RuCl(p-cymene)[(S,S)-Ts-DPEN] – Noyori Catalyst 
To a stirred solution of (S,S)-TsDPEN (0.05 g, 0.136 mmol, 2.0 equiv.), and [RuCl2(p-
cymene)]2 (0.04 g, 68.00 μmol, 1.0 equiv.) in CH2Cl2 (1 mL) was added freshly powdered 
KOH (0.11 g, 2.04 mmol, 15.0 equiv.). The resulting solution was stirred for 1 hour and 
then distilled water (1.5 mL) added. The biphasic mixture was stirred for a further 30 
minutes, until the organic phase turned a deep purple colour. The layers were separated, 
and the organic layer washed with distilled water (1.5 mL). The combined organic phases 
were dried over powdered CaH2 and the solvent removed in vacuo to leave the title 
compound as a fine purple powder. (0.04 g, 0.63 μmol, 93%).  
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 (S)-1-Phenylethan-1-ol105 
 
Scheme 119. 
Acetophenone [182] (0.10 g, 0.83 mmol, 1.0 equiv.) was dissolved in anhydrous 
isopropanol (10 mL) and degassed under vacuum until boiling. The flask was flushed 
with argon four times before the previously prepared Noyori catalyst was added via 
cannula. This was then heated to 80°C and stirred vigorously. The reaction was monitored 
by TLC until complete and then allowed to cool to room temperature. The mixture was 
then reduced under vacuum to give the crude product as a black oil. The crude product 
was then purified by column chromatography using petroleum ether and ethyl acetate 
(6:1) (Rf = 0.42) as eluent to give the pure product as a pale, yellow oil. (75.00 mg, 0.61 
mmol, 73%). δH (400 MHz, CDCl3) 7.25-7.35 (m, 5H), 4.84 (q, 1H, J=6.8 Hz), 1.47 (s, 
3H). δc (100 MHz, CDCl3) 145.97, 128.69, 128.34, 125.52, 70.41, 25.25. IR (NaCl) v 
3351, 3029, 2973, 2874 cm-1. HRMS (ESI) m/z 145.0624 (C8H10ONa
+ required 
145.0621). [α]D
20 = -22.00 (c. 1.05, CH2Cl2).
105 
 
 
 
 
 
 
 
 
 
154 
 
Methyl (S)-5-hydroxy-7-(trimethylsilyl)hept-6-ynoate106 
 
Scheme 120. 
Methyl 5-oxo-7-(trimethylsilyl)hept-6-ynoate [118] (1.00 g, 4.42 mmol, 1.0 equiv.) was 
dissolved in anhydrous isopropanol (10 mL) and was degassed until boiling. argon was 
then added through a balloon and degassed a further 3 times, refilling with argon each 
time. Noyori catalyst was dissolved in dichloromethane (3 mL) and added to the reaction 
vessel via cannula. The flask was evacuated again a further three times before being left 
to stir under argon at 80°C for 1 hour. The reaction was monitored by TLC until finished. 
After this time, the flask was taken off the heat and left to cool for 10 minutes. It was then 
transferred to a round bottomed flask and the solvent evaporated under reduced pressure 
to leave a dark, brown crude oil. This was immediately purified by silica gel column 
chromatography using petroleum ether and ethyl acetate (5:1) as eluent. This provided 
the title compound as a pale, yellow oil. (0.87 g, 3.79 mmol, 85%). δH (400 MHz, CDCl3) 
5.28 (s, 1H), 4.37 (t, 1H, J=6.2 Hz), 3.66 (s, 3H), 2.35-2.46 (m, 2H), 1.95 (quin, 2H, 
J=7.2 Hz), 1.69-1.83 (m, 2H), 0.08 (s, 9H). δc (100MHz, CDCl3) 174.13, 106.43, 89.67, 
62.70, 51.75, 36.92, 33.60, 20.46, 0.19. IR (NaCl) v 3442, 2957, 2171, 1736 cm-1.  HRMS 
(ESI) m/z 229.1255 (C11H21O3Si
+ requires 229.1256). [α]D
20 = -24.74 (c 1.0 CH2Cl2).
106 
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Methyl 5-((tert-butyldimethylsilyl)oxy)hept-6-ynoate 
 
Scheme 121. 
Methyl 5-hydroxyhept-6-ynoate [144] (0.28 g, 1.79 mmol, 1.0 equiv.) and imidazole 
(0.13 g, 1.97 mmol, 1.1 equiv.) were dissolved in dichloromethane (6 mL) and stirred for 
5 minutes. Tert-butyldimethylsilyl chloride (0.30 g, 1.97 mmol, 1.1 equiv.) was added 
and the mixture was left to stir at room temperature overnight. After this time, the mixture 
was then filtered, and the filtrate evaporated under reduced pressure to yield the title 
compound as a pale, yellow oil. (0.45 g, 1.66 mmol, 84%). δH (400 MHz, CDCl3) 4.31-
4.37 (m, 1H), 3.66 (s, 3H), 2.37 (s, 1H) 2.32-2.38 (m, 2H), 1.63-1.72 (m, 4H), 0.88 (s, 
9H), 0.12 (s, 6H). δc (100 MHz, CDCl3) 174.06, 85.22, 76.78, 62.43, 51.61, 37.80, 33.73, 
29.78, 25.82, 20.68, -0.12. IR (NaCl) v 3309, 2954, 2858, 1740, 1463 cm-1. HRMS (ESI) 
m/z 293.1543 (C14H26O3SiNa
+ required 293.1544). [α]D
20 = -27.83 (c 1.0 CH2Cl2). 
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4-Methyl-8-(phenylethynyl)dihydro-4λ4,8λ4-[1,3,2]oxazaborolo[2,3-
b][1,3,2]oxazaborole-2,6(3H,5H)-dione 
 
Scheme 122. 
To a three-necked flask equipped with reflux condenser and nitrogen bubbler was added 
ethynylboronic acid MIDA ester [98] (0.10 g, 0.55 mmol, 1.0 equiv.), iodobenzene (95.00 
mg, 0.37 mmol, 1.0 equiv.), Pd[PPh3]2Cl2 (13.60 mg, 19.34 μmol, 0.04 equiv.), CuI (3.00 
mg, 19.34 μmol, 0.04 equiv.), and anhydrous THF (20 mL). The reaction was then heated 
to 80 °C and diisopropylamine (0.19 g, 1.48 mmol, 2.7 equiv.) added which resulted in a 
temporary colour change to yellow and then gradually turned to a deep brown. This was 
left under N2 atmosphere, heating at 80°C and stirred overnight. The next day the reaction 
was allowed to cool slowly to room temperature and diluted with ethyl acetate (15 mL). 
This solution was transferred to a separating funnel and washed with distilled water (3 x 
10 mL), before being washed with brine (3 x 20 mL). The organic extract was then dried 
over magnesium sulphate and reduced under vacuum to yield the crude product as a dark, 
brown oil. This was then purified by column chromatography using ethyl acetate and 
petroleum ether (3:1) (Rf = 0.28) as eluent to give the pure product as a pale, yellow oil. 
(0.12 g, 0.47 mmol, 85%). δH (400 MHz, CDCl3) 7.49-7.47 (m, 3H), 7.39-7.32 (m, 2H), 
4.01, (d, 2H, J=17.0 Hz), 3.92-3.88 (d, 2H, J=17.0 Hz), 3.07 (s, 3H). δc (100 MHz, 
CDCl3) 167.94, 131.77, 128.86, 128.07, 122.72, 117.44, 100.02, 61.55, 47.87. IR (NaCl) 
v 3020, 2194, 1765, 1241, 1022 cm-1. HRMS (ESI) m/z 280.740 (C13H12O4NBNa
+ 
required 280.0740).  
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4-Methyl-8-(p-tolylethynyl)dihydro-4l4,8l4-[1,3,2]oxazaborolo[2,3-
b][1,3,2]oxazaborole-2,6(3H,5H)-dione50 
 
Scheme 123. 
To a three-necked flask equipped with reflux condenser and nitrogen bubbler was added 
ethynylboronic acid MIDA ester [98] (0.10 g, 0.55 mmol, 1.0 equiv.), iodotoluene (78.00 
mg, 0.37 mmol, 1.0 equiv.), Pd[PPh3]2Cl2 (13.60 mg, 19.34 μmol, 0.04 equiv.), CuI (3.00 
mg, 19.34 μmol, 0.04 equiv.), and anhydrous THF (15 mL). The reaction was then heated 
up to 80°C and diisopropylamine (0.19 g, 1.48 mmol, 2.67 equiv.) added which resulted 
in a temporary colour change to yellow and then gradually turned to a deep brown. This 
was left under N2 atmosphere, heating at 80°C and stirred overnight. The next day the 
reaction was allowed to cool to room temperature and diluted with ethyl acetate (15 mL). 
This solution was transferred to a separating funnel and washed with distilled water (3 x 
10 mL), before being washed with brine (3 x 10 mL). The organic extract was then dried 
over magnesium sulphate and reduced under vacuum to yield the crude product as a dark, 
brown oil. This was then purified by column chromatography using ethyl acetate and 
petroleum ether (3:1) (Rf = 0.34) as eluent to give the pure product as a pale, yellow oil. 
(0.13 g, 0.47 mmol, 85%). δH (400 MHz, CDCl3) 7.36 (d, 2H, J=8.0 Hz), 7.15 (d, 2H, 
J=8.0 Hz), 4.00 (d, 2H, J=16.8 Hz), 3.88 (d, 2H, J=16.8 Hz), 3.05 (s, 3H), 2.31 (s, 3H). 
δc (100 MHz, CDCl3) 168.61, 139.67, 132.48, 129.91, 120.97, 100.74, 62.28, 48.43, 
21.39. IR (NaCl) v 3020, 2194, 1765, 1241, 1022 cm-1. HRMS (ESI) calculated 
forC14H14BNO4 271.1016 found 271.1005.
50 
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Methyl (E)-5methyl (E)-5-((tert-butyldimethylsilyl)oxy)-9-(4-methyl-2,6-
dioxotetrahydro-2H-4l4,8l4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-8-yl)non-8-
en-6-ynoate-((tert-butyldimethylsilyl)oxy)-9-(4-methyl-2,6-dioxotetrahydro-2H-
4l4,8l4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-8-yl)non-8-en-6-ynoate 
 
Scheme 124. 
To a three-necked flask equipped with reflux condenser and nitrogen bubbler was added 
methyl 5-hydroxyhept-6-ynoate [143] (0.20 g, 0.72 mmol, 1 equiv.), (E)-(2-iodovinyl) 
benzene (0.22 g, 0.72 mmol, 1.0 equiv.), Pd[PPh3]2Cl2 (0.02 g, 0.04 mmol, 0.04 equiv.), 
CuI (4.80 mg, 0.03 mmol, 0.04 equiv.), and anhydrous THF (15 mL). The reaction was 
then heated to 80°C and diisopropylamine (0.20 g, 1.93 mmol, 2.67 equiv.) added which 
resulted in a temporary colour change to yellow and then gradually turned to a deep 
brown. This was left under N2 atmosphere, heating at 80°C and stirred overnight. The 
next day the reaction was allowed to cool slowly to room temperature and diluted with 
ethyl acetate (15 mL). This solution was transferred to a separating funnel and washed 
with distilled water (3 x 10 mL), before being washed with brine (3 x 10 mL). The organic 
extract was then dried over magnesium sulphate and reduced under vacuum to yield the 
crude product as a dark, brown oil. This was immediately purified by column 
chromatography using petroleum ether and ethyl acetate (1:9) (Rf = 0.35) as eluent, to 
give the title compound as a pale, yellow oil. (0.16 g, 0.36 mmol, 50%). δH (400 MHz, 
CDCl3) 6.00-6.61 (q, 2H, J=18.4 Hz) 4.46 (t, 1H, J=5.6 Hz), 4.03 (d, 2H, J=16.4 Hz), 
3.71 (d, 2H, J=16.4 Hz), 3.64 (s, 3H), 2.84 (s, 3H), 2.32 (t, 2H, J=6.8 Hz), 1.68-1.74 (m, 
4H), 0.89 (s, 9H), 0.09 (3H, s), 0.08 (s, 3H). δc (100 MHz, CDCl3) 174.04, 168.01, 
137.22, 132.19, 132.09, 128.60, 128.56, 123.82, 92.73, 84.03, 63.03, 61.67, 51.62, 47.17, 
37.84, 33.74, 26.93, 20.80, 31.20, 18.31, -4.35. IR (NaCl) v 3056, 1769, 1601, 1461 cm-
1. HRMS (ESI) m/z 474.2090 (C21H34O7NBSiNa
+ required 474.2085). [α]D
20 = -43.78 (c 
1.0 CH2Cl2).  
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Pd(OAc)2/SPhos Catalyst 
An oven-dried flask was charged with Pd(OAc)2 (5.60 mg, 25.00μmol, 1.0 equiv.) and 
SPhos (0.02 g, 0.05 mmol, 2 equiv.). The flask was then flushed with nitrogen and toluene 
(3.0mL) added. The resulting mixture was stirred at 23°C for 45 minutes resulting in dark 
red solution. The catalyst was then immediately utilized in the cross-coupling reaction.  
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Methyl (8E,10E)-5-((tert-butyldimethylsilyl)oxy)-12,13-dihydroxytrideca-8,10-
dien-6-ynoate 
 
Scheme 125. 
An oven dried flask was charged with methyl (E)-5-((tert-butyldimethylsilyl)oxy)-9-(4-
methyl-2,6-dioxotetrahydro-2H-4l4,8l4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborol-8-
yl)non-8-en-6-ynoate [190] (12.00 mg, 26.60 μmol, 1.0 equiv.) and (S,E)-4-iodobut-3-
ene-1,2-diol (11 mg, 50.08 μmol, 1.9 equiv.) as a solution in  anhydrous THF (1.5mL), 
the Pd/SPhos catalyst solution was added too. Degassed 1M NaOH(aq) was then added to 
the vial. The reddish reaction mixture was then stirred for 24 hours at room temperature. 
After this time, the resulting heterogenous deep orange mixture was diluted with ethyl 
acetate and dried over magnesium sulfate and filtered. The filtrate was then filtered 
through a short pad of celite and the filtrate concentrated to approximately 0.5 mL to give 
the crude product. This was purified by column chromatography using 100% ethyl acetate 
as the eluent to give the title compound as a pale, yellow oil. (1.02 mg, 2.67 μmol, 10%). 
δH (400 MHz, CDCl3) 6.32-6.38 (dd, 1H, J=15.6, 10.8Hz). 6.32-6.38 (dd, 1H, J=15.6, 
10.8 Hz), 5.76-5.78 (d, 1H, J=6.4 Hz), 5.72-5.74 (d, 1H, J=6.4 Hz), 5.61-5.65 (d, 1H, 
J=16.4 Hz), 4.49 (m, 1H), 4.31 (m, 1H), 3.66 (s, 3H), 3.48-3.52 (m, 2H), 2.35 (t, 2H, J=6 
Hz), 1.66-1.79 (m, 4H), 0.88 (s, 9H), 0.11 (s, 6H). δc (100 MHz, CDCl3) 174.04, 140.41, 
133.71, 131.28, 112.11, 93.84, 83.36, 76.78, 72.64, 66.34, 63.17, 51.63, 37.91, 33.77, 
25.89, 20.85, 18.33, -4.93. IR (NaCl) v 3400, 2925, 2343, 1750, 1649, 1601, 1446, 1277. 
HRMS (ESI) m/z 405.2068 (C20H34O5SiNa
+ required 405.2075). [α]D
20  = -36.47 (c 1.0 
CH2Cl2). 
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Methyl (8E,10E)-5-((tert-butyldimethylsilyl)oxy)-12-hydroxy-13-(tosyloxy)trideca-
8,10-dien-6-ynoate 
 
Scheme 126. 
A flask was charged with methyl (8E,10E)-5-((tert-butyldimethylsilyl)oxy)-12,13-
dihydroxytrideca-8,10-dien-6-ynoate [193] (0.01 g, 26.13 μmol, 1.0 equiv.) and  
dichloromethane (5 mL). The resulting solution was cooled to 0°C and triethylamine 
(0.01 mL, 0.13 mmol, 5.0 equiv.), 4-toluenesulfonyl chloride (6.48 mg, 33.97 μmol, 1.3 
equiv.) and DMAP (approximately 1 mg) were added. The reaction was stirred at room 
temperature for 3 hours. After this time, the mixture was poured into a separating funnel 
containing HCl (1M, 10 mL). The layers were separated, and the organic layer washed 
with saturated aqueous sodium carbonate (3 x 5 mL) and brine (3 x 5 mL). The organic 
layers were dried over sodium sulphate, and the solvent removed under vacuum to give 
the crude product as a dark, brown oil which was carried forward without further 
purification. (7.71 mg, 14.37 μmol, 55%). δH (400 MHz, CDCl3) 7.77 (d, 2H, J=8.0 Hz), 
7.34 (d, 2H, J=8.0 Hz), 6.43 (dd, 1H, J=15.2, 10.8 Hz), 6.31 (dd, 1H, J=15.2, 10.8 Hz), 
5.61 (d, 1H, J=6.0 Hz), 5.58 (d, 1H, J=6.0 Hz), 4.49-4.47 (m, 1H), 4.05-4.02 (d, 1H, 
J=4.6 Hz), 3.89 (dd, 1H, J=10.4, 7.6 Hz), 3.65 (s, 3H), 2.44 (s, 3H), 1.78-1.67 (m, 4H), 
0.89 (s, 9H), 0.10 (s, 6H). δc (100 MHz, CDCl3) 173.99, 139.99, 132.19, 131.19, 130.07, 
128.09, 112.82, 82.53, 72.89, 69.82, 63.15, 51.62, 37.89, 33.75, 25.88, 21.78, 20.83, 8.71, 
-4.39. IR (NaCl) v 3400, 3083, 2953, 2927, 2854, 1769, 1649, 1601, 1565, 1446, 1277 
cm-1. HRMS (ESI) m/z 559.2156 (C27H40O7SSiNa
+ required 559.2139). [α]D
20 = -73.63 (c 
1.0 CH2Cl2). 
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Methyl (8E,10E)-5-((tert-butyldimethylsilyl)oxy)-11-((S)-oxiran-2-yl)undeca-8,10-
dien-6-ynoate 
 
Scheme 127. 
A flask was charged with Methyl (8E,10E)-5-((tert-butyldimethylsilyl)oxy)-12-hydroxy-
13-(tosyloxy)trideca-8,10-dien-6-ynoate [194] ( 7.71 mg, 21.15 μmol, 1.0 equiv.) and 
diethyl ether (5 mL). An aqueous solution of NaOH (2M, 0.05 mL, 0.11 mmol, 5.0 equiv.) 
was added to the ethereal solution and the resulting biphasic mixture was stirred 
vigorously at room temperature for 24 hours. The layers were separated and extracted 
with diethyl ether (5 mL), washed with saturated aqueous sodium carbonate (3 x 5 mL) 
and brine (3 x 5 mL). The organic layers were dried over magnesium sulphate and 
reduced under vacuum to give the crude product as a dark, orange oil which was carried 
forwards without further purification. (3.47 mg, 9.52 μmol, 45%). δH (400 MHz, CDCl3) 
6.49 (dd, 1H, J=14.6, 17.0 Hz), 5.64 (m, 1H), 5.46 (d, 1H, J=7.8 Hz), 5.42 (d, 1H, J=7.8 
Hz), 4.50-4.49 (m, 1H), 3.66 (s, 3H), 3.38-3.34 (m, 1H), 3.01-2.99 (m, 1H), 2.69-2.67 
(m, 2H), 2.34 (t, 2H, J=7.2 Hz), 1.77-1.69 (m, 4H), 0.89 (s, 9H), 0.10 (s, 6H). δc (100 
MHz, CDCl3) 173.91, 133.56, 128.56, 128.01, 112.11, 94.08, 83.27, 51.52, 37.84, 33.69, 
29.70, 25.80, 20.77, -4.46. IR (NaCl) v 3583, 2926, 2854, 1737, 1659, 1598, 1447, 1277 
cm-1. HRMS (ESI) m/z 387.1962 (C20H32O4SiNa
+ required 387.1951). [α]D
20 = -25.83 (c 
1.0 CH2Cl2). 
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Methyl (8E,10E,12R)-5-((tert-butyldimethylsilyl)oxy)-12-hydroxypentadeca-8,10-
dien-6,14-diynoate 
 
Scheme 128. 
Lithium acetylide ethylene diamine complex (1.50 mg, 19.20 μmol, 1.0 equiv.), was 
dissolved in DMSO (1 mL) and stirred at 0°C. Methyl (8E,10E)-5-((tert-
butyldimethylsilyl)oxy)-11-((S)-oxiran-2-yl)undeca-8,10-dien-6-ynoate [196] (7.71 mg, 
19.71 μmol, 1.0 equiv.) was added dropwise. When addition was complete, the reaction 
mixture was left to stir at 0°C for 18 hours. After this time, the mixture was poured onto 
ice, extracted with diethyl ether (3 x 2 mL) and washed with brine (3 x 2 mL). The organic 
extracts were dried over sodium sulphate, filtered, and then reduced under vacuum. 
Unfortunately, full characterisation of this compound was unavailable due to the low 
amount of product.  
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1-Phenylbut-3-yn-1-ol107 
 
Scheme 129. 
Styrene oxide (0.35 g, 3.78 mmol, 1.0 equiv.) was added dropwise at 0°C to a suspension 
of lithium acetylide ethylene diamine complex (0.45 g, 3.78 mmol, 1.0 equiv.) in DMSO 
(5 mL). Once the addition was complete, the mixture was stirred at 0°C for 18 hours. 
After this time, the mixture was poured onto ice, extracted with diethyl ether (3 x 10 mL) 
and washed with brine (3 x 10 mL). The organic extracts were dried over sodium 
sulphate, filtered, and then reduced under vacuum. The crude product was then purified 
by column chromatography using petroleum ether and ethyl acetate (5:2) (Rf = 0.55) as 
eluent to give the product as a colourless oil. (0.41 g, 2.87 mmol, 76%). δH (400 MHz, 
CDCl3) 7.38-7.35 (m, 5H), 4.83 (td, 1H, J=6.4, 2.8Hz), 2.73 (s, 1H), 2.63-2.61 (m, 1H), 
2.06 (t, 1H, J=2.6 Hz). δc (100 MHz, CDCl3) 142.61, 128.32, 128.10, 125.92, 80.89, 
72.42, 71.10, 29.47. IR (NaCl) v 3391, 3063, 2911, 2119, 1603 cm-1.107 
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(E)-4-Methyl-8-(4-phenylbut-1-en-3-yn-1-yl)dihydro-4l4,8l4-
[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborole-2,6(3H,5H)-dione 
 
Scheme 130. 
To a three-necked flask equipped with reflux condenser and nitrogen bubbler was added 
ethynylbenzene (0.43 g, 1.64 mmol, 0.7 equiv.), trans-2-iodovinylboronic acid MIDA 
ester [107] (0.25 g, 2.45 mmol, 1.0 equiv.), Pd[PPh3]2Cl2 (0.06 g, 85.67 μmol, 0.04 
equiv.), CuI (16.00 mg, 85.67 μmol, 0.04 equiv.), and anhydrous THF (30 mL). The 
reaction was then heated up to 80°C and diisopropylamine (0.66 g, 6.54 mmol, 2.67 
equiv.) added which resulted in a temporary colour change to yellow and then gradually 
turned to a deep brown. This was left under N2 atmosphere, heating at 80°C and stirred 
overnight. The next day the reaction was allowed to cool slowly to room temperature and 
diluted with ethyl acetate (20 mL). This solution was transferred to a separating funnel 
and washed with distilled water (3 x 10 mL), before being washed with brine (3 x 10 
mL). The organic extract was then dried over magnesium sulphate and reduced under 
vacuum to yield the crude product as a dark, brown oil. This was purified by column 
chromatography using petroleum ether and ethyl acetate (1:3) (Rf = 0.25) as eluent, to 
give the title compound as a pale, yellow oil. (0.38 g, 1.35 mmol, 55%). δH (400 MHz, 
CDCl3) 7.57-7.17 (m, 5H), 6.21 (d, 1H, J=17.8 Hz), 6.08 (d, 1H, J=17.8 Hz), 3.99 (d, 2H, 
J=16.0 Hz), 3.65 (d, 2H, J=17.2 Hz), 2.73 (s, 3H). δc (100 MHz, CDCl3) 168.50, 132.21, 
47.26, 132.02, 128.57, 128.69, 123.82, 123.01, 91.31, 89.34, 61.78. IR (NaCl) v 3056, 
1769, 1603, 1459, 1041, 1002 cm-1. HRMS (ESI) m/z 306.0908 (C15H14O4NBNa
+ 
required 306.0892).  
 
 
 
 
 
166 
 
Methyl 5-(((S)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)-7-
(trimethylsilyl)hept-6-ynoate 
 
Scheme 131. 
Methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate [136] (0.01 g, 43.79 μmol, 1.0 equiv.), 
and pyridine (0.01 mL, 135.75 μmol, 3.1 equiv.), were added to a 5 mL round bottomed 
flask and dissolved in anhydrous chloroform (1 mL). S–(+)-MTPA-Cl (0.02 mL, 83.20 
μmol, 1.9 equiv.) was added and the mixture stirred at room temperature under nitrogen 
atmosphere for 24 hours. After this time, the reaction mixture was extracted with diethyl 
ether (3 x 2 mL) and washed with water (3 x 2 mL). The combined organic extracts were 
dried over sodium sulphate, filtered, and reduced under vacuum to give the crude 
compound as a pale, yellow oil. (6.00 mg, 31%, 13.49 μmol). δH (400 MHz, CDCl3) 7.59-
7.58 (m, 3H), 7.39-7.38 (m, 3H), 5.50 (t, 1H, J=5.6 Hz), 3.67 (s, 3H), 3.54 (s, 3H), 2.37-
2.34 (m, 2H), 1.90-1.84 (m, 2H), 1.81-1.73 (m, 2H), 0.14 (s, 9H). δc (100 MHz, CDCl3) 
173.67, 165.64, 129.66, 128.53, 127.56, 100.49, 92.23, 70.02, 66.30, 55.62, 51.79, 33.67, 
33.31, 20.58, 0.29. IR (NaCl) v 3434, 2957, 2601, 1741, 1637, 1451, 1253, 1168 cm-1. 
HRMS (ESI) m/z 467.1472 (C21H27O5F3SiNa
+ required 467.1455).  
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Methyl 5-(((R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoyl)oxy)-7-
(trimethylsilyl)hept-6-ynoate 
 
Scheme 132. 
Methyl 5-hydroxy-7-(trimethylsilyl)hept-6-ynoate [136] (0.01 g, 43.79 μmol, 1.0 equiv.), 
and pyridine (0.01 mL, 135.75 μmol, 3.1 equiv.), were added to a 5 mL round bottomed 
flask and dissolved in anhydrous chloroform (1 mL). R–(+)-MTPA-Cl (0.02 mL, 83.20 
μmol, 1.9 equiv.) was then added and the mixture stirred at room temperature under 
nitrogen atmosphere for 24 hours. After this time, the reaction mixture was extracted with 
diethyl ether (3 x 2 mL) and washed with water (3 x 2 mL). The combined organic 
extracts were dried over sodium sulphate, filtered, and reduced under vacuum to give the 
crude compound as a pale, yellow oil. (5.30 mg, 27%, 11.93 μmol). δH (400 MHz, CDCl3) 
7.41-7.37 (m, 5H), 4.40-4.36 (m, 1H), 3.67 (s, 3H), 3.56-3.55 (m, 3H), 2.37 (t, 2H, J=7.0 
Hz), 1.83-1.68 (m, 4H), 0.15 (s, 9H). δc (100 MHz, CDCl3) 174.06, 170.46, 129.72, 
128.42, 127.29, 106.19, 92.52, 89.82, 69.86, 55.51, 51.65, 29.38, 28.42, 20.52, 1.02. IR 
(NaCl) v 3069, 2956, 2850, 2177, 1962, 1742, 1636, 1489, 1452, 1252, 1168, 1081, 1016, 
989 cm-1. HRMS (ESI) m/z 467.1472 (C21H27O5F3SiNa
+ required 467.1455).  
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Ethynylboronic acid MIDA ester 51 
 
Scheme 133. 
To an oven dried 3-necked flask equipped with stirrer bar, pressure equalising addition 
funnel and two rubber septa was added anhydrous THF (7.5 mL) and trimethyl borate 
(0.61 mL, 5.50 mmol, 1.1 equiv.) and the resulting solution was cool to -78°C. The 
addition funnel was charged with ethynylmagnesium bromide [189] (5.00 mL, 2.50 
mmol, 1.0 equiv.) which was added dropwise over 30 minutes. The reaction was removed 
from the bath and allowed to warm to room temperature over the course of 3 hours 
resulting in white slurry. A separate oven-dried three-necked flask equipped with stirrer 
bar, thermometer, addition funnel and a distillation train was charged with MIDA (1.62 
g, 11.00 mmol, 2.2 equiv.) and DMSO (7.5 mL). This was brought to an internal 
temperature of 130°C. Hexanes (5 mL) was added dropwise to the MIDA solution 
resulting in a light orange solution. The previously prepared solution was added via 
cannula under a positive pressure of N2 at a rate such that the internal temperature 
remained between 120°C-160°C. After the addition the reaction vessel was washed with 
THF and the washes added via cannula. The remaining THF and methanol were allowed 
to distil off. The reaction vessel was allowed to cool to room temperature and then added 
to a separatory funnel with water (10 mL), brine (10 mL), ethyl acetate (15 mL) and 
acetone (10 mL). The organic layers were separated, and the organic layer extracted twice 
with 10 mL ethyl acetate: acetone (3:2) (Rf = 0.30). The organic layers were washed with 
brine (3 x 10 mL), dried over magnesium sulphate and reduced under vacuum to form a 
light brown solid. This solid was dissolved in acetone (2.5 mL) and then precipitated by 
the dropwise addition of diethyl ether (approx. 30 mL). The resulting solid was collected 
via filtration and washed with ether. The solid was dissolved using acetone (8 mL) and 
activated charcoal added. This was stirred for 30 mins and filtered through celite, washing 
with acetone. The resulting solution was reduced under vacuum to afford the title 
compound as a pale orange solid. (0.20 g, 45%, 1.13 mmol). Melting point 115-120°C. 
δH (400 MHz, CDCl3) 3.97 (d, 2H, J=16.8 Hz), 3.83 (d, 2H, J=16.8 Hz), 3.00 (s, 3H), 
169 
 
2.67 (s, 1H). δc (100 MHz, CDCl3) 167.85, 61.51, 47.87. IR (NaCl) v 3275, 3004, 2959, 
2079, 1772, 1453, 1334, 1236, 1027 cm-1.51 
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E-2-Iodovinylboronic acid MIDA ester51 
 
Scheme 134. 
An oven dried 3-necked flask was charged with ethynylboronic acid MIDA ester [98] 
(0.20 g, 1.11 mmol, 1 equiv) and AIBN (0.09 g, 0.55 mmol, 0.5 equiv.). An over dried 
air condenser was fitted to the flask. The flask was then evacuated three times and refilled 
with nitrogen. Anhydrous THF (11 mL) and tributyl tin hydride (1M in cyclohexane) 
(1.66 mL, 1.5 equiv.) were added successively and the flask heated to 70°C overnight. 
After this time, the flask was allowed to cool slowly to room temperature. Meanwhile, a 
separate oven dried flask was charged with I2 (0.56 g, 2.21 mmol, 2.0 equiv.) dissolved 
in anhydrous THF (approximately 5 mL). The reaction flask was then cooled to -78°C 
and the iodine solution added dropwise via cannula over 30 mins. The reaction was then 
left to stir at 78°C for 3 hours and then allowed to slowly warm to room temperature. The 
mixture was then treated with 10% sodium thiosulfate solution (10 mL) and transferred 
to a separating funnel where it was extracted with ethyl acetate (3 x 10 mL). The organic 
layers were then washed with thiosulfate solution (3 x 10 mL) and brine (3 x 10 mL) 
before being dried over magnesium sulphate, filtered, and concentrated under vacuum. 
The remaining oil was treated with ether to precipitate the product and remove the tin 
before being filtered again and the filter cake collected and dried to give the pure product 
as a white solid. (0.34 g, 98%, 1.09 mmol). Melting point 128-134°C. δH (400 MHz, 
CDCl3) 6.82 (s, 2H), 3.97-3.92 (d, 2H, J=17.2 Hz), 3.81-3.77 (d, 2H, J=16.8 Hz), 2.77 
(s, 3H). δc (100 MHz, CDCl3) 168.05, 90.48, 61.74, 46.97. IR (NaCl) v 3583, 3002, 2653, 
1744, 1584, 1448, 1334, 1282.51 
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Appendices 
The biological data for E1 resolvin compound analogues, was collected using the 
following methods, carried out by Luke Baker.108 
Cell Culture 
The C2C12 murine myoblast cell line (C2C12) was used for all experiments. C2C12’s 
were cultured at 37°C and 5% CO2 (HeraCell, Thermo Scientific, UK) in growth medium 
(GM) composed of: Dulbecco’s modified Eagle’s medium (DMEM) (Fisher Scientific, 
UK) plus 20% FBS (PAN Biotech, Germany), and 1% penicillin–streptomycin (PS) 
solution (Invitrogen, Paisley, UK), until 80-95% confluency was attained. Cells were then 
enzymatically dissociated using Trypsin-EDTA (Sigma Aldrich, UK) and counted using 
the trypan blue exclusion method and subsequently seeded into 12 well plates (Thermo-
Scientific) at a density of 12.5x10-3 cells/cm2 in standard GM. Cells were grown to 
confluency (approximately 3 days), at which point medium was changed to 
differentiation media (DM) composed of DMEM (Fisher Scientific, UK) plus 2% Horse 
Serum (HS) (Fisher Scientific, UK), and 1% penicillin–streptomycin (PS) solution 
(Invitrogen, Paisley, UK) to initiate differentiation. Following three days of 
differentiation, myotubes were exposed to one of 10 conditions: (I) Vehicle Control 
(CON): DM + 0.1 μl/ml EtOH; (II) LPS (LPS): DM + 100 ng/ml LPS (Sigma Aldrich, 
UK); (III) methyl 5-hydroxy-7-phenylhept-6-ynoate (e229): DM + 100 ng/ml LPS + 200 
µM methyl 5-hydroxy-7-phenylhept-6-ynoate; (IV) methyl 5-hydroxy-7-(p-tolyl)hept-6-
ynoate (e246): DM + 100 ng/ml LPS + 200 µM methyl 5-hydroxy-7-(p-tolyl)hept-6-
ynoate; (V) methyl 7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-ynoate (e251): DM + 100 
ng/ml LPS + 200 µM methyl 7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-ynoate; (VI) 
methyl (E)-5-hydroxy-9-phenylnon-8-en-6-ynoate (e252): DM + 100 ng/ml LPS + 200 
µM methyl (E)-5-hydroxy-9-phenylnon-8-en-6-ynoate; (VII) methyl 5-hydroxy-7-
(trimethylsily)hept-6-ynoate (e245): DM + 100 ng/ml LPS + 200 µM methyl 5-hydroxy-
7-(trimethylsily)hept-6-ynoate; (VIII) methyl (Z)-5-hydroxy-7-phenylhept-6-enoate 
(e276): DM + 100 ng/ml LPS + 200 µM methyl (Z)-5-hydroxy-7-phenylhept-6-enoate; 
(IX) methyl (Z)-5-hydroxy-7-(p-tolyl)hept-6-enoate (e278): DM + 100 ng/ml LPS + 200 
µM methyl (Z)-5-hydroxy-7-(p-tolyl)hept-6-enoate; (X) methyl (Z)-7-(4-(tert-
butyl)phenyl)-5-hydroxyhept-6-enoate (e270): DM + 100 ng/ml LPS + 200 µM methyl 
(Z)-7-(4-(tert-butyl)phenyl)-5-hydroxyhept-6-enoate and subsequently analysed for 
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mRNA expression, membrane integrity and metabolic activity. Specifically, RNA was 
extracted after 3 h of experimental treatment with time points taken from previous work 
(***Baker et al., 2017***). In a separate experimental set-up, cells were exposed to 
condition medium for 3 h also. Pre and post this exposure a Alamar Blue® assay was 
conducted to determine metabolic activity. Further to this, post 3 h conditioning cells 
were fixed for immunocytochemistry analysis to subjectively determine membrane 
integrity. All experiments were conducted with cells between passages 4 and 8 (n=9, 
across 3 biological repeats for each analysis method). 
RNA Extraction 
Cells isolated for mRNA analysis were lysed in 400 μl of TRI Reagent and frozen at -
80˚C prior to further analysis. RNA extraction was performed as per the manufacturer’s 
instructions. In brief, chloroform was added to ensure dissociation of nucleotide 
complexes (0.2 ml per 1 ml of TRI reagent), and samples were agitated and left to stand 
for 5 mins before being centrifuged at 12,000 g for 15 min. The aqueous phase was 
removed and 2-proponal (0.5 ml per 1 ml of TRI reagent) was added to the aqueous phase 
and mixed by inversion. Following 10 minutes’ incubation at room temperature samples 
were centrifuged at 12,000 g for 10mins to pellet RNA. RNA pellets were washed in 75% 
ethanol, centrifuged for a further 5mins at 7,500 g, and air dried for 5-10 mins. Once 
isolated, RNA was suspended in 50 μl RNA storage solution (Ambion, Life 
Technologies) and stored in RNase free tubes for mRNA analysis. 
RT-qPCR 
One step quantitative RT-qPCR was used to determine expression of target mRNA’s in 
C2C12 cultures. Primer sequences (Table 15) were checked for specificity and assay 
efficiency by performing standard curve analysis with a top standard of 200 ng of RNA. 
Output was analysed using ViiA 7 RUO Software where melt curve analysis was used to 
check for specificity of primers. Optimisation of standard curves was assumed with 
efficiencies of 100 ± 10%.  
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Table 15 - Setup of RT-qPCR tests. 
Target Gene FWD/RVS Primer Sequence (5’-3’) NCBI reference 
RPIIβ FWD: GGTCAGAAGGGAACTTGTGGTAT 
RVS: GCATCATTAAATGGAGTAGCGTC 
NM_153798.2 
IL-6 FWD: AAGAAATGATGGATGCTACC 
RVS: GAGTTTCTGTATCTCTCTGAAG 
NM_031168.1 
 
Reactions were made up in 384 well RNase free plates (Applied Biosystems, UK) and 
consisted of 20 ng (4 ng/µl) of RNA, 0.1 μl of both forward and reverse primers (Life 
Technologies), 0.1 μl of Quantifast Reverse Transcriptase kit (Qiagen) and 4.7 μl of 
SYBR green mix (Qiagen) to create 10 μl reactions. Once prepared, plates were 
transferred to the ViiA 7™ Real Time PCR thermal cycler (Applied Biosystems, Life 
Technologies) which was programmed to perform the following steps: 10 min hold at 
50°C (reverse transcription), followed by a 5 min hold at 95 °C (activation of ‘hot start’ 
Taq polymerase), and cycling between 95 °C for 10s (denaturation) and 60 °C for 30 s 
(annealing and extension). Fluorescence was detected after every cycle and data was 
analysed using RPIIβ as the housekeeping gene. Data was made relative using the 
comparative Ct method with any changes in target genes being in comparison to that of 
the vehicle control condition for each experimental repeat.109  
Metabolic Activity 
Metabolic activity was measured using the Alamar blue® (AB) assay. This is a 
quantifiable assay that measures the cells ability to maintain a reducing environment 
within the cell cytosol. The resazurin within the AB solution is cell permeable and non-
toxic. On passing the cell membrane, resazurin gets reduced to resorufin which fluoresces 
can be measured. AB solution was made up 1:10 in serum free GM. At the designated 
time point cells were incubated in AB medium for 4 h. Post incubation, 100µl of AB 
solution was removed from each well into a black bottomed 96-well plate with all 
samples being measured in triplicate. Samples were quantified using a wave length 
analyser (Varioskan LUX Reader, Thermo-Fisher) at 540-570 nm. 
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Fluorescent Staining 
Cells grown on 13 mm coverslips in 12 well plates were fixed with 3.7% formaldehyde 
solution made up in PBS for 30 min. Fixed cells were then washed in TBS twice and cells 
were permeabilised using a 0.2% Triton X-100 (Sigma) solution made up in TBS for 1 
hour. Following a further two washes cells were stained with Phalloidin (1:200 in TBS) 
to visualise the F-actin filaments in myotubes and DAPI (1:1000) to counter stain nuclei. 
After an hour of incubation, cells were washed 3 x with TBS and subsequently mounted 
onto microscope slides with Flouromount™ aqueous mounting medium (Sigma Aldrich). 
Images were captured using a Leica DM2500 fluorescent microscope (Leica, UK) at 20x 
magnification and 7 images were obtained per coverslip, equating to 21 images per 
condition, per biological repeat. Subjective analysis was used to evaluate the presence of 
myotubes post conditioning phase. 
Statistical Analysis 
Data are presented as means ± SEM unless otherwise stated (n=9). Statistical analyses 
were performed using SPSS v.23 (SPSS Inc., Chicago, IL, US). Data were tested for 
normal distribution and homogeneity of variance. A one-way analysis of variance 
(ANOVA), or non-parametric equivalent, for a between-between design was used to 
analyse the differences between conditions at a single time point. For comparisons across 
time points, a one-way analysis of variance (ANOVA), or non-parametric equivalent, for 
a between-between design was used to analyse the differences between both time and 
condition and any interaction effect between the two. Where significance was reported, 
Bonferroni post-hoc tests or a series of non-parametric equivalents were used to identify 
where any significance lay between conditions and time points. Statistical significance 
was assumed if p≤0.05. Further analysis of effect sizes (r) were used to calculate the 
magnitude of effect: Trivial <0.02; Small 0.2-0.5; Moderate 0.5-0.8; Large >0.8.110 
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NMR Spectra of Key Intermediates 
 
 
 
182 
 
 
 
 
 
183 
 
 
 
 
 
184 
 
 
 
 
185 
 
 
 
 
